Kinetic Studies of Actin Folding by the Chaperonin CCT by Stuart, Sarah Frances
  
Kinetic Studies of Actin Folding by the 
Chaperonin CCT 
 
 
 
Sarah Frances Stuart 
 
 
Department of Chemistry 
Imperial College London 
 
 
Thesis submitted in partial fulfilment of the requirements for the 
degree of Doctor of Philosophy of Imperial College London and the  
Diploma of Imperial College 
 
September 2011 
 
 
 
 
  
2 
 
Declaration 
 
The work presented in this thesis which is submitted towards the degree of 
Doctor of Philosophy of Imperial College London is my own unless 
otherwise cited or acknowledged within the text. 
 
 
Sarah Frances Stuart 
 
September 2011 
3 
 
Abstract 
The chaperonin containing TCP1 (CCT) is an essential protein in 
eukaryotes, and is vital for the correct folding of various obligate substrates 
including the cytoskeletal proteins actin and tubulin and the WD40 repeat 
containing proteins Cdc20 and Cdh1. CCT is highly complex and interacts 
with some proteins only transiently; as such the study of the mode of 
binding and the mechanism by which proteins are folded by the molecular 
chaperone is very challenging. I have used spectroscopic techniques to 
study the folding of Cdh1 and actin by CCT. 
 
The dimensions of CCT are such that Förster resonance energy transfer 
(FRET) could be used to measure distances within the complex, providing 
that fluorophores could be selectively introduced. Through labelling of a 
fragment of the WD40 propeller of Cdh1 and binding of a fluorescently 
labelled calmodulin (CaM) to the calmodulin binding peptide (CBP) tag 
introduced into two CCT subunits, it was hoped that subunits which bind to 
this region of Cdh1 could be identified. Following expression and 
purification of a stable Cdh1 fragment, methods for selective labelling of the 
protein were developed. The complex formed between the fluorescently 
labelled Cdh1 fragment, CaM and CCT was isolated by sucrose gradient. 
Unfortunately, no significant, reproducible FRET signal could be identified, 
indicating that this technique was not suited to the study of Cdh1 folding by 
CCT. 
 
Actin is an essential eukaryotic protein which polymerises to form filaments 
involved in many different cellular processes. CCT subunits which interact 
with actin have been identified, but the mechanism by which actin is folded 
is not well understood and has previously relied on the trapping of actin-
CCT complexes from non-functional systems. Since the discovery of PLP2 
as a cofactor involved in the actin folding process in yeast, pure in vitro 
actin assays have been possible. Through labelling of the C-terminus of 
actin with the environmentally sensitive fluorophore acrylodan, it was 
possible to monitor the kinetics of actin folding by CCT spectroscopically. 
Non-hydrolysable ATP analogues were used which allowed the 
identification of two separate stages in the actin folding process on CCT, an 
initial rearrangement of the two domains of actin followed by packing of the 
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actin C-terminus. The importance of the actin C-terminus in actin folding 
and stability was highlighted by the effect of the probe with which actin was 
labelled on folding.  
 
The effect of mutations in CCT on the rate of actin folding was also 
investigated using the spectroscopic folding assay, as well as the effect of 
truncations of PLP2. It was found that the mutant CCTanc2, which is from a 
strain of yeast that produces defective actin structures and contains a 
mutation in subunit CCT4, behaves differently to wild type CCT at higher 
temperatures and concentrations of ATP. PLP2 appears to be exceptionally 
important for productive actin folding by CCTanc2.  
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1 Introduction 
1.1 Protein Folding 
1.1.1 Principles of Protein Folding 
The folding of a protein from the nascent polypeptide chain leaving the 
ribosome to its native tertiary or quaternary structure is a highly complex 
process. The necessary information for the protein to fold correctly is 
contained within its amino acid sequence as to reach its native 
conformation through random searching through the sequence would take 
an impossibly long period of time.  According to Levinthal’s paradox, for a 
protein of 101 amino acids in length, searching through 1013 conformations 
per second, it would take 1027 years to explore all the possible 
combinations [1, 2]. As such, mechanisms must exist by which a protein is 
able to adopt its native, functional structure in a more defined manner. 
 
The process is initiated by short range interactions amongst the backbone 
of amino acids which lead to the formation of local areas of structure within 
a protein such as α-helices. Medium range interactions can then affect the 
structure leading to contact between neighbouring regions which results in 
small ordered parts of the protein. These can then interact via long range 
interactions, sometimes resulting in rearrangements of the partially folded 
regions, to give the protein tertiary structure [3].  
 
The process of protein folding is often depicted by an energy landscape, 
with the protein passing through various transition states and energy 
minima before achieving its native state [4]. Proteins can be trapped in local 
energy minima, and at times this can lead to the formation of aggregates or 
to targeting of misfolded proteins for degradation by the proteasome.  
 
1.1.2 Protein Misfolding in Disease 
Many diseases are associated with protein misfolding which results in the 
formation of insoluble aggregates or depletion of an essential protein as the 
misfolded proteins are targeted for degradation. The protein α-synuclein is 
found in plaques in a number of diseases, including Alzheimer’s and 
Parkinson’s diseases [5]. Various factors contribute to the progression of 
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these diseases, both genetic and environmental, and their development is 
not always due to mutation in α-synuclein [5]. Other diseases associated 
with protein misfolding and aggregation include prion diseases such as 
bovine spongiform encephalopathy (BSE, more frequently known as mad 
cow disease), and the human equivalent, Creutzfeld-Jakob Disease (CJD) 
[6]. In some diseases, such as cystic fibrosis, misfolded proteins are 
ubiquitinated and degraded by the proteasome resulting in deficiencies in 
essential proteins which lead to very serious conditions [7]. Mutations in the 
tumour suppressor p53 are found in 50 % of tumours and lead to misfolding 
of the protein [8], with insufficient correctly folded protein to allow it to 
perform its DNA repair role within the cell. With such a range of diseases 
and conditions associated with protein misfolding, it is clear that an 
understanding of the mechanisms by which proteins are folded, both 
correctly and incorrectly, is needed in order to find ways to compensate for 
or correct these errors. While for some proteins folding is spontaneous, 
others require assistance to assume their correct conformation, or to 
escape from a stable misfolded state. This role is often performed by a 
group of proteins known as chaperones. 
 
1.1.3 Chaperones 
Within the cell a number of chaperones exist which aid the formation of 
native proteins and help to prevent aggregation within the highly crowded 
cell. These vary widely in size and structure, and there are many different 
classes, which are generally categorised into groups based on their 
molecular weight and function. Since chaperones are frequently most 
active and highly expressed under stress conditions, such as high 
temperatures, they are often described as heat shock proteins (Hsp), and 
this is reflected in the terms used to describe groups of chaperones. For 
example, the Hsp70 family of proteins, which includes DnaK, which binds to 
partially folded proteins to prevent aggregation in E. coli, are approximately 
70 kDa in size [9].  
 
The Hsp60 family of chaperones are more commonly known as molecular 
chaperones or chaperonins. These are large protein complexes made up of 
monomers of approximately 60 kDa, which form a double toroid structure. 
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Non-native substrates are encapsulated within one ring of the chaperonin 
and are folded and released following binding and hydrolysis of ATP [10]. 
 
Chaperonins can be categorised into two different classes, Group I and 
Group II. The Group I chaperonin GroEL is the most studied and best 
characterised due to its relative simplicity when compared with the Group II 
chaperonins, the eukaryotic chaperonin CCT and its archaeal counterpart 
the thermosome [11]. Being composed of 14 identical subunits, both 
structural and mechanistic studies can more readily be performed on the 
bacterial chaperonin than on the Group II chaperonins which are 
structurally similar to GroEL but are usually made up of non-identical 
subunits. 
 
1.1.4 The Prokaryotic Chaperonin GroEL  
GroEL is essential for growth in bacteria, and is present at much higher 
concentrations than is required for cell growth at 37°C, although under 
stress conditions greater amounts of the chaperonin are required [11-13]. 
Although less complex than its eukaryotic and archaeal counterparts, it has 
the same double toroid structure in which substrate proteins are 
encapsulated for folding. The two rings of the chaperonin are each formed 
of seven identical subunits which consist of an equatorial domain, an 
intermediate domain and an apical domain. Each subunit is 57 kDa in size, 
with nucleotide binding sites located on the equatorial domain which links 
the two rings. The intermediate domain provides a link to the apical domain 
which contains substrate binding information. In GroEL each subunit 
interacts with two subunits within the same ring, and the rings are 
staggered so that each subunit also interacts with two subunits of the 
opposing ring [14]. GroEL requires a co-chaperone, GroES, which binds to 
the apical domains and forms a lid to the cavity (Figure 1) [15]. The 
complex formed is approximately 180 Å in height, and has a diameter of 
approximately 140 Å [15].  
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Figure 1: Crystal structure of the GroEL-GroES complex [15]. GroEL is made 
up of two back to back rings shown in green and yellow, with one subunit 
picked out in blue in the top ring. The co-chaperone GroES is shown in pink 
and the location of ADP is shown in red in the top ring. 
 
Chaperonins operate in a nucleotide dependent cycle, with folding and 
release of the native substrate protein requiring ATP binding and 
hydrolysis. A conserved motif, GDGTT, is found in the nucleotide binding 
region of all chaperonins, which is located on the external face of the 
equatorial domain as shown in yellow in Figure 1 [16, 17]. The nucleotide 
interacts directly with some residues as well as with a Mg2+ cation found at 
the site [16, 17]. ATP binding and hydrolysis demonstrate positive 
cooperativity within a ring [18], while inter-ring binding of ATP shows 
negative cooperativity [19]. 
 
GroEL is a relatively promiscuous chaperonin thought to bind substrates of 
a range of sizes in a non-specific manner. This molecular chaperone is 
essential for the folding of some substrates, although the number of 
obligate substrates is much less than the number of proteins which can 
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associate with GroEL [20, 21]. The inside of the apical domain of the GroEL 
subunit contains a hydrophobic region which is important for the binding of 
both substrate proteins and for the co-chaperone GroES [22]. Smaller 
proteins can be encapsulated fully within the cavity, although some 
substrates appear to be too large to be enclosed in this way [23]. The 
mechanism of protein folding by GroEL was thought to be largely passive, 
with the cavity providing a protected environment in which proteins could 
attain their native state, possibly through several rounds of binding and 
release. In this way GroEL would act as an ‘Anfinsen cage’ to prevent any 
unwanted interactions with other components within the cell [24-26]. This 
may be the case for some substrates, although recent work has revealed 
certain features of GroEL which suggest a more active, or at least more 
specific, role for the chaperonin, such as the size of the cavity and the 
nature of the amino acids located at certain points of the apical domain 
[27]. Other work suggests that GroEL acts as a passive Anfinsen cage to 
prevent aggregation and allow folding of the substrate in a sequestered 
environment, following a similar trajectory to that observed at high dilution 
of the substrate [28]. 
 
A recent study has found that in the Group I plant chaperonin Cpn60 from 
chloroplasts in Arabidopsis thaliana, which is made up of two types of 
subunit, Cpn60α and Cpn60β, some subunits are required for substrate 
specificity while others play a more general role [29]. 
 
There are two forms that each ring of GroEL can adopt: the tense (T) state 
which has a higher affinity for substrate proteins, and the relaxed (R) state, 
which has a lower affinity for non-native substrates but a higher affinity for 
ATP [30]. Different conformations of the chaperonin complex are achieved 
according to the levels of nucleotide present, and TT, TR and RR 
complexes have been observed using cryo-EM [31, 32]. The overall state of 
the chaperonin varies throughout the folding cycle. Furthermore, the GroES 
binding properties of GroEL differ as the folding reaction progresses. A ring 
of GroEL bound to GroES is described as having a cis conformation, and 
forms a large enough cavity to fully encapsulate small substrate proteins of 
up to approximately 70 kDa in size and fold them via a cis folding 
mechanism (Figure 2) [33]. 
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Figure 2: Cis mechanism proposed for folding of small substrate proteins by 
GroEL [33]. A non-native substrate binds to the chaperonin and is 
encapsulated within the cavity by GroES. Following ATP hydrolysis in the cis 
ring and ATP binding in the trans ring, GroES is discharged and the 
substrate is released in either its fully folded form, or in a partially unfolded 
or misfolded state. The chaperonin can then bind another substrate protein. 
 
For larger proteins which cannot be fully contained within the chaperonin 
ring, a trans folding mechanism has been proposed, by which substrate 
proteins can be bound to the trans, or GroES-free ring [23]. The co-
chaperone binds to the opposite ring of the complex [33]. Smaller proteins 
can also be folded by the trans mechanism, but this is a more time 
consuming and inefficient process [34]. Figure 3 shows the mechanism of 
aconitase folding by GroEL, which proceeds via the trans mechanism [23]. 
 
 
Figure 3: Mechanism of folding of aconitase (Aco) by GroEL [23]. The 
substrate, which is too large to fit fully within the cavity of GroEL, is folded in 
an ATP driven cycle, then forms a stable complex between the apo form of 
aconitase (apoAco) and GroEL. The active holo form (holoAco) is formed by 
the binding of a Fe4S4 complex. 
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1.1.5 The Thermosome  
The thermosome is a Group II chaperonin found in archaea. As for GroEL, 
the thermosome is a double toroid structure with two rings of subunits 
surrounding a substrate binding cavity. The basic structure of each subunit 
is the same as for the bacterial chaperonin, with an equatorial, intermediate 
and apical domain. However, the apical domain of the Group II chaperonins 
has an extra helical extension which acts as a lid to close the cavity and 
removes the need for a co-chaperone equivalent to GroES. Furthermore, 
instead of rings made up of seven identical subunits, each ring of the 
thermosome from Thermoplasma acidophilum is made up of eight which 
alternate between the α subunit and the β subunit (Figure 4) [35]. 
 
 
Figure 4: Crystal structure of the hexadecameric thermosome from 
Thermoplasma acidophilum [35]. The α subunits are shown in red and the β 
subunits in blue. 
 
The substrate protein is encapsulated within one ring of the archaeal 
chaperonin, as for its bacterial counterpart. Binding of ATP to one ring does 
induce conformational changes with a 45° counter-clockwise rotation of the 
apical domains and partial closure of the lid [36], but ATP hydrolysis is 
required for full closure of the cavity [37]. Upon lid closure, subunits within 
the thermosome move as a single body, unlike GroEL in which the 
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conformation of the equatorial domains is very similar in both the open and 
closed states. This results in a large reduction of the volume of the cavity 
and renders the internal walls of the chaperonin highly hydrophilic in nature  
[38]. 
 
The thermosome and CCT are structurally very similar, although the 
repetition of subunits in the thermosome makes it slightly less complex. 
This has allowed the crystal structure of the α-only thermosome to be used 
as a basis for a model of the CCT structure which led Dekker et al to solve 
the crystal structure of the eukaryotic chaperonin [39, 40]. 
 
With regards to mechanism, studies of the thermosome have revealed 
significant differences between the Group I and Group II chaperonins [36-
38]. However, it does not necessarily follow that the mechanism of protein 
folding by CCT will be identical. The increased complexity and substrate 
specificity conferred by the eight different subunits within the eukaryotic 
chaperonin mean that conformational rearrangements and the manner of 
protein folding may well be different. As such, studies of the thermosome 
could prove useful as a starting point for mechanistic studies of CCT, but 
many features could differ, such as the nature of interactions between 
substrates and the chaperonin as the folding reaction progresses.  
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1.2 Chaperonin Containing TCP1 (CCT) 
1.2.1 CCT Structure and Function 
CCT has the same double toroid structure as GroEL and the thermosome. 
However, it is a more complex protein, and each ring consists of eight 
different subunits. These subunits are labelled CCT1 to CCT8 in yeast and 
CCTα to CCTζ in mammals. Each subunit has an equatorial and 
intermediate domain, as well as an apical domain which like the 
thermosome contains a helical protrusion which can act as lid for the 
chaperonin. Liou and Willison determined the arrangement of the subunits 
within the ring using the analysis of micro-complexes formed between 
different subunits in mouse testis as shown in Figure 5 [41]. 
 
 
Figure 5: The orientation of subunits within a ring of CCT from mouse testis 
from Liou and Willison [41]. 
 
The two rings of CCT are stacked directly on top of one another, with the 
equatorial domain of a subunit interacting with one subunit from the 
opposite ring, unlike GroEL where the rings are staggered [42]. The inter-
ring arrangement of CCT was first assigned in 2007 by determining EM 
structures of CCT bound to monoclonal antibodies [42] as shown in Figure 
6. More recently, based on evidence from the crystal structure [40], it was 
found that the rings are in fact shifted round by one subunit with respect to 
one another (Figure 7). This was not detected by EM as there is a slight 
twist to the subunit, so based purely on visualisation of the structure at 
lower resolution, the antibody would appear to be bound to a subunit further 
round the ring [40, 42]. 
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Figure 6: The original inter-ring arrangement of the subunits of CCT as 
determined by cryo-EM using antibodies which bind to CCTε and CCTδ [42]. 
 
 
Figure 7: The inter-ring arrangement of the subunits of CCT as determined by 
X-ray crystallography [40]. The order of the subunits within each ring is the 
same as in the previous arrangement (see Figure 6 [42]), however the rings 
are shifted one subunit with respect to one another, meaning that there are 
inter-ring homomeric interactions between CCTδ and CCTδ. For ease of 
comparison the mammalian annotation (CCTα-CCTθ instead of CCT1-8) of 
the subunits is used, although yeast CCT was used for the crystal structure. 
 
Intriguingly, the crystal structure of CCT reveals homomeric interactions 
between subunits CCT4 and CCT6 of the two rings (Figure 7). This was 
confirmed by making mutations in these subunits to switch the position of 
amino acids involved in two salt bridges identified in the structure at the 
inter-ring interface (K. R. Willison, unpublished results). Another interesting 
structural feature that can be seen in the crystal structure is that the N-
terminus of subunit CCT5 is found on the external face of the chaperone 
[40]. Possible roles include the interaction with CCT binding partners, or 
regulation of the cellular location of CCT through an interaction with actin 
filaments [43].  
 
One significant difference between CCT and GroEL is the manner in which 
ATP is hydrolysed. Hydrolysis of ATP by the eukaryotic chaperonin occurs 
in a sequential as opposed to a concerted manner [44]. Through 
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constructing mutations in the GDGTT motif in the ATP binding site in yeast 
CCT in vivo, a single firing direction for ATP binding and hydrolysis starting 
with CCT1 has been proposed [45]. In the crystal structure of CCT, only 
three subunits have fully occupied ATP binding sites: CCT5, CCT6 and 
CCT8 [40], which further demonstrates the difference in behaviour of the 
different subunits with respect to ATP binding and hydrolysis.  
 
CCT also displays nested allostery, with intra-ring positive cooperativity and 
inter-ring negative cooperativity with respect to ATP binding [46]. In the 
yeast mutant CCTanc2, which contains the G345D mutation in subunit 4 of 
the chaperonin, this allostery is lost, demonstrating that single mutations 
can have a very significant effect on the allosteric behaviour of the 
chaperonin. Despite this huge effect on ATP allostery, only a two-fold 
decrease in the yield of native actin is observed [47].  
 
1.2.2 CCT Interactome 
CCT is known to interact with many different proteins, with upper estimates 
suggesting that as many as 9 to 15 % of newly synthesised proteins bind to 
the chaperonin [48], although only a few are known to be obligate 
substrates. Identifying the role of the other proteins requires more work; 
many could act as cofactors or have another role in the assembly of 
correctly folded proteins. Various high-throughput studies have identified 
proteins that interact with CCT, and importantly there have been two 
studies in which the interactome of CCT was investigated specifically. 
Dekker et al [49] used mass spectrometry (MS) to identify proteins bound to 
yeast CCT purified by a calmodulin binding peptide (CBP) tag inserted into 
the chaperone followed by sucrose gradient centrifugation. Proteins 
involved in a wide range of cellular processes were identified, including the 
cell cycle and TOR signalling pathways, chromatin modification and the 
cytoskeletal network. A strong link was found to septins, a group of proteins 
involved in budding in yeast, with significant effects on the cellular 
localisation of septin patches in some yeast strains containing mutant CCT 
[49]. Another study of CCT interacting proteins found that 7 % of the 
proteins studied associate with CCT following translation [50]. With 
widespread influences on many pathways in the cell, it is likely that CCT is 
essential for cell viability, and further work is required to identify the full 
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range of obligate substrates and the role that the chaperonin plays in 
protein folding and complex formation. 
 
1.2.3 Substrates 
1.2.3.1 Actin and Tubulin 
The most well-known and best characterised substrates of CCT are the 
cytoskeletal proteins actin and tubulin. These are essential components of 
the cell and form filaments which not only give structure to the cell but also 
provide tracks for the motor proteins myosin, kinesin and dynein. These 
motor proteins work in an ATP-dependent manner and are involved in 
processes such as muscle contractions, movement of flagella and cilia, and 
the transport of vesicles [51]. Actin is discussed in section 1.3. 
 
Although actin and tubulin bind to GroEL, they are not released in their 
native form and require CCT in order to fold correctly [52]. Structural 
studies of complexes formed between actin and tubulin and CCT have 
been carried out using cryo-EM to reveal the binding of the substrate 
across the central cavity. Actin and tubulin interact with different CCT 
subunits, but they bind in a similar way with the protein in an ‘open’ 
conformation across the chaperonin. Actin binds in a 1:4-conformation 
(Figure 8), interacting with CCTδ and either CCTβ or CCTε [53].  
 
 
Figure 8: Structure of actin bound across the cavity of CCT [53]. 
 
Tubulin also binds to the apical domains of CCT subunits across the cavity, 
but in a 1:5-conformation. Again, two possible modes of binding have been 
observed; in the first, one domain of tubulin interacts with CCTε and the 
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other with CCTβ, CCTγ and CCTζ, whereas in the second one domain 
binds to CCTζ and the other to CCTε, CCTδ and CCTβ [54] (Figure 9). 
Consequently, the binding of tubulin is a more complex process. 
 
 
Figure 9: Structure of tubulin bound to CCT [54]. 
 
There are differences to the overall structure of CCT with tubulin bound 
across the central cavity compared to the actin-bound complex. In the 
tubulin-bound complex, the apical domains adopt a semi-closed position, 
whereas the actin-bound complex resembles the substrate-free chaperonin 
[54]. Actin is seen to bind below the helical protrusion of the apical domain, 
lower down than tubulin, which binds to a larger area including some of the 
helical protrusion of the subunit [40, 54].  
 
The partially folded substrate binds to the open complex, and upon binding 
of ATP to CCT the apical domains of the chaperonin undergo a large shift 
to close the central cavity of the complex, rotating round to enclose the 
substrate protein. EM studies of the complex reveal that both actin and 
tubulin then take on a conformation that is very similar to that of the native 
monomer, but remain bound to the apical domains of the chaperonin [44]. 
This is consistent with later studies looking at FRET within the actin-CCT 
complex which show that as the cavity of the chaperonin is closed, actin 
takes on a more compact structure [55]. The sequential nature of ATP 
binding and hydrolysis by CCT could well reflect the specificity of the 
folding reaction, perhaps with different stages of folding and release being 
associated with hydrolysis at different subunits. This would allow the 
chaperonin to play a more active role in the folding of substrates and the 
releasing of substrates in their native form within one folding cycle, in 
33 
 
contrast to GroEL which can take several cycles to complete the folding of 
a protein [56]. The mechanism of actin folding is discussed in Chapter 8. 
 
1.2.3.2 WD40 Repeat-containing Proteins 
Many proteins have been found to contain a motif known as a WD40 repeat 
domain, which ranks among the top ten most abundant domains in 
eukaryotes [57]. Each repeat consists of a sequence of approximately 40 
amino acids, with conserved tryptophan and aspartic acid residues (or WD) 
towards the C-terminus [58]. A β-propeller structure is formed, with each 
blade consisting of the WD40 repeat which is made up of four antiparallel β 
strands. The strands are labelled A to D, with A being the innermost strand 
of the blade [59]. The WD40 motif is found across many species and 
proteins and is involved in a variety of processes from cell division, 
apoptosis, and mRNA synthesis to chromatin assembly. The diversity of 
function combined with the frequency of occurrence of the motif across 
different species implies that it has existed since very early in the 
development of eukaryotes [58, 60]. 
 
The crystal structure of the WD40 propeller has been solved in a variety of 
proteins, the first of which was the 7-bladed G protein β subunit [61]. The 
propeller has a toroid structure, which forms a rigid platform that can be 
used to bring other proteins together, thereby allowing them to interact with 
one another. Loops between the β-strands give functionality to the surfaces 
of the protein, which leads to the wide range of roles of WD40 repeat-
containing proteins despite having similar sequences and structures [58, 
61]. Figure 10 shows the structure of the WD40 domain of the WD40 repeat 
containing protein Ski8p, which also contains seven repeats [62]. The 
propeller is held together by a ‘structural tetrad’ consisting of four 
conserved amino acids within each blade. A hydrogen bonding network is 
formed between a tryptophan residue found in strand C, either a serine or a 
threonine residue in strand B, a histidine located in the loop between 
strands D and A, and an aspartic acid residue between strands B and C 
[63]. 
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Figure 10: The WD40 propeller found in Ski8p, which is made up of seven 
repeats labelled 1 to 7. Each repeat forms a blade of the propeller from 
antiparallel β-strands, strand 7D (blue) is located at the N-terminus while 
strands 7A, B and C are located at the C-terminus (red) of the polypeptide 
chain [62]. 
 
In order to form the propeller, the N- and C-termini must be brought 
together. Strand 7D is located at the N-terminus of the motif, preceding 
strand 1A in the amino acid sequence (Figure 10). The mechanism by 
which this occurs is likely to be different for different proteins, as some 
WD40-repeat containing proteins require CCT in order to fold correctly, 
whereas others do not interact with the chaperonin [64]. Studies of the 
interaction between yeast Cdc20 and CCT [65] have revealed that CCT is 
essential for the formation of the native Cdc20. It was also demonstrated 
that a region in blades 3 and 4 of the propeller, as well as some residues of 
blade 5, were important for binding to the chaperonin. Analysis of the CCT 
binding regions of actin using alanine scanning revealed a sequence ILASL 
that is required for CCT binding, with a similar sequence, ILAS, being 
located in the CCT binding region of Cdc20. These residues were also 
found to have an effect on CCT binding [66]. The cavity within CCT is of a 
comparable size to the WD40-repeat domain of Cdc20 and Cdh1, so it is 
likely that this region is folded within the cavity of the CCT complex [67] 
(Figure 11). 
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Figure 11: A model of the Gβ-transducin superimposed on the cavity of CCT. 
The WD40 domain is of a comparable size to the cavity within the chaperone 
[67]. 
 
1.2.3.3 Other Substrates 
As mentioned above, many CCT-interacting proteins have been identified, 
although many of these are likely to act as co-factors and assist in the 
loading and folding of other substrates. Known CCT substrates include the 
Von Hippel-Lindau (VHL) tumour suppressor, an E3 ubiquitin ligase 
involved in substrate recognition for the VHL protein complex [68]. Two 
regions of the protein, Box1 and Box2, are required for binding to a 
hydrophobic region of the cavity of the chaperonin [69]. The cytosolic 
protein Gα-transducin [70], the cell cycle control protein cyclin E [71] and 
the hepatitis B virus capsid protein [72] also require CCT for folding and 
assembly. 
 
1.2.4  Phosducin-Like Proteins 
Phosducin is a phosphoprotein with a structure based around a core 
thioredoxin fold (Figure 12). Phosducin-like proteins, often abbreviated to 
PhLPs, have a similar structure to phosducin, consisting of the thioredoxin 
fold surrounded by a helical domain located at the N-terminus and a 
charged region at the C-terminus [73]. They can be divided into three 
groups, PhLP1, PhLP2 and PhLP3, all of which have been found to 
associate with CCT [74].  
50Å
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Figure 12: The 2.70 Å crystal structure of the thioredoxin fold domain from 
human phosducin-like protein 2 [75]. 
 
In yeast there are two PhLPs, PLP1, which corresponds to PhLP3, and 
PLP2 corresponding to PhLP2. These interact with CCT to assist in the 
folding of actin and tubulin [76, 77]. The precise function of this interaction 
is not known. However, it has been demonstrated that PLP1 can form a 
stable ternary complex with CCT and tubulin [77], whereas PLP2 forms a 
complex with CCT and actin, and improves the efficiency of actin folding 
[76]. Interestingly, PLP2 is essential for cell growth whereas PLP1 is not 
[74, 77-79], suggesting that the functions of PLP1 can be performed by 
other proteins whereas those of PLP2 cannot.  
 
Mapping of the CCT and actin binding sites on PLP2 has been performed 
by the analysis of complexes formed between truncated forms of PLP2 and 
either CCT or actin, as well as by the inhibition of actin binding in the 
presence of a monoclonal anti-PLP2 antibody [76]. CCT-binding 
information is contained in residues 60-89 of PLP2, towards the N-
terminus, whereas actin binds at the C-terminal region of the thioredoxin 
fold [76] (Figure 13). Crosslinking studies have shown interactions between 
CCT1, CCT4 and CCT8 and PLP2 [40]. 
 
 
Figure 13: Diagram of the PLP2 sequence showing the thioredoxin fold 
domain (TRX, light blue), the CCT-binding region between residues 60-89 of 
PLP2 (red) and the actin-binding region (green lines). 
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In a recent analysis of the apical domain of CCT it has been shown that 
there is a region which significantly resembles peroxiredoxin, a thioredoxin-
like protein. This is true of the Group I and Group II chaperonins, and 
signals that the insertion of a peroxiredoxin was a prominent early event in 
the evolution of chaperonins. That CCT interacts with many proteins 
containing thioredoxin folds could also be explained in this way [80]. 
 
PLP2 can be used in a purified in vitro folding assay with yeast CCT and 
actin (see section 6.2 for further details) [76]. In contrast, using 
radiolabelled human β-actin and rabbit CCT in an in vitro 
transcription/translation system, the human orthologue of PLP2, PDCL3, is 
unable to fold actin [76]. Comparison of the sequences of PLP2 and PDCL3 
shows that the C-termini of the two proteins are very different, and 
replacement of the PDCL3 C-terminus with that of PLP2 returns actin 
folding activity to the system [76]. Regulation of PDCL3 is likely to be 
regulated by phosphorylation, so as work on the more complex mammalian 
system progresses, it might be possible to fold β-actin within a purified 
system [76]. In the meantime, the discovery of PLP2 as a cofactor for CCT 
in yeast greatly enhances the possibilities for studying this relatively simple 
but undoubtedly related actin folding process, and I have investigated this 
system in this thesis. 
 
1.2.5  Role in Disease 
Playing such an important role in the regulation of protein folding in 
eukaryotes, it is likely that CCT is associated with a range of diseases. For 
example, CCT is required for cell proliferation [81], and differential 
expression of CCT subunits has been identified by proteomic analysis in a 
range of different cancers including colorectal, oesophageal and breast 
cancer, although the role of CCT in these processes requires further 
elucidation [82, 83]. Differential expression of CCT subunits also appears to 
be a factor in the healing of wounds without a scar; in a rabbit model it has 
been found that CCTε is underexpressed in fetal fibroblasts relative to the 
levels present in adult fibroblasts. This was not the case for CCTβ [84]. 
 
The subunits of CCT share a high level of homology with some proteins 
involved in Bardet-Biedl syndrome (BBS) [85, 86]. BBS is a genetic 
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condition which results in symptoms such as obesity, mental retardation, 
polydactyly and retinal degeneration [87]. One of the proteins implicated, 
BBS6, evolved from CCTα relatively recently, although there is less 
homology than between  CCT subunits, and perhaps significantly, the 
sequence at the ATP hydrolysis site of CCT is particularly different [85]. It 
has been found that the proteins BBS6, BBS10 and BBS12 interact with 
several CCT subunits, and CCT is essential for the formation of the 
BBSome [86].  
 
A mutation in BBS6, G345E, causes BBS, which is associated with defects 
in the formation of cilia [85]. Interestingly, in Tetrahymena, the CCT 
subunits CCTα and CCTδ are important for assembly of cilia [88]. The 
G346E mutation in CCTα, which is equivalent to the aforementioned 
mutation in BBS6, leads to temperature sensitivity, with misshapen, slowly 
growing cells at 30°C relative to 16°C [88]. This could indicate that CCTα is 
able to perform the role of BBS6 in non-vertebrate systems [88], and further 
demonstrates the similarities that exist between these two proteins which 
share the same evolutionary root.  
 
The effect of mutations in CCT substrates can also play a role in disease. 
For example, certain mutations in α-skeletal muscle actin result in 
congenital myopathies. In some severe cases, these mutants remain 
trapped on CCT and are unable to go through a functional cycle of folding 
and release [89]. 
 
CCT has been found to interact with proteins from viruses such as the 
influenza virus [90] and Mason-Pfizer monkey virus [91]. These studies 
indicate a role for the chaperonin in the life cycle of viruses. A greater 
understanding of the way in which CCT works to assist protein folding 
should allow greater insight into the role of the chaperonin in disease.  
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1.3 Actin 
1.3.1 Structure of G-actin 
The crystal structure of G-actin was first solved for the DNase I bound form 
by Kabsch et al. [92] (Figure 14). They found that the structure was very 
similar for both the ATP and ADP bound form, with two domains, a large 
and a small domain, surrounding the nucleotide binding site and a high 
affinity dication binding site in a central cleft. Actin can be further split into 
four subdomains, with a linking hinge between the two main regions joining 
subdomains 1 and 3 [92]. Both the N- and C- termini are located in 
subdomain 1, which also contains the four tryptophan residues found in 
actin. Subdomain 1 and subdomain 2, which contains the flexible DNase I 
binding loop, make up the small domain, which is actually similar in size to 
the large domain which is comprised of subdomains 3 and 4 [92]. 
 
Actin was first crystallised without an actin-binding protein in 1977 [93], 
although these crystals were too small for X-ray diffraction, and the 
uncomplexed structure was only published in 2001 [94]. 
 
 
 
Figure 14: Structure of the G-actin monomer with ATP (purple) and Ca
2+
 
(yellow) bound in the central cavity [92]. 
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1.3.2 Structure of the F-actin Filament 
The actin filament is an essential element of the cytoskeleton in eukaryotes. 
A parallel double helix is formed with a barbed and a pointed end, which 
can grow rapidly through polymerisation at the barbed end of the filament 
[95]. Crystallisation of the F-actin filament has not been achieved, and as 
such models of the F-actin filament are based around data from X-ray 
diffraction and the structure of the monomer. The Holmes model of F-actin 
[96] was published at the same time as the structure of the actin monomer 
in 1990 [92]. More recently a high resolution model based on high 
resolution X-ray diffraction data was published by Oda et al in 2009 [97], 
and a further model which incorporates the Oda model but also maintains 
the stereochemistry within the actin monomer was published by 
Splettstoesser et al [98]. The structure of the monomer within F-actin is 
similar to that of G-actin. The main difference is that while the monomer 
has a twisted structure between the large and small domains, in the 
filament the arrangement of these two domains is more planar, going 
through a twist of approximately 20° [97, 98]. 
 
Subdomain 3 interacts primarily with subdomain 4 of the neighbouring 
monomer, while the C-terminus of actin interacts with the DNase I binding 
loop [96]. A helical filament with a maximum diameter of 90 to 95 Å is 
formed with the large domain of actin near the axis [96]. Significantly, many 
of the interactions formed between actin monomers in the F-actin filament 
are also involved in binding to CCT [99]. 
 
1.3.3 Actin Unfolding 
Actin can be chemically unfolded to a partially folded intermediate which 
can then only be refolded by CCT. This process has been studied for rabbit 
skeletal muscle α-actin by stopped flow, which revealed a series of 
intermediates along the unfolding pathway (equation 1) [100]. 
N.ATP.Ca2+ I1.ATP + Ca
2+ I2 + ATP I3
  (1)
 
Ethylenediaminetetraacetic acid (EDTA) can chelate the divalent cation 
bound at the centre of the native actin monomer N, leading to the formation 
of an ATP-bound intermediate I1. ATP is then rapidly lost leading to the 
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formation of intermediate I2 which can spontaneously rearrange to form the 
stable intermediate I3 which can then bind to CCT [100].  
 
1.3.4 Actin Folding 
Many studies have been performed on protein folding by the bacterial 
chaperonin GroEL, but there are fewer investigations into the kinetics of 
protein folding by CCT. The complex nature of the eukaryotic chaperonin 
makes folding by CCT harder to study. For example, CCT cannot be 
directly labelled in a selective manner, and as discussed in Chapter 5, 
introduction of a fluorophore by binding of a fluorescently labelled 
calmodulin to the CBP tag in CCT is not suited to studies of protein folding 
due to the flexibility of the tag and the additional distance introduced. 
Therefore, labelling of CCT is not a practical method to study 
conformational changes during the folding cycle of actin. However, it is 
possible to monitor the actin molecule itself during the folding process. 
 
Actin contains four tryptophan residues, all of which are located in 
subdomain 1. Of these, two contribute significantly to the intrinsic 
fluorescence of actin [102]. While intrinsic tryptophan fluorescence has 
been used to investigate the unfolding of rabbit skeletal muscle α-actin 
[100], it cannot be readily applied to the study of actin folding by the CCT 
due to the presence of so many fluorescent amino acid residues within the 
subunits of the ternary chaperonin complex.  
 
There are four cysteine residues in the actin sequence, only one of which is 
labelled when the protein is incubated with a thiol-reactive dye. This 
residue, Cys 374, is the penultimate amino acid in the actin sequence and 
in the G-actin monomer is located near the hinge region joining the large 
and small domains [94] (Figure 15). Labelling of actin at this pivotal region 
in the folding process is very useful in studies of the reaction, since 
changes in the environment of a fluorophore at this site can be used to 
understand the events that occur during the folding process. I have used 
this method in this thesis to investigate the transition from the unfolded, 
CCT-bound actin to native actin, and the development of a spectroscopic 
actin folding assay is discussed in Chapter 6. 
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Figure 15: The crystal structure of actin bound to ADP (light blue) and Ca
2+
 
(orange), and labelled at Cys 374 with tetramethylrhodamine (purple) in 
subdomain 1 (yellow) [94]. 
 
While GroEL is likely to play a relatively passive role in the folding of 
substrate proteins, it seems probable that CCT takes a more active part in 
the actin folding process. This can be seen from the specific interactions 
between certain CCT subunits and the actin monomer [53], as well as 
evidence from homo-FRET experiments in which the actin monomer is 
stretched across the cavity of the chaperonin [55, 101]. The extent to which 
CCT is able to manipulate the substrate molecule is as yet unknown; while 
it may be released into the cavity at some stage to allow folding to occur, 
the substrate protein could well remain tethered to the chaperonin 
throughout the folding process. 
 
A pure in vitro folding assay has been established for Act1 involving CCT 
and PLP2 (see section 6.2), however rabbit α-actin cannot be folded by this 
system [76]. Furthermore, although PLP2 has a stimulatory effect on actin 
folding, the human orthologue PDCL3 is inhibitory [76], demonstrating 
significant differences between the phosphorylation control mechanisms for 
yeast and mammalian actin folding (K. R. Willison, unpublished results). As 
such, only folding of Act1 can be studied in this folding assay as yet. Act1 is 
more stable to unfolding than rabbit α-actin [103], but through introduction 
Subdomain 1
Subdomain 2
Subdomain 3
Subdomain 4
The crystal structure of G-actin (Otterbein et al), with
ADP (light blue) bound in the nucleotide binding cleft
and Ca2+ (orange). Actin is labelled at C374 with
tetramethylrhodamine (TAMRA, purple)
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of a fluorescent label, Alexa Fluor 488 labelled Act1 (488Act1) can be 
unfolded onto CCT in the presence of the 10 % v/v glycerol required to 
stabilise the chaperone in three hours [76]. The introduction of an 
exogenous probe allows much more scope in the study of actin folding 
kinetics. Intrinsic tryptophan fluorescence within the actin monomer is 
masked by CCT, whereas labelling the substrate protein with a fluorophore 
allows the folding reaction to be studied spectroscopically. In the in vitro 
folding assay developed by McCormack et al. [76], 488Act1 folding was 
monitored by native polyacrylamide gel electrophoresis (PAGE), allowing 
the rate of folding of 488Act1 to be studied under different concentrations of 
ATP and MgCl2. The limitations of this technique are that the time 
resolution and accuracy is limited by the number of data points that can be 
taken, and slight errors in sample collection or loading of the gel within a 
folding time course can affect the results and make quantification difficult. 
However, this assay is visually easy to interpret, and allows ready 
discrimination between actin released in a native and non-native state. It 
also demonstrates that actin is not only folded by the chaperonin but is 
released in its native state which can be confirmed through binding to actin 
binding proteins. 
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1.4 Techniques for Investigating Protein Folding 
Protein folding is a complex process and there are many techniques which 
can provide some insight into the mechanism by which this occurs. A 
combination of theory and experiment can be used to characterise fully the 
mechanisms by which proteins can fold. Simulations of protein folding can 
provide a lot of information on the details of the process with regards to the 
transitions which take place and the probable sites at which interactions will 
occur, but are dependent on knowledge of the structure(s) of the protein. 
Calculations must then be backed up by experimental evidence to confirm 
the theory. Knowledge of mutations likely to affect the protein structure and 
function derived from simulations can assist greatly in the design of suitable 
experiments. This is because it suggests amino acids that are important for 
stability or are involved in reactions, providing a useful starting point for 
mutation studies of the protein of interest.  
 
1.4.1 Protein Folding Simulations 
Once a high resolution structure of a protein has been determined, or that 
of another protein with a high level of homology with the protein of interest, 
simulations can be carried out to investigate conformational 
rearrangements which occur or differences in the structure which will come 
about as a result of mutations. These can be very informative with regards 
to the mechanism by which a protein folds, since they can show transitions 
which occur as the reaction progresses. Simulations are useful for 
reactions which occur over a short period of time, which would not be 
accessible using experimental techniques. However, the size of a protein 
means that these calculations are computationally very expensive, and 
therefore transitions which occur over a longer period of time cannot be 
investigated. In order to minimise the number of calculations, a particular 
region of interest may be focused upon. Alternatively, a mutation may be 
considered to affect only those amino acids directly in contact with it, with 
the remainder of the protein considered to be unchanged from its native 
state. Some protein folding simulations include ‘chaperonins’ in which 
forces are applied to the model in order to simulate the environment of the 
cavity of the chaperonin [104, 105]. Properties that cannot be studied 
experimentally, such as cavity size, can be simulated in order to study the 
mechanism by which folding occurs [106]. 
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1.4.2 Fluorescence Techniques 
Fluorescence is a useful tool to investigate conformational changes within 
proteins. Different techniques can provide different but complementary 
information, such as the composition of protein complexes, and distances 
and environments within a complex either at given points in time or 
continuously throughout the course of a reaction. Some methods suitable 
for studying the folding of proteins using fluorescence are discussed below. 
 
1.4.2.1 In-Gel Fluorescence 
Fluorescently labelled proteins can be visualised on polyacrylamide gels 
using excitation of the fluorophore with an appropriate light source. The gel 
is then scanned at the emission wavelength. SDS PAGE can be used to 
identify proteins which are fluorescently labelled based on their size, 
whereas native PAGE can demonstrate the formation of protein complexes. 
Bands can be quantified to determine the amount of the fluorescent protein 
present in each lane. This is used to monitor changes in composition within 
a complex as a reaction proceeds. However, there is limited time 
resolution, so in order to study the kinetics of a reaction this procedure is 
used in conjunction with a time-resolved technique which monitors the 
reaction more continuously. 
 
1.4.2.2 Förster Resonance Energy Transfer 
Fluorescence (or Förster) resonance energy transfer (FRET) occurs when 
two fluorophores, a donor with an emission spectrum that overlaps with an 
acceptor absorption spectrum, are in sufficiently close proximity for non-
radiative transfer of energy to occur between the two. This can be used to 
determine distances between the two fluorophores, as the efficiency of 
energy transfer is inversely proportional to the sixth power of the distance 
between the two fluorophores [107]. FRET can be used to measure 
distances comparable to the Förster distance, R0, of the FRET pair. R0 is 
defined as the distance at which the efficiency of energy transfer is 50 %, 
and can range from 20 to 90 Å. It is given by equation (2) [107]: 
 
R0 = 0.211[κ
2n-4QDJ(λ)]
1/6 (2) 
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where κ2 is an orientation factor relating to the donor and acceptor 
fluorophores, n is the refractive index of the sample, QD is the donor 
quantum yield and J(λ) is the overlap integral which is based on the overlap 
between the donor emission spectrum and the acceptor absorbance 
spectrum. The efficiency of energy transfer is related to the distance 
between the two fluorophores, R, by equation (3) [107]: 
 
E = R0
6 / (R0
6 + R6)  (3) 
 
There are two ways in which FRET can be measured; with steady-state 
measurements a decrease in the donor emission and an increase in the 
acceptor emission are observed, whereas with time-resolved FRET a 
change in the lifetime of the donor fluorophore is measured. Steady-state 
FRET is frequently used to study binding interactions, whilst the time-
resolved measurements are used for determination of distances [107].  
 
Generally a FRET pair of fluorophores will consist of two different dyes with 
different absorption and emission spectra. This approach should be 
referred to more precisely as hetero-FRET. Energy transfer can also occur 
between identical fluorophores with overlapping absorption and emission 
spectra. This is known as homo-FRET, and can be much simpler as the 
two fluorophores can be introduced by the same method. Although no 
change in the emission spectra is observed, the relative orientation of the 
fluorophores means that a change in anisotropy is observed when energy 
transfer is taking place [108]. Homo-FRET has been used to observe 
conformational changes within actin upon binding to the CCT and folding 
[55, 101], and protein folding within the cavity of GroEL has been 
investigated by measuring FRET between intrinsic tryptophan residues and 
an external 5-(2-acetylaminoethylamino) naphthalene-1-sulfonic acid 
(AEDANS) tag bound to human carbonic anhydrase II [109]. FRET is suited 
to the study of changes in conformation because relative values rather than 
absolute distances are required.  
 
1.4.2.3 Stopped Flow 
Stopped flow is a technique used to monitor the progression of a reaction 
over time. The components of the reaction are rapidly injected from 
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separate syringes into a sample chamber then the flow is stopped, meaning 
that the components are rapidly and efficiently mixed. A change in the 
fluorescence of the sample is measured allowing continuous monitoring 
throughout the reaction. This change can be due to FRET, or due to a 
change in the environment surrounding the fluorophore as is the case of 
intrinsic tryptophan fluorescence. The type of equipment used affects the 
mixing time which in turn affects the minimum time period which can be 
observed. By observing the course of the reaction at different wavelengths, 
the spectra of the starting product and the final product can be obtained, 
and spectral deconvolution can be used to identify intermediates in the 
process. This technique was used to investigate actin unfolding using the 
intrinsic tryptophan fluorescence which is sufficiently different between the 
native and unfolded forms, as was discussed in section 1.3.3 [100]. 
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1.5 Fluorescent Labelling of Proteins 
1.5.1 Intrinsic Tryptophan Fluorescence 
Some naturally occurring amino acids are fluorescent and as such many 
proteins have an intrinsic fluorescence. These are the aromatic amino acids 
tryptophan, tyrosine and phenylalanine. Of these, intrinsic tryptophan 
fluorescence is most frequently used as it has the highest extinction 
coefficient and can be selectively excited over tyrosine and phenylalanine 
at 295 nm [110]. Intrinsic tryptophan fluorescence can be a useful tool to 
investigate conformational changes within proteins as it is environmentally 
sensitive. The wavelength and intensity of tryptophan fluorescence can be 
used to report on the state of a protein. The main advantage of this 
technique is that no external probe has to be introduced, and it can be used 
for techniques such as stopped flow (section 1.4.2.3). However, in order to 
probe fluorescence at a particular site, mutation of any naturally occurring 
tryptophans is required, as well as insertion at the desired location. The 
small size of the amino acid relative to many exogenous fluorophores 
means that it will have less impact on the local structure within a protein. 
Also, when labelling with a fluorophore, the accessibility of the site is an 
important consideration, whereas as long as the mutation does not affect 
the stability of the protein, introduction of a tryptophan should not pose this 
problem. The major disadvantage of intrinsic tryptophan fluorescence is the 
prevalence of tryptophan residues within proteins. Particularly in large 
proteins, it can be hard to distinguish between the contributions from 
different residues, and there may be little change in the global emission 
spectrum of the protein. This is the case in the ternary Act1-CCT-PLP2 
complex, where individual contributions from tryptophan residues cannot be 
distinguished from one another. 
 
1.5.2 Fluorescent Proteins 
The discovery of green fluorescent protein (GFP) and its incorporation as 
an in vivo fluorescent tag revolutionised the way in which processes could 
be observed within cells, and as such Shimomura, Chalfie and Tsien were 
awarded the Nobel Prize in Chemistry 2008 for their roles in the discovery 
and use of GFP [111]. GFP was first isolated from jellyfish in the 1960s 
[112]. It is now used as a fusion protein to visualise the protein of interest 
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within cells, and a variety of mutations yielding different coloured 
fluorescent proteins have been developed which allow labelling with 
multiple colours within an organism and FRET studies to be carried out 
[113]. 
 
While fluorescent proteins are very well suited to the study of cellular 
location of a protein of interest, they are less appropriate when investigating 
systems in vitro. These large, bulky fluorophores can be as large as the 
protein to which they are attached and as such cannot be used for 
measurements of distance by FRET (see section 1.4.2.2), only the 
proximity of two probes. Furthermore, the probe could interfere with the 
structure or any interactions of the protein, which is always a potential 
problem with introducing a fluorescent label but is particularly the case for a 
fluorophore of this size.  
 
1.5.3 Small Molecule Fluorescent Probes 
As the applications of fluorescent labelling of proteins have become 
increasingly widespread, a diverse range of small molecule fluorescent 
probes have been developed for the introduction of an exogenous label. 
Typical probes contain either a thiol-reactive group, such as a maleimide, 
or an amine-reactive group such as an N-hydroxysuccinimidyl (NHS) ester. 
Labelling of amines is fairly non-specific since the majority of proteins have 
many accessible amine groups. The relatively infrequent occurrence of 
cysteine residues in proteins means that the use of a thiol-reactive 
fluorophore generally results in much fewer labels within a protein. Site-
directed mutagenesis can be used to remove some residues to allow a 
single labelling site within the protein. Labelling of amines can be useful if 
the aim is simply to visualise the protein, for example antibody labelling. 
However, for many applications it is better to label proteins at known 
positions. Labelling of cysteine residues is one of the most commonly used 
methods, although other techniques exist such as native chemical ligation 
(NCL) which allows selective labelling of an N-terminal cysteine in the 
presence of other thiol groups. This method is discussed in section 4.3.5. 
 
Many commercially available small molecule probes are derivatives of 
either fluorescein or rhodamine (Figure 16). The excitation and emission 
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spectra for fluorescein and carboxytetramethylrhodamine (TAMRA) are 
shown in Figure 17. There is a significant overlap of the emission spectrum 
of fluorescein and the excitation spectrum of TAMRA, making them suitable 
as a FRET pair, so combinations of these dyes and their derivatives are 
frequently used in this way. 
 
Figure 16: The structures of fluorescein, carboxymethylrhodamine, and Alexa 
Fluor 488 [114], a commonly used derivative of fluorescein. 
 
Figure 17: The excitation (dashed line) and emission (solid line) spectra for 
fluorescein (green) and carboxytetramethylrhodamine (blue) [115]. 
 
Fluorescein is inexpensive and readily available, and its maximum 
excitation and emission wavelengths are around 494 nm and 521 nm 
-
3 3
- -
Carboxytetramethylrhodamine (TAMRA)
Fluorescein (FITC)
Alexa Fluor 488 C5 maleimide
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respectively, depending on the solvent [114]. Many variations on this 
structure have been developed in order to increase the photostability and 
quantum yield and to reduce changes in emission due to pH. Perhaps the 
best known of these is Alexa Fluor 488 (Molecular Probes), but other 
companies have also developed equivalents such as PromoFluor 488 
(PromoKine) and HiLyte Fluor 488 (Anaspec). Other red dyes include Alexa 
Fluor 555 and Alexa Fluor 568 (Molecular Probes).  
 
The cyanine dyes are also used as small molecule probes and these have 
a different structure to that of fluorescein and rhodamine (Figure 18). The 
emission wavelength can be adjusted from below 500 nm to over 750 nm, 
and varies greatly depending on the length of the linker within the molecule 
[116]. These dyes are categorised according to this linker, with Cy3 at 
around 590 nm and Cy5 generally over 650 nm [116]. 
 
 
Figure 18: The structure of a Cy3 dye, which contains a three carbon linker 
[116]. 
 
Smaller dyes exist which fluoresce at lower wavelengths. Some examples 
of these are 5-({2-((iodoacetyl)amino)ethyl}amino)naphthalene-1-sulfonic 
acid (IAEDANS) and acrylodan (Figure 19). Free acrylodan has a low 
quantum yield, however upon reaction with a thiol prodan is formed, a dye 
designed to be highly sensitive to changes in polarity, leading to much 
increased fluorescence [117].  
 
Cy3
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Figure 19: The structure of IAEDANS, prodan, and the thiol reactive 
derivative of prodan acrylodan. 
  
IAEDANS Prodan
Acrylodan
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2 Project Aims 
2.1 Folding of Cdh1 by CCT 
The aim of this work is to investigate protein folding by the chaperonin 
CCT, looking at two known obligate substrates, Cdh1 and actin. Using 
expression and selective labelling of a fragment of the WD40 repeat-
containing protein Cdh1 with a donor fluorophore, the interaction with the 
chaperonin is studied by FRET. A second fluorophore is selectively 
introduced into the complex using a fluorescently labelled calmodulin that 
binds to the CBP tag located in either CCT3 or CCT6. The aim of this is to 
identify the subunit(s) involved in the interaction between this region of the 
WD40 propeller and the chaperonin by calculating the relative distances 
between the donor fluorophore attached to the substrate protein and the 
acceptor on calmodulin bound at the two different sites on CCT. 
 
2.2 Folding of Act1 by CCT 
Actin folding is one of the key functions of CCT, and a pure in vitro folding 
assay has been developed to follow the reaction by native PAGE. This 
assay is adapted to allow the folding reaction to be followed 
spectroscopically, thereby allowing a greater range of folding conditions to 
be studied and compared. This is done through the labelling of actin with an 
environmentally sensitive fluorophore at the highly reactive cysteine located 
at the C-terminus. This location is ideal for labelling in order to monitor the 
folding reaction, since it is situated at the hinge region between the large 
and small domains which are known to bind across the cavity of the 
chaperonin in the open, nucleotide-free complex. By monitoring changes in 
the fluorescence as the folding reaction progresses, the kinetics and 
mechanism of actin folding by both wild-type and mutant CCT is studied.  
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3 Methods and Materials 
3.1 Protein Purification 
In order to study the folding of Cdh1 and Act1 by CCT, several proteins had 
to be purified. CCT and Act1 were purified from yeast lysate, while 
fragments of Cdh1, PLP2 and CaM were overexpressed in E. coli and 
purified by affinity chromatography using tags inserted into the sequence. 
 
Proteins expressed in E. coli were overexpressed in BL21(DE3) competent 
cells, using pET11b as the expression vector. CBP-tagged CCT and actin 
were expressed in the yeast strain BJ2168.  
 
3.1.1 Purification of CCT 
S. cerevisiae lysate overexpressing CCT3-CBP, CCT6-CBP or CCTanc2 
(Clare Hall) was transferred to a 250 ml centrifuge tube (Corning). The 
following were added per 100 ml of lysate: one protease inhibitor tablet 
(Roche Complete EDTA-free, dissolved in 500 μl H2O), 200 μl CLAP 
(Chymostatin, 5 mg/ml, Leupeptin, 10 mg/ml, Antipain, 5 mg/ml and 
Pepstatin A, 5 mg/ml, dissolved in 1 ml DMSO, Sigma), 200 μl aprotonin 
(Sigma), 1 mM EDTA, 2 mM DTT, 0.01 % w/v LDAO. After centrifugation at 
4650 x g for 1 hour at 4°C, the supernatant was applied to Calmodulin 
Affinity Resin (5 ml per 50 ml lysate, Stratagene). CaCl2 was added to a 
final concentration of 5 mM and the resin was mixed overnight at 4°C. The 
resin was then washed with 12.5 ml Cal-Eq buffer (20 mM HEPES pH 8, 1 
M NaCl, 2 mM CaCl2, 1 mM TCEP, 0.01 % w/v LDAO, 20 % v/v glycerol). 
After mixing for 15 minutes the sample was centrifuged at 340 x g for 2 
minutes at 4°C. This wash was repeated twice. The resin was then washed 
with 12.5 ml Cal-Wash buffer (20 mM HEPES pH 8, 150 mM KCl, 0.1 mM 
TCEP, 0.01 % w/v LDAO, 20 % v/v glycerol), mixed for 15 minutes at 4°C, 
and then centrifuged at 340 x g for 2 minutes at 4°C. This wash was 
repeated twice. For the first elution, 5 ml Cal-Elute buffer (20 mM HEPES 
pH 8, 150 mM KCl, 2 mM EGTA, 1 mM TCEP, 0.01 % w/v LDAO, 20 % v/v 
glycerol) was added to the resin. After mixing for 45 minutes at 4°C the 
mixture was centrifuged at 340 x g for 2 minutes at 4°C and the flowthrough 
was collected. Two further elutions of 10 ml and 5 ml were carried out. The 
flowthrough from these elutions was concentrated (Amicon Ultra Centrifugal 
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Filter Device, 100 K MWCO) and the combined elutions were applied to a 
10 to 40 % w/v sucrose gradient (20 mM HEPES pH 8, 150 mM KCl, 0.01 
% w/v LDAO, 15 % v/v glycerol, 1 mM TCEP, 10 to 37.5 % w/v sucrose in 
increments of 2.5 %). The gradients were centrifuged at 25 000 rpm for 64 
to 68 hours at 4°C (Beckmann Coulter Optima L-100 XP, SW28 rotor), then 
collected in fractions of 1.5 ml. SDS-PAGE was used to determine the 
fractions containing CCT, which were then concentrated using a 15 ml filter 
unit (Amicon Ultra Centrifugal Filter Device, 100 K MWCO) and centrifuging 
at 2450 x g, 4°C until a volume of approximately 1 ml was reached. 10 ml 
buffer (20 mM HEPES pH 8, 150 mM KCl, 0.01 % w/v LDAO, 1 mM TCEP, 
15 % v/v glycerol) was added and then the solution was concentrated to 1 
ml again. This wash was repeated a final time. The concentration was 
determined with a NanoDrop 1000 using MW 963.99 kDa and ε 320.24 x 
1000. 
 
3.1.2 Act1 Purification and Labelling 
Yeast lysate was centrifuged (2 hours, 27 500 rpm, 4°C, Beckmann Coulter 
Optima L-100 XP, SW28 rotor) and the cleared lysate was bound to a 
DNase I-Affigel column equilibrated in Buffer G (10 mM Tris pH 7.5, 0.2 mM 
CaCl2, 0.5 mM ATP, 0.2 mM DTT) at 4 °C. The column was washed with 20 
ml Buffer G, followed by 20 ml Buffer G + 10 % v/v formamide, 20 ml Buffer 
G + 0.2 mM NH4Cl, and finally a further 20 ml Buffer G. Act1 was eluted 
with Buffer G + 50 % v/v formamide, and collected in 1 ml fractions. The 
fractions containing actin were identified firstly by applying 3 µl to blotting 
paper and Coomassie staining since this is much quicker than SDS PAGE 
and actin is unstable in formamide. The presence of actin in these fractions 
was confirmed by SDS PAGE. A 10 µl sample of each fraction was added 
to 10 µl 2 x SDS gel loading buffer and after boiling for 3 minutes, 12 µl of 
this was loaded onto a 10 % SDS gel. 
 
Actin containing fractions from the DNase I column were loaded onto a 
Mono-Q HR 5/5 column (GE Healthcare) equilibrated in 10 mM Tris pH 7.5, 
0.2 mM CaCl2, 50 µM ATP. The column was washed with the same buffer 
plus 100 mM KCl, then a gradient of 100 to 300 mM KCl was applied and 
actin was eluted with approximately 210 mM KCl.  The actin containing 
fractions were identified by SDS PAGE as for elution from the DNase I 
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column. The fractions containing actin were combined and the 
concentration was estimated using the NanoDrop 1000 (Thermo Scientific) 
based on the extinction coefficient at 290 nm of 0.63 ml mg-1 cm-1 [118] 
then 1 mM ATP and 2 mM MgCl2 were added and kept on ice for 
polymerisation. The elution buffer contained sufficient KCl to support this. 
 
3.1.3 PLP2 Purification 
His-tagged PLP2 was overexpressed in E. coli using the vector pET11b-
His-PLP2 in BL21(DE3) competent cells. An overnight culture was grown at 
37°C with shaking in L-broth (100 µg/ml ampicillin). From this starter 
culture, 1 ml was spun down per 25 ml of L-broth. Cultures were grown to 
an optical density at 600 nm (OD600) of between 0.5 and 1 as determined 
by spectroscopically. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was 
added to a final concentration of 1 mM. Cultures were incubated at 37°C 
with shaking for 3 hours then pelleted and stored at -20°C.  
 
Pellets of PLP2 were thawed and resuspended in BugBuster (Novagen, 
150 µl per 1.5 ml pellet). Benzonase (Novagen, 0.15 µl per 1.5 ml pellet) 
was added and the sample was vortexed for 1 minute. After mixing on a 
rotating wheel at room temperature for 10 minutes, the sample was 
centrifuged for 10 minutes (16 000 x g). The soluble fraction was added to 
Zymo His-Affinity resin (Zymo Research, 250 µl resin per 600 µl soluble 
fraction) in a Zymo-Spin P1 column (Zymo Research) and mixed for 4 
minutes. After centrifugation for 5 to 10 s, the column was washed with His-
Binding Buffer (Zymo Research; 50 mM sodium phosphate pH 7.7, 300 mM 
NaCl, 10 mM imidazole, 0.03 % v/v Triton X-100). The column was 
centrifuged for 5 to 10 s then this wash step was repeated. To elute the 
protein, His-Elution buffer (Zymo Research; 50 mM sodium phosphate pH 
7.7, 300 mM NaCl, 250 mM imidazole) was added. After one minute the 
column was centrifuged for 5 to 10 s and the eluate was collected. The 
concentration was determined by NanoDrop estimating 1 Abs to be 1 
mg/ml (typically between 0.3 and 1 mg/ml). PLP2 was then either aliquoted 
and stored at -80°C immediately or dialysed into 20 mM HEPES pH 8, 75 
mM KCl before storing. 
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3.1.4 Cdh1 Expression and Purification 
3.1.4.1 Site-Directed Mutagenesis 
Single amino acid changes were carried out using the QuikChange® Site-
Directed Mutagenesis Kit (Stratagene). The PCR reaction mix consisted of 
the template DNA (5 to 50 ng), forward and reverse primers (125 ng), and 
dNTPs supplied with the kit (1 μl) in 20 mM Tris-HCl pH 8.8, 10 mM KCl, 10 
mM (NH4)2SO4, 2 mM MgSO4, 0.1 % v/v Triton X-100, 0.1 mg/ml nuclease–
free bovine serum albumin (BSA). PfuTurbo DNA polymerase (2.5 U/μl, 1 
μl) was added immediately before starting the PCR program. The program 
started with 30 seconds at 95°C and was followed by 16 cycles of 30 
seconds at 95°C, 1 minute at 55°C and 7 minutes at 65°C. The reaction 
mixture was cooled on ice for 2 minutes, and then the restriction enzyme 
Dpn I (10 U/μl, 1 μl) was added. The mixture was centrifuged for 1 minute 
then incubated at 37°C for 1 hour. 
 
3.1.4.2 Transformation into XL1-Blue Supercompetent Cells 
XL1-Blue Supercompetent cells (Stratagene) were thawed on ice and 50 μl 
was aliquoted into a pre-chilled 14 ml BD Falcon polypropylene round-
bottomed tube. Dpn I-treated DNA (1 μl) was added and the mixture was 
swirled to mix then incubated on ice for 30 minutes. After a heat-pulse of 45 
seconds at 42°C, the transformation reaction was placed on ice for a further 
2 minutes then incubated for 1 hour at 37°C with shaking. The 
transformation reaction was spread on an L-Agar plate containing 100 
μg/ml ampicillin and the inverted plates were incubated overnight at 37°C or 
over the weekend at room temperature. 
 
3.1.4.3 Minipreps 
L-broth containing 100 μg/ml ampicillin was inoculated with cells from a 
single colony and incubated overnight at 37°C with shaking. From this 
starter culture, 4.5 ml was pelleted and the DNA purified using QIAprep 
Spin Miniprep Kit (QIAGEN). The pellet was resuspended in 250 μl buffer 
P1 supplied with the kit, and then 250 μl buffer P2 was added. The 
suspension was mixed by inversion, then 350 μl buffer N3 was added and 
the suspension was mixed again. After centrifugation for 10 minutes, the 
supernatant was transferred to a QIAprep spin column. The column was 
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centrifuged for 1 minute then washed with 750 μl buffer PE and centrifuged 
for 1 minute followed by a further minute of centrifugation following removal 
of the flowthrough to ensure no ethanol from buffer PE remained. DNA was 
eluted by the addition of 50 μl H2O to the column. After standing for 1 
minute, the column was centrifuged for 1 minute and the flowthrough was 
collected. The concentration of the DNA was determined using the 
NanoDrop 1000 (Thermo Scientific). 
 
3.1.4.4 Sequencing 
A PCR reaction mixture consisting of template DNA for sequencing (varying 
concentrations, 11 μl), either the forward or reverse primer for pET vectors 
(3.2 pmol/μl, 1 μl), BigDye Terminator v1.1 (Applied Biosystems, 4 μl) and 
the PCR reaction buffer (200 mM Tris pH 8.8, 5 mM MgCl2, 4 μl) underwent 
25 thermal cycles of 30 seconds at 90°C, 15 seconds at 50°C and 4 
minutes at 60°C. The sequencing reaction was cleaned up using the DyeEx 
2.0 Spin Kit (QIAGEN). Resin in the spin columns provided was 
resuspended by gentle vortexing and centrifuged for 3 minutes at 750 x g to 
remove the storage buffer. The PCR reaction mixture was applied to the 
resin and centrifuged for 3 minutes at 750 x g, and the flowthrough was 
collected and dried in a 1.5ml Eppendorf tube for sequencing.  
 
3.1.4.5 Transformation into BL21(DE3)s 
BL21(DE3) competent cells were thawed on ice and 50μl was aliquoted into 
a pre-chilled 14ml BD Falcon polypropylene round-bottomed tube. Miniprep 
DNA (1 μl) was added and the mixture was swirled before incubation on ice 
for 30 minutes. After a heat-pulse of 45 seconds at 42°C followed by 
incubation on ice for 2 minutes, 450 μl SOC medium (2 % w/v tryptone, 0.5 
% w/v yeast extract, 10 mM NaCl, 10 mM MgCl2, 20 mM MgSO4) was 
added and the mixture was incubated for 1 hour at 37°C with shaking. The 
transformation reaction was spread on plates (≤ 250 μl) and incubated 
either overnight at 37°C or over the weekend at room temperature. 
 
3.1.4.6 IPTG Inductions 
L-broth media (with ampicillin, 100 μg/ml, 6 ml) was inoculated with cells 
from glycerol stocks and incubated overnight at 37°C with shaking. Of this 
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starter culture, 1 ml was pelleted for each 25 ml of media for the induction 
(800 x g, 3 min), resuspended in 0.5 ml L-broth and added to L-broth (100 
μg/ml ampicillin). Cultures were incubated at 37°C until an OD600 of 
between 0.5 and 1 was reached. IPTG (1 mM final concentration) was 
added and the cultures were incubated for a further 3 hours at 37°C. Cells 
were then stored as pellets at -20°C. 
 
3.1.4.7 Cdh1 Refolding 
Cell pellets were resuspended in BugBuster Protein Extraction Reagent 
(Novagen, 1 ml per 10 ml of culture; 1 Roche Complete Mini EDTA free 
protease inhibitor tablet per 10 ml extraction reagent), and lysozyme (200 
μg/μl) and benzonase (25 units per 1 ml extraction reagent) were added. 
The suspension was vortexed for 1 minute, and then mixed on a rotating 
wheel at 4°C for 30 minutes. After centrifugation at 16 000 x g for 30 
minutes at 4°C, the supernatant was discarded and pellets were washed 
twice with a 1/10 dilution of BugBuster Protein Extraction Reagent.  
 
The washed pellets were resuspended in buffer A (5 M Gu-HCl, 50 mM 
sodium phosphate pH 7.8, 2 μl per 1 ml of the initial cell culture) and 
incubated at room temperature for 15 minutes. They were then centrifuged 
for 10 minutes at 16 000 x g, and the supernatant was transferred to a 
clean tube. Buffer B (4 M Gu-HCl, 50 mM sodium phosphate pH 7.8, 3.2 μl 
per 1 ml culture) was added, and after incubation at room temperature for 
30 minutes, buffer C (2 M Gu-HCl, 50 mM sodium phosphate pH 7.8, 8 μl 
per 1 ml culture) was added. The mixture was incubated at room 
temperature for a further 30 minutes, then another 4 μl per 1 ml of culture of 
buffer C was added. After 15 minutes, buffer D (50 mM sodium phosphate 
pH 7.8, 150 mM KCl, 40 μl per 1 ml culture) was added dropwise, and the 
sample was transferred to a Slide-A-Lyzer Dialysis Cassette (Pierce, 10 
000 MWCO) and dialysed against no less than 750 ml of 50 mM sodium 
phosphate pH 7.8, 150 mM KCl, 0.5 mM TCEP at 4°C. After 1 hour, the 
buffer was changed and the sample was dialysed overnight. 
 
After removing the sample from the dialysis cassette, it was centrifuged for 
10 minutes, 16 000 x g, 4°C and concentrated in an Amicon Ultra 
Centrifugal Device (Millipore, 10 000 MWCO) by centrifugation at 2450 x g. 
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3.2 Gel Electrophoresis 
10 % or 12.5 % polyacrylamide gels containing sodium dodecyl sulphate 
(SDS) were used to analyse protein samples by SDS PAGE. For most 
samples, equal volumes of the sample and 2x SDS gel loading buffer were 
used, although after purification of the CCT, Cdh1 342-469 and CaM 
complex by sucrose gradient, 5x SDS gel loading buffer was used. These 
samples were boiled for 3 minutes then spun down before loading onto the 
gel. 
 
For native PAGE, 6 % polyacrylamide gels with 1 mM ATP were used for 
analysis of actin folding assays. Native gel loading buffer was added to 
each sample. 
 
Purification of DNA fragments was carried out with 1 % agarose in TAE 
gels containing ethidium bromide to allow visualisation of bands with UV 
light. Bands were excised and the DNA extracted from the gel using the 
QIAQuick gel Extraction kit (QIAGEN). 
 
3.2.1 Recipes and Buffers 
3.2.1.1 SDS PAGE 
12.5 % resolving gel - 12.5 % v/v acrylamide, 0.3 % v/v bis-acrylamide, 375 
mM Tris pH 8.8, 0.1 % v/v SDS, 0.1 % TEMED, 0.1 % w/v  ammonium 
persulphate. 
10% SDS gels – 10 % v/v acrylamide, 0.3 % v/v bis-acrylamide, 375 mM 
Tris pH 8.8, 0.1 % v/v SDS, 0.1 % v/v TEMED, 0.1 % w/v ammonium 
persulphate. 
Stacking gel – 4 % v/v Acrylamide, 0.1 % v/v bis-acrylamide, 125 mM Tris 
pH 6.8, 0.1 % v/v SDS, 0.1 % v/v TEMED, 0.1 % w/v ammonium 
persulphate. 
Running buffer – 250 mM Tris, 1.92 M glycine, 0.1 % v/v SDS 
2x SDS gel loading buffer – 100 mM Tris pH 6.8, 200 mM DTT, 4 % v/v 
SDS, 20 % v/v glycerol, bromophenol blue to colour. 
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3.2.1.2 Native PAGE 
6 % resolving gel – 6 % acrylamide, 0.15 % v/v bis-acrylamide, 370 mM 
Tris pH 8.8, 0.05 % v/v TEMED, 0.1 % w/v ammonium persulphate. 
Stacking gel – 3.2 % acrylamide, 0.12 % v/v bis-acrylamide, 57 mM Tris pH 
8.8, 0.05 % v/v TEMED, 0.15 % w/v ammonium persulphate. 
Running Buffer – 250 mM Tris, 1.92 M glycine. 
Native gel loading buffer – 125 mM Tris pH 8.8, 84 % v/v glycerol, 
bromophenol blue to colour. 
 
Coomassie Stain – 46 % v/v methanol, 8 % v/v acetic acid, 0.9 mM Brilliant 
Blue R 
Coomassie Destain - 30 % v/v methanol, 7 % v/v acetic acid. 
 
 
  
62 
 
3.3 Western Blotting 
3.3.1 Transfer to Membranes 
Protein bands from gels were transferred to either Hybond-C nitrocellulose 
membrane (GE Healthcare), or Hybond ECL nitrocellulose membrane (GE 
Healthcare) using the Mighty Small Transphor system (GE Healthcare). 
Transfer was performed for 1 hour at 4°C, 400 mA, 100 V, or overnight at 
room temperature, 100 mA, 100 V, using 192 mM glycine, 25 mM Tris, 200 
mM methanol, pH 8.3 as the transfer buffer. To confirm that proteins had 
been transferred, the membrane was stained with Ponceau S (Sigma). 
After rinsing with PBSA (170 mM NaCl, 3.3 mM KCl, 10 mM KH2PO4, 1.7 
mM Na2HPO4, pH 7.2) to remove the stain, the membrane was blocked 
with 5 % w/v milk powder (Marvel) in PBSA. The membrane was then 
incubated in the primary antibody at the appropriate dilution (see Table 1) 
in 5 % w/v milk powder in PBSA for 1 hour. After washing 3 times with 
TBST (140 mM NaCl, 5 mM KCl, 25 mM Tris, 0.1 % v/v Tween, pH 7.4) 
and once with TBS (140 mM NaCl, 5 mM KCl, 25 mM Tris, pH 7.4), the 
membrane was then incubated in the secondary antibody (see Table 1) at a 
dilution of 1:1000 in 5 % w/v milk powder in PBSA for 1 hour. The wash 
with TBST and TBS was repeated.  
 
For imaging by film, SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Scientific) was used. The membrane was incubated for 5 minutes 
in the mixture, then blotted dry and exposed to film.  
 
Fluorescent ECL Plus (GE Healthcare) was used where more accurate 
quantification of bands was used. The mixture was applied to the 
membrane and left protected from light for 5 minutes. The membrane was 
then air dried and scanned on a Typhoon 9400 Variable Mode Imager (GE 
Healthcare), and bands were quantified using ImageQuant software (GE 
Healthcare). 
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3.3.2 Antibodies 
The primary antibodies used to identify different proteins, the dilution at 
which they were used (in 5 % w/v Marvel milk powder in TBST) and the 
corresponding secondary antibodies are shown in Table 1. 
 
Protein of interest Primary antibody Dilution Secondary antibody 
CCT Anti-CCTε 1:10000 Anti-Rabbit HRP (Sigma) 
Act1 Anti-Act1 1:500 Anti-Rabbit HRP (Sigma) 
PLP2 Anti-PLP2 ‘1f’ 1:2000 Anti-Rat-HRP (Sigma) 
Cdh1 
Anti-Cdh1 1:4000 Anti-Mouse HRP (Sigma) 
Anti-His (Sigma) 1:2000 Anti-Rat-HRP (Sigma) 
 
Table 1: Antibodies used for western blot analysis. 
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3.4 Fluorescent Labelling 
Fragments of Cdh1 and CaM were labelled with fluorophores in order to 
investigate the folding of the WD40 propeller by CCT. Act1 and ActA were 
also fluorescently labelled in order to study actin folding by the chaperonin. 
 
3.4.1 Synthesis of Fluorophore Thioester Derivatives for NCL 
3.4.1.1 PromoFluor 488 2-mercaptoethanesulfonate 
PromoFluor 488 NHS-ester (PromoKine, 10 mg, 16 μmol) was dissolved in 
250 μl DMF and added to 0.1 M sodium borate pH 8.3, 35 mM 
mercaptoethanesulphonate (MES). After stirring for 2 hours at room 
temperature the dye was purified by RP-HPLC and lyophilised. The 
resulting orange solid was analysed by MALDI-MS (MW 614, 6 g, 10 μmol, 
62.5% yield). 
 
3.4.1.2 Rhodamine Red-X 2-mercaptoethanesulfonate 
Rhodamine Red-X NHS-ester (Invitrogen, 10 mg, 13 μmol) was dissolved 
in 250 μl DMF and added to 0.1 M sodium borate pH 8.3, 29 mM MES. 
After stirring for 2 hours at room temperature, the dye was purified by RP-
LC and lyophilised. The pink solid obtained was analysed by MALDI-MS 
(MW 796, hydrolysis product MW 669, 6.4 mg, 8 μmol, 61.5 % yield).  
 
3.4.2 Labelling of Cdh1 342-469 by NCL 
The concentrated protein was incubated with FMDV 3Cpro (final 
concentration approx. 0.3 μM) at 4°C for at least 5 hours with mixing. When 
purification was required, the cleaved protein was isolated using Strep-
Tactin Sepharose resin (IBA). The resin (100 μl per 300 μl of sample) was 
added to a CoStar Spin-X centrifuge filter (0.22 μm) and equilibrated in 
buffer W (100 mM Tris pH 8, 150 mM NaCl), centrifuging for 30 s, 700 x g, 
4°C to remove the buffer. The sample was loaded onto the resin and mixed 
at 4°C for 10 minutes to allow protein to bind. After centrifugation for 30 s, 
700 x g, 4°C, the resin was washed with 4 x 100 μl buffer W, then eluted 
with 3 x 50 μl buffer E (100 mM Tris pH 8, 150 mM NaCl, 2.5 mM D-
desthiobiotin). For the elutions, centrifugation for 30 s, 700 x g, 4°C was 
followed by a 15 s spin at full speed. The elutions were combined. The 
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thioester derivative of the fluorophore being used to label Cdh1 was added 
to a final concentration of 0.4 mM with 20 mM MESNA to prevent unwanted 
side reactions with other cysteine residues. The labelling reaction was 
carried out overnight at 4°C (72 h for Rhodamine Red-X 2-
mercaptoethanesulfonate). Free dye was removed by buffer exchange into 
20 mM HEPES pH 8, 150 mM KCl, 0.01 % w/v LDAO, 1 mM TCEP, 15 % 
v/v glycerol using Zeba Spin Desalting Columns (Pierce, 0.5 ml columns). 
 
3.4.3 Labelling of Cdh1 342-469-C349A 
Cdh1 342-469-C349A was labelled while bound to Strep-Tactin Sepharose 
resin. The resin (100 μl per 300 μl of sample) was added to a CoStar Spin-
X centrifuge filter (0.22 μm) and equilibrated in buffer W (100 mM Tris pH 8, 
150 mM NaCl), centrifuging for 30 s, 700 x g, 4°C to remove the buffer. The 
sample was loaded onto the resin and mixed at 4°C for 10 minutes to allow 
protein to bind. After centrifugation for 30 s, 700 x g, 4°C, the resin was 
washed with 4 x 100 μl buffer W, then resuspended in 150 μl buffer W and 
2 μl AF488-C5-maleimide (Invitrogen) was added. The resin was mixed 
overnight at 4°C then washed with 5 x 150 μl buffer W before eluting with 3 
x 75 μl buffer E (100 mM Tris pH 8, 150 mM NaCl, 2.5 mM D-desthiobiotin) 
by centrifuging for 30 s at 700 x g then 15 s at full speed. 
 
3.4.4 Labelling of CaM 
A 3 ml pellet of BL21(DE3) cells overexpressing CaM was resuspended in 
300 μl Novagen BugBuster Protein Extraction Reagent and 0.3 μl 
Benzonase, then vortexed for 1 minute and mixed on a rotating wheel at 
room temperature for 15 minutes. The CaM was labelled whilst bound to 
His-Affinity resin using the Zymo His-Spin Protein Miniprep Kit (Zymo 
Research). His-Affinity resin (120 μl) was added to a Zymo-Spin P1 column 
and centrifuged at 16 000 x g for 5 to 10 s. The soluble CaM fraction was 
loaded onto the resin (140 μl) and mixed at room temperature for 4 minutes 
before centrifugation to remove the unbound sample. The resin was 
washed with 2 x 200 μl His-Binding buffer. His-Binding buffer was added to 
the resin as well as 5 μl of 5 mM stock of the maleimide derivative of the 
dye being used (AF488, AF555, AF568 or QSY7; Invitrogen) and mixed 
overnight at 4°C. The unbound dye was removed by centrifuging for 5 to 
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10s followed by washing with 5 x 400 μl His-Binding buffer. The labelled 
CaM was then eluted by addition of 100 μl His-Elution buffer and incubated 
at room temperature for 1 minute before centrifuging for 5 to 10 s. The 
elution was repeated and the flowthrough of the two elutions combined. 
 
3.4.5 Labelling of PLP2 
Labelling of His-tagged PLP2 was carried out as for CaM, but using a 1.5 
ml cell pellet and resuspending in 150 μl BugBuster Protein Extraction 
Reagent with 0.15 μl Benzonase. All other quantities used were the same. 
 
3.4.6 Fluorescent Labelling of Actin 
3.4.6.1 AEDANSAct1 
At the same time as addition of ATP and MgCl2 for polymerisation, 5-((2-
((iodoacetyl)amino)ethyl)amino)naphthalene-1-sulfonic acid (IAEDANS, 
Sigma) was added in a 5-fold molar excess over actin. The mixture was 
incubated for 16 h on ice and then centrifuged for 2 h, 4°C, 150 000 x g 
using a TLS-55 rotor (Beckman Coulter). The supernatant was discarded 
and the pellet was resuspended in 10 mM Tris pH 7.5, 0.2 mM DTT, 0.2 
mM CaCl2, 50 µM ATP and dialysed for 16 hours against the same buffer at 
4°C. The sample was then centrifuged for 2 h, 4°C, 150 000 x g to remove 
any aggregates. The actin concentration and labelling efficiency were 
determined using the NanoDrop 1000 using the extinction coefficient 6 x 
103 M-1 cm-1 for AEDANS at 337 nm [119]. The labelling efficiency was 80 
%. 
 
3.4.6.2 AcrylAct1 and 488Act1 
Before addition of the dye, actin was polymerised on ice for 30 minutes. A 
20-fold molar excess of acrylodan (Anaspec) or a five-fold excess of Alexa 
Fluor 488 C5 maleimide (Invitrogen) was added and the mixture was kept 
on ice for 16 h. The labelling reaction mixture was then centrifuged for 2 h, 
4°C, 150 000 x g. The supernatant was discarded and the pellet was 
resuspended in 10 mM Tris pH 7.5, 0.5 mM β-mercaptoethanol, 0.2 mM 
CaCl2, 50 µM ATP and dialysed for 70 hours against the same buffer at 
4°C. The sample was then centrifuged for 2 h, 4°C, 150 000 x g to remove 
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any aggregates. The actin concentration and labelling efficiency were 
determined using the NanoDrop 1000 using the extinction coefficient 1.85 x 
104 at 385 nm for acrylodan [120] and 7.1 x 104 at 494 nm for Alexa Fluor 
488 [100]. The labelling efficiencies were 60 to 80 % for AcrylAct1 and 90 % 
for 488Act1. 
 
3.4.6.3 AcrylActA 
Purified ActA (64.8 µM, kindly donated by Dr Gabriel Altschuler) was 
dialysed into 2 mM Tris pH 7.5, 0.1 mM CaCl2, 0.2 mM ATP. The ActA was 
then polymerised on ice for 2 hours by addition of 50 mM KCl, 1 mM ATP 
and 2 mM MgCl2. Acrylodan (625 µM) was added and the mixture was 
incubated on ice for 4 hours. The labelled ActA was dialysed into 10 mM 
Tris pH 7.5, 0.2 mM CaCl2, 50 µM ATP, 0.5 mM β-mercaptoethanol and 
stored at -80°C. The final concentration of ActA was 16 µM, with a labelling 
efficiency of 80 %. 
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3.5 Preparation of Fluorescent Oligonucleotide Pairs 
Complimentary oligonucleotides that were fluorescently labelled with AF488 
and AF555 were used to confirm that FRET could be observed between 
these fluorophores using the equipment to be used to investigate the 
folding of Cdh1. Oligonucleotide (1) (see below) or the unlabelled 
equivalent was incubated with either oligonucleotide (2) or (3) in 20 mM 
HEPES, 150 mM NaCl, 10 mM MgCl2 at 37°C for 30 minutes. An excess of 
(2) or (3) was used to ensure that all the donor-labelled oligonucleotide was 
conjugated. The double-stranded DNA was purified by gel electrophoresis 
on a 12.5 % native polyacrylamide gel and the DNA was extracted from the 
excised bands by electro-elution into 90 mM Tris-borate, 25 mM NaCl using 
the Elutrap Electro-Elution System (Schleicher and Schuell). Fluorescence 
emission spectra were collected using the PTI QuantaMaster™ UV Vis 
Spectrofluorometer. 
 
The sequences of the oligonucleotides used were as follows: 
(1) 5' AF488-TTCGATAGTAGAGTGCTTCTATCATCGATAA-3' 
(2) 5'TTATCGATGATAGAAGCACTCTACTATCGAA-AF555 3'             
(3) 5'TTATCGATGATAGAAGCACTCTACTA-AF555 3'         
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3.6 Interaction between Cdh1 and CCT 
Ternary complexes were formed between CCT, the Cdh1 fragment and 
CaM. These were then purified by sucrose gradient centrifugation, and the 
fluorescence emission was measured to observe any FRET which occurred 
between the fluorescently labelled Cdh1 fragment and CaM. 
 
3.6.1 Purification of Cdh1-CCT Complexes by Sucrose Gradient 
Either CCT3 or CCT6 was incubated with either 488Cdh1 342-469 C349A, 
555CaM or both. A large excess of the Cdh1 fragment and CaM was used. 
Samples were diluted with 20 mM HEPES, 150 mM KCl, 0.01 % w/v LDAO, 
15 % v/v glycerol to give a final glycerol concentration of 10 % v/v, and 
CaCl2 was added to a final concentration of 2 mM.  The samples were 
incubated for at least 20 minutes before loading onto a 10 to 40 % sucrose 
gradient (20 mM HEPES pH 8, 150 mM KCl, 0.01 % w/v LDAO, 15 % v/v 
glycerol, 1 mM TCEP, 0 to 40 % w/v sucrose in increments of 2.5 %). The 
gradients were centrifuged at 48 000 rpm for approximately 18 hours 
(Beckmann Coulter Optima L-100 XP, SW55 rotor). The gradients were 
collected in 600 μl fractions and the fractions were analysed by SDS PAGE. 
 
3.6.2 Fluorescence Measurements 
Measurements were made using a PTI QuantaMaster™ UV Vis 
Spectrofluorometer. The software used was Felix 32 Analysis, version 1.2. 
Slits were set at distances from 2 nm to 4nm. Excitation and emission 
spectra were obtained using a step size of 1 nm and an integration time of 
1 s. A quartz cuvette with a 2 mm path length was used. Fluorescence was 
measured at 90° to the excitation source in an L-format. 
 
For measurement of fluorescence from fluorescein and AF488 and FRET, 
samples were excited at 488 nm and the emission was scanned from 500 
nm to 650 nm to limit direct excitation of the acceptor.  
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3.7 Gel-Based Actin Folding Assays 
Actin folding by CCT was followed by native PAGE to demonstrate the 
release of native actin from the chaperonin. Fluorescence emission was 
used to monitor actin levels in the samples. 
 
3.7.1 488Act1 
488Act1 (162 nM) was unfolded at room temperature with 1.5 mM EDTA in 
the presence of CCT or CCTanc2 (462 nM) and PLP2, PLP2 60-286 or 
PLP2 1-244 (454 nM) in 20 mM HEPES pH 8, 75 mM KCl, 10 % v/v 
glycerol, 1 mM TCEP and protected from light. Before addition of EDTA, a 
2.5 µl sample was removed and diluted in 10 µl 20 mM HEPES pH8, 10 % 
v/v glycerol, 1 mM CaCl2. This sample was kept on ice.  
 
After unfolding, a further 2.5 µl sample was removed and added to the 
same buffer. A 5x ATP buffer (20 mM HEPES pH 8, 50 mM KCl, 50 mM 
MgCl2, 10 mM ATP) was added to give a final concentration of 2 mM ATP, 
10 mM MgCl2. The reaction mixture was incubated at 30°C for 15 minutes 
and 3.13 µl aliquots were removed at 5 minutes intervals. These were 
added to 10 µl 20 mM HEPES pH8, 10 % v/v glycerol, 1 mM CaCl2 and 
kept on ice. After 15 minutes, a second aliquot was taken and added to 10 
µl 20 mM HEPES pH8, 10 % v/v glycerol, 1 mM CaCl2, 645 nM DNase I. A 
third aliquot was added to 20 mM HEPES pH8, 10 % v/v glycerol, 1 mM 
CaCl2, 380 nM vitamin D binding protein (VDBP). 
 
NGLB (1.5 µl) was added to each time point, and samples were run on a 6 
% native gel containing 1 mM ATP with 0.1 mM ATP in the running buffer. 
Gels were scanned on a Typhoon 9400 Variable Mode Imager (GE 
Healthcare) using the 488 nm laser and measuring emission at 520 nm with 
a bandpass of 20 nm. Fluorescent bands were quantified using 
ImageQuant (GE Healthcare). Gels were then Coomassie stained. 
 
3.7.2 AcrylAct1 
AcrylAct1 (1.8 µM) was unfolded onto CCT (2.1 µM) in the presence of PLP2 
(2.1 µM) and 1.5 mM EDTA at room temperature in 20 mM HEPES pH 8, 
75 mM KCl, 10 % v/v glycerol, 1 mM TCEP and protected from light. A 7.5 
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µl sample was taken before addition of EDTA and diluted with 10 µl 20 mM 
HEPES pH 8, 10 % v/v glycerol, 1 mM CaCl2. This was kept on ice for 
analysis by native PAGE. After unfolding for 3 hours, a second 7.5 µl 
sample was taken and diluted in the same way. 
 
To the remaining reaction mixture, a 5x ATP/MgCl2 mix was added to give 
a final concentration of 2 mM ATP, 10 mM MgCl2. The reaction mixture was 
incubated at 30°C and 9.4 µl aliquots were taken at 5 minute intervals. 
These were added to 10 µl 20 mM HEPES pH 8, 10 % v/v glycerol, 1 mM 
CaCl2 and kept on ice for analysis by native PAGE. After 15 minutes, two 
further aliquots were taken and added to 10 µl 20 mM HEPES pH8, 10 % 
v/v glycerol, 1 mM CaCl2 containing either 3.2 µM DNase I or 1.92 µM 
VDBP. 
 
NGLB (1.5 µl) was added to each sample and the entire sample was 
loaded onto a 6 % native gel containing 1 mM ATP, with 0.1 mM ATP in the 
running buffer. Bands were visualised using a UV lamp. Gels were then 
Coomassie stained. 
 
3.7.3 AcrylActA compared to AcrylAct1 
AcrylActA (2.7 µM) or AcrylAct1 (2.7 µM) was unfolded with 1.5 mM EDTA in 
20 mM HEPES pH 8, 75 mM KCl, 1 mM TCEP, 2 µM ATP for 10 minutes. 
Samples were taken before and after unfolding for analysis by native 
PAGE. CCT (2 µM) and PLP2 (0.9 µM) and glycerol (10 % v/v) were added, 
with a final actin concentration of 1.8 µM. The mixture was incubated at 
room temperature for 10 minutes. After taking a sample for native PAGE, 
ATP (2 mM) and MgCl2 (10 mM) were added and the mixture was 
incubated at 30°C. Samples were taken at 5 minute intervals and analysed 
by native PAGE. Fluorescent bands were visualised using a UV lamp, then 
the gel was Coomassie stained. 
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3.8 Spectroscopic Actin Folding Assays 
Folding of fluorescently labelled actin was followed spectroscopically, 
allowing measurements of the kinetics of actin folding by CCT. 
 
3.8.1 Fluorescence Spectroscopy 
All fluorescence measurements were made using a PTI QuantaMaster 40 
UV Vis spectrophotometer and FeliX32 software (Photon Technology 
International Inc.). The excitation slits were set to 2 nm to minimise 
photobleaching, while the emission slits were set to 4 nm. Fluorescence 
emission spectra were smoothed using a 7-point Savitzky-Golay smoothing 
filter [121] to determine maximum emission wavelengths, although raw data 
was used for determining the area under the curve. 
 
3.8.2 AEDANSAct1 
Fluorescence emission spectra were collected exciting at 365 nm and 
measuring emission spectra from 400 to 550 nm with a step size of 1 nm 
and an integration time of 1 s.  
 
3.8.3 AcrylAct1 
Fluorescence emission spectra were collected exciting at 380 nm and 
measuring emission spectra from 400 to 550 nm with a step size of 1 nm 
and an integration time of 1 s for unfolding measurements, and from 425 to 
525 nm with an integration time of 0.5 s for release assays. For timebased 
emission scans, and excitation wavelength of 380 nm and an emission 
wavelength of 470 nm were used. 
 
3.8.4 Folding Assays Using ATPγS and AMP-PNP 
Spectroscopic folding assays were carried out using AcrylAct1 and 488Act1 
was used to observe the process by native PAGE. Act1 was unfolded onto 
CCT in the presence of PLP2 with EDTA as for other folding assays. A 5x 
concentrated nucleotide mixture was then added, consisting of 50 mM 
ATPγS or AMP-PNP, 250 mM MgCl2, 20 mM HEPES pH 8, 50 mM KCl, so 
that the final nucleotide concentration was 10 mM. The sample was 
incubated for 10 minutes at 30°C, then a 5x ATP mixture containing 10 mM 
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ATP, 50 mM MgCl2, 20 mM HEPES pH8, 70 mM KCl, 0.8 mM TCEP, 8 % 
v/v glycerol was added so that the final concentration of ATP was 2 mM. 
Samples were analysed as for previous folding assays by fluorescence 
emission following addition of ATP or by native PAGE.  
 
3.8.5 Data Analysis 
Raw data obtained from the spectrophotometer was analysed using 
GraphPad Prism 5 (GraphPad Software). Rate constants were obtained by 
fitting a single exponential to the curve excluding the data for the first 50 
seconds of the scan, since a mixing phase could be seen at this time. Rate 
constants were calculated as the mean of at least three independent 
experiments with error bars representing the standard deviation. Arrhenius 
plots in which the rate constant k and temperature T were plotted as ln(k) 
against 1/T (K-1) were used to obtain the activation energy of the folding 
reaction and also to observe trends in the rate of folding as the temperature 
was increased. 
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4 Labelling of Proteins for Assembly of the Ternary 
CCT Complex 
4.1 Aims 
In order to investigate protein folding by CCT using fluorescence 
spectroscopy, pure proteins that could be selectively labelled were 
required. Yeast CCT, actin and PLP2 were purified, as well as fragments of 
the WD40 repeat-containing protein Cdh1 and CaM. These were then used 
to form ternary complexes to investigate folding of substrates by CCT 
(Figure 20). While some proteins could be recombinantly overexpressed in 
E. coli, others had to be purified from yeast lysate. Labelling of proteins 
depended on the number of reactive cysteine residues present; where 
more than one was present, either an alternative labelling technique to the 
use of a thiol-reactive dye was required, or site directed mutagenesis in 
order to remove any alternative labelling sites was employed. 
 
 
Figure 20: Diagrams of the ternary complexes of CCT used in this thesis, 
made up of actin, PLP2 and CCT or a fragment of Cdh1, CaM bound to either 
CCT3 or CCT6, and CCT. 
 
Purification and selective labelling of all the components of the in vitro actin 
folding assay are well established. CCT can be obtained from yeast lysate 
by affinity purification due to the insertion of a calmodulin binding peptide 
(CBP) tag [122]. Actin is also obtained from the same lysate and is purified 
by affinity purification and ion exchange chromatography. PLP2 can be 
readily expressed in bacteria as a soluble monomer. 
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For studying the folding of Cdh1 by CCT, a method of purification and 
labelling a fragment of the WD40 propeller capable of binding to the 
chaperonin had to be developed. Two methods of labelling were used: 
either native chemical ligation (NCL), which requires an N-terminal cysteine 
to be introduced to the construct by cleavage with the foot and mouth 
disease 3C protease (FMDV 3Cpro), or labelling with the maleimide 
derivative of the desired dye following site-directed mutagenesis to remove 
a cysteine residue. In order to introduce a second label into the system to 
measure FRET, CaM was also fluorescently labelled. 
 
In this chapter, the methods for purification of the different components of 
the CCT system are described. Labelling techniques and protocols are also 
discussed. 
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4.2 CCT Purification 
The purification of CCT can be a very complex process requiring several 
rounds of different chromatographic steps to obtain pure and functional 
protein.  Fortunately, the insertion of an affinity tag into the apical domain of 
either subunit 3 or subunit 6 of yeast actin (Figure 21) [49, 122] accelerates 
simplifies the process greatly. This tag consists of a Strep tag, a His tag 
and a calmodulin binding peptide (CBP) tag attached via a flexible linker to 
the external face of CCT. 
 
 
Figure 21: Location of the affinity tag inserted into the apical domain of 
CCT3, inserted between P374 and K375 [122]. 
 
Purification of CCT modified in this way, referred to as CCT3 or CCT6, 
depending on the subunit in which the tag has been inserted, is a relatively 
simple, albeit still lengthy process. Clarified yeast lysate is bound to a 
calmodulin (CaM) resin. Washing with ATP allows release of CCT-bound 
substrates and cofactors thereby enhancing the purity of the eluted CCT. A 
sucrose gradient is used to isolate the intact CCT complex which is then 
buffer exchanged to remove sucrose and concentrated. 
 
4.2.1 Affinity Purification with CaM Resin 
Yeast lysate containing CCT3 or the mutant CCTanc2, which was also 
tagged in subunit 3, was centrifuged and the supernatant was bound to 
CaM resin by mixing overnight at 4°C with 5 mM CaCl2 to allow the CBP 
tag to bind to CaM. The resin was then washed; the first three washes 
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contained 5 mM ATP, 0.5 mM ADP, 15 mM MgCl2 and 1 M NaCl, and this 
was followed by two washes still containing 5 mM ATP, 0.5 mM ADP and 
15 mM MgCl2 but replacing the NaCl with 150 mM KCl. These nucleotide 
wash steps were all performed at room temperature since release from 
CCT is slower at lower temperatures. A final wash step without nucleotide 
was performed at 4°C and then CCT was eluted with 2 mM EGTA, which 
chelates the Ca2+ required for the CaM-CBP interaction.  
 
4.2.2 Sucrose Gradient Purification of CCT 
Elutions from the CaM resin were loaded onto 10 to 37.5 % w/v sucrose 
gradients and centrifuged at 82 000 x g for 64 to 68 hours. The sucrose 
gradient is not dissimilar to gel filtration in that proteins are purified based 
on their size; larger protein complexes are found in lower fractions 
containing a higher percentage of sucrose. In this way intact CCT is 
isolated from any individual subunits that are present due to dissociation 
during the previous purification step. The fractions containing CCT were 
identified by SDS PAGE (Figure 22). The eight subunits, which are all 
approximately 60 kDa in size, migrate as a group and cannot be individually 
identified by Coomassie staining. The intact complex is found in fractions 
containing approximately 25 to 30 % w/v sucrose. 
 
 
Figure 22: Sucrose gradient purification of CCT. The intact CCT complex is 
found in the lower fractions of the gradient at approximately 25 % w/v 
sucrose. 
 
It can be seen that the CCT complex purified by this two-step process of 
affinity purification followed by sucrose gradient yields very pure protein, 
with no other protein bands being visible by Coomassie staining (Figure 
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22). This is achieved by the addition of ATP to the first wash steps, which 
removes substrates and cofactors from the chaperonin [49]. After buffer 
exchange and concentration of the CCT-containing fractions, a yield of 
approximately 15 mg/ml is typically obtained. CCT is stored in a buffer 
containing 15 % v/v glycerol at -80°C to keep the complex stable. 
 
  
79 
 
4.3 Purification and Labelling of Cdh1 Fragments and 
CaM for FRET 
4.3.1 Resolubilisation of Cdh1 Fragments 
Blades 3 to 5 of Cdc20 have been found to bind to CCT [65], as does the 
equivalent region of Cdh1 (K. R. Willison, unpublished results). Therefore 
fragments of Cdh1 containing either blades 3 to 6 (Cdh1 342-512) or 
blades 3 to 5 (Cdh1 342-469) of the WD40 repeat unit, as shown in Figure 
23, were used to study folding.  
 
 
Figure 23: Diagram representing the WD40 domain of Cdh1. The protein 
fragments expressed contained either blades 3 to 5 (Cdh1 342-469) or 3 to 6 
(Cdh1 342-512) of the Cdh1 WD40 repeat domain. 
 
Since Cdh1 requires CCT to fold correctly, it is insoluble when 
overexpressed in bacteria, as are fragments of the protein. Consequently, 
overexpression in E. coli results in the protein being found in insoluble 
inclusion bodies which must be resolubilised in a manner that allows them 
to be folded and stable. There are advantages to expressing proteins in 
inclusion bodies; large quantities of proteins can be obtained, and the 
protein is less exposed to proteases within the cell that may lead to 
cleavage and breakdown. In order to resolubilise the protein, the washed 
inclusion bodies are resuspended in guanidine hydrochloride (Gu-HCl), 
then the sample is diluted slowly in order to reduce the concentration of the 
denaturant. Finally the sample is dialysed, and the solubilised protein is 
ready to use. Despite being expressed in inclusion bodies, Cdh1 fragments 
break down, presumably due to proteolysis by endogenous bacterial 
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proteins. However, the protein can be readily resolubilised in this manner to 
yield quite high amounts of protein (Figure 24).  
 
 
Figure 24: (a) IPTG induction of Cdh1 342-469; (b) refolding of Cdh1 342-469, 
showing the insoluble pellet after dialysis and the refolded protein fragment. 
 
4.3.2 Purification of Cdh1 Fragments 
Initially, it was hoped that the problem of the protein breaking down could 
be readily solved by locating the breakdown site and introducing a mutation 
that would be resistant to proteolytic cleavage. Based on previous MALDI-
MS data [123], it was probable that breakdown was occurring around amino 
acids R453 and L454 in the Cdh1 sequence. Alanine scanning 
mutagenesis was used to selectively change two amino acids, either R452 
and R453 or L454 and K 456, to alanine using the Stratagene QuikChange 
Kit. This technique was successfully used to generate the mutations in 
Cdh1 342-469 as well as the longer fragment, Cdh1 342-512, which 
contains blades 3 to 6 of the propeller (Figure 23). 
 
The mutated Cdh1 fragments were expressed and refolded (Figure 25 and 
Figure 26). Instead of the original breakdown product, a smaller fragment 
was observed. In addition, very little of the full-length protein remained. 
These two factors suggest that mutation of the Cdh1 sequence is not an 
ideal method to prevent breakdown of the protein. 
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Figure 25: IPTG Inductions of mutated Cdh1 fragments. RRAA1: His-Cdh1 
342-512 RRAA; RRAA2: His-Cdh1 342-469 RRAA; LKAA1: His-Cdh1 342-512 
LKAA; LKAA2: His-Cdh1 342-469 LKAA 
 
 
Figure 26: Refolding of Cdh1 342-512 RRAA and Cdh1 342-512 LKAA 
compared to the native Cdh1 342-512 
 
4.3.3 Affinity Purification of Cdh1 342-469 
A simple way of purifying proteins is through the use of an affinity tag. Many 
tags are very large, which means they must be removed after purification 
has been achieved. In addition, the effect on solubility of the tag must be 
considered, since work carried out in the Willison laboratory suggests that 
soluble Cdh1 fragments can be more susceptible to proteolysis (K. R. 
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Willison, unpublished results). A construct was previously developed to 
allow generation of a cysteine residue at the N-terminus of the Cdh1 
fragment 342-469 [123]. A polyhistidine (His) tag is located at the N-
terminus of the construct, upstream of a FMDV 3Cpro cleavage site, 
PAKQC. Cleavage of this construct with FMDV 3Cpro yields the N-terminal 
cysteine which can then react selectively with a thioester in the presence of 
other thiols (see section 4.3.5) [123]. 
 
Since breakdown appears to be occurring from the C-terminus, the His tag 
cannot be used to isolate the full-length protein, so other affinity tags were 
considered. The Strep-tag binds very strongly to streptavidin, and can be 
released by the addition of biotin. The sequence of the original Strep-tag 
was WRHPQFGG. However, the system was optimized so that the Strep-
tag II, with the sequence WSHPQFEK, can be purified using a modified 
streptavidin known as Strep-Tactin. The main advantage of the Strep-tag II 
is that it can be added at either terminus, unlike the Strep-tag which must 
be added at the C-terminus [124, 125]. By introducing the Strep-tag II 
sequence at the C-terminus of the Cdh1 fragment, it should be possible to 
purify the full length protein. In addition, if used after cleavage with FMDV 
3Cpro, it should be possible to remove the protease in the wash steps. A 
diagram of the Cdh1 fragment expressed is shown in Figure 27. 
 
 
Figure 27: Diagram representing the Cdh1 fragment expressed for labelling 
by NCL. A polyhistidine (His) tag is located at the N-terminus of the 
construct, followed by the cleavage recognition sequence for FMDV 3Cpro. 
This is followed by blades 3 to 5 of the Cdh1 WD40 propeller, and finally a 
Strep-tag at the C-terminus. 
 
The Strep-Tactin purification step removed the majority of the breakdown 
product, as well as the protease present in the sample (Figure 28). The 
micro-centrifuge spin method used rapidly purified the protein, and could 
also be used to purify the labelled protein after the native chemical ligation 
step, thereby removing the free dye.  
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Figure 28: Strep-Tactin purification of Cdh1 342-469 after cleavage with the 
FMDV 3C protease. 
 
4.3.4 Labelling of Internal Cysteines 
There are only two naturally occurring cysteine residues in the yeast Cdh1 
fragment from G342-D469. By mutating one of these, it should be possible 
to selectively label the fragment at different points using commercially 
available maleimide dyes. Site directed mutagenesis was used to mutate 
C349 to an alanine. The cleavage site for the FMDV 3Cpro was removed, so 
that the His tag was located directly upstream of the Cdh1 sequence. This 
fragment Cdh1 342-469 C349A could be refolded and purified using Strep-
Tactin resin in the same way as before. The protein fragment was readily 
labelled by incubation with AF488 C5-maleimide overnight at 4°C (Figure 
29). 
 
Figure 29: Analysis of the refolding and labelling of Cdh1 342-469 C349A by 
SDS-PAGE. (a) Coomassie stained gel, (b) scan of fluorescence emission at 
532nm. Lane 1: refolded Cdh1 342-469 C349A; lane 2: after concentration; 
lane 3: after purification by Strep-Tactin resin; lane 4: after labelling with 
AF488. 
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4.3.5 Native Chemical Ligation 
The mechanism of native chemical ligation (NCL) is very straightforward 
(Figure 30). Nucleophilic attack of the thioester by a thiol group can occur 
at any cysteine residue in the protein sequence. However, this is a 
reversible process, except where it occurs at an N-terminal cysteine. At the 
N-terminus, an irreversible spontaneous intramolecular rearrangement 
occurs which drives the reaction to completion, forming a native peptide 
bond between the thioester and the cysteine residue. The conditions 
required for NCL are ideal for peptide and protein synthesis, since the 
reaction occurs at neutral pH in aqueous solutions. NCL can be used to join 
two peptides together, which can be very useful as non-naturally occurring 
amino acids can be incorporated synthetically [126], as peptides made on a 
peptide synthesiser can be used. This can also allow small proteins to be 
made by ligation of shorter synthetic peptides which would otherwise have 
to be expressed. It is also a useful technique for selective labelling of the 
target protein with a fluorophore [127]. 
 
 
Figure 30: The mechanism of NCL. (a) Nucleophilic attack of the thioester by 
the thiol of cysteine; (b) a spontaneous intramolecular rearrangement leads 
to the irreversible formation of the peptide bond [126]. 
 
4.3.5.1 Synthesis of Rhodamine Red and PromoFluor 488 Thioesters 
The mercaptoethanesulfonate thioesters of Rhodamine Red-X and 
PromoFluor 488 were synthesized from commercially available NHS esters. 
PromoFluor 488, from PromoKine, was chosen as it has very similar 
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excitation and emission wavelengths to fluorescein, but is more 
photostable, is more soluble in water and is less sensitive to pH. 
Rhodamine Red-X is excited at higher wavelengths, and could potentially 
be used as a FRET pair with fluorescein. The fluorophores were dissolved 
in DMF and added to sodium mercaptoethanesulfonate (MESNA) dissolved 
in 0.1 M sodium borate buffer, pH 8.3. After stirring at room temperature for 
3 hours, the final products were analysed by RP-HPLC (Figure 31) and 
MALDI-MS. The reaction went to completion for both of the fluorophores, 
although for the Rhodamine Red thioester, there appeared to be some 
hydrolysis of the product. 
 
Figure 31: Analysis by RP-HPLC of (a) PromoFluor 488 2-
mercaptoethanesulfonate and (b) Rhodamine Red-X 2-
mercaptoethanesulfonate. 
 
4.3.5.2 Labelling of Cdh1 342-469 with Rhodamine Red and 
PromoFluor 488 
The refolded Cdh1 fragment was cleaved with FMDV 3Cpro, and then 
incubated with the fluorescein, PromoFluor 488 or Rhodamine Red 
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thioester. Labelling could be achieved with all three fluorophores (Figure 
32), although a very long incubation time was required for labelling 
Rhodamine Red-X thioester at 4°C. Labelling with the Rhodamine Red-X 
thioester also appears to be less specific. This could be due to the lower 
purity of the fluorophore. 
 
 
Figure 32: Labelling of Cdh1 342-469 with fluorescein (lane 1), PromoFluor 
488 (lane 2) and Rhodamine Red-X (lane 3). (a) Coomassie stained gel, (b) 
fluorescence emission at 526 nm, (c) fluorescence emission at 610 nm. 
 
4.3.6 Purification and Labelling of CaM 
A mutated CaM containing a single cysteine introduced into the central α-
helix (Figure 33) and a His-tag can be overexpressed in E. coli and purified 
from the soluble fraction by immobilised metal affinity chromatography with 
a nickel column. While bound to the resin, Alexa Fluor 555 maleimide was 
added and labelling was carried out at 4°C overnight. 555CaM was eluted 
from the resin with imidazole (Figure 34). Although some impurities were 
present, CaM was the main protein present and further purification by 
sucrose gradient following formation of the Cdh1-CCT-CaM complex meant 
that this single purification step was sufficient.  
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Figure 33: NMR-derived structure of CaM from D. melanogaster in the 
absence of Ca
2+
. Mutation of an aspartic acid residue in the centre of the α-
helix to cysteine allows fluorescent labelling of CaM at a site which does not 
interfere with binding to the CBP inserted into CCT. 
 
 
Figure 34: SDS PAGE analysis of CaM and 
555
CaM. The Coomassie stained 
gel is shown on the left hand side, with in-gel fluorescence shown on the 
right. 
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4.4 Actin Purification 
Since actin requires CCT to fold, it cannot be expressed in bacteria. Yeast 
Act1 was purified and labelled from S. cerevisiae lysate by a well-
established protocol involving affinity chromatography followed by ion 
exchange chromatography. The resulting actin was polymerised and 
labelled before depolymerisation to yield selectively labelled G-actin [100]. 
 
4.4.1 Affinity Chromatography of Act1 using DNase I 
The first step in purification of Act1 from yeast lysate is affinity 
chromatography using an Affigel-DNase I column which binds native 
monomeric actin. Spun down yeast lysate was loaded onto the column, and 
Act1 was eluted from the column with 50 % v/v formamide. Act1 is unstable 
in formamide, so fractions containing the most protein were identified by 
applying samples of each fraction to blotting paper and Coomassie 
staining, which is more rapid than running an SDS gel, although it can only 
reveal which fractions contain protein and not the identity of the protein.  
These fractions were immediately loaded onto a Mono-Q column, and the 
presence of Act1 was confirmed by SDS PAGE (Figure 35). 
 
 
Figure 35: Formamide elution of Act1 from a DNase I affinity column 
analysed by SDS PAGE. The eluate was collected as 1.5 ml fractions as 
indicated. Here, fractions 8 to 17 were loaded onto a Mono Q column. 
 
4.4.2 Ion Exchange Chromatography of Act1 
Native Act1 eluted from the DNase I column was further purified by ion 
exchange chromatography using a Mono Q anion exchange column to 
remove cofilin. A gradient of 100 mM to 300 mM KCl over 50 minutes at a 
flow rate of 0.4 ml/min was applied and Act1 was eluted with approximately 
220 mM KCl (Figure 36 and Figure 37).  
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Figure 36: Ion exchange chromatography of Act1. Act1 was eluted from a 
Mono Q column with a gradient of 100 to 300 mM KCl. The fractions indicated 
were analysed by SDS PAGE (Figure 37). 
 
 
Figure 37: SDS PAGE analysis of fractions collected from ion exchange 
purification of Act1. 
 
4.4.3 Polymerisation and Fluorescent Labelling of Act1 
The purified Act1 was polymerised by addition of 1 mM ATP and 2 mM 
MgCl2; there was sufficient KCl present in the elution buffer to allow efficient 
polymerisation. For fluorescent labelling of Act1, acrylodan, Alexa Fluor 488 
C5 maleimide or IAEDANS were added in a 20-fold, five-fold or 10-fold 
excess, respectively. After incubation overnight, the polymerised actin was 
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centrifuged and the supernatant discarded, thereby removing any 
remaining free dye and any non-native actin.  
 
The pellet was resuspended and dialysed into a low ATP buffer to 
depolymerise actin. The labelling efficiencies were approximately 90 % for 
488Act1, 60 to 80 % for AcrylAct1 and 80 % for AEDANSAct1. Single labelling of 
the actin monomer was confirmed by matrix assisted lased desorption 
ionisation mass spectrometry (MALDI-MS). When run on polyacrylamide 
gels, 488Act1 was imaged using the Typhoon 9400 Variable Mode Imager, 
whereas AcrylAct1 and AEDANSAct1, which are excited at a much lower 
wavelength than 488Act1, were imaged using a UV lamp. Single fluorescent 
bands for fluorescently labelled Act1 were observed by SDS PAGE, 
demonstrating the purity of the labelled protein (Figure 38 and Figure 39). 
Purified ActA was labelled with acrylodan in the same way as Act1, by 
addition of the dye to polymerised actin followed by centrifugation and 
dialysis to remove free dye and any non-native protein (Figure 39). 
 
 
 
 
Figure 38: Coomassie blue stained gel of 
AEDANS
Act1 (left lane) and imaging 
by UV lamp of the same gel (right lane). 
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Figure 39: Coomassie blue staining (left) and imaging by UV lamp (right) of 
SDS PAGE analysis of purified 
Acryl
Act1 and 
Acryl
ActA.  
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4.5  Purification of PLP2 
PLP2 modified to contain a His-tag can be readily overexpressed in E. coli. 
This PLP2 is functional and can be used to form a stable ternary complex 
with CCT and Act1. The truncations of PLP2, PLP2 1-244 and PLP2 60-
286, can also be tagged, overexpressed and purified in this way [76]. 
These truncations contain the thioredoxin fold domain of PLP2 (residues 89 
to 246) which incorporates an actin binding site (220 to 245), as well as the 
CCT-binding region 60 to 89 [76]. Figure 40 shows these truncations with 
respect to the full length PLP2. 
 
 
Figure 40: Diagram of the PLP2 and the truncations used. PLP2 contains a 
thioredoxin fold (89 to 246; TRX) which includes an actin binding region (220 
to 245; green shading), and a CCT-binding region (60 to 289; red) which are 
essential for the formation of a stable ternary complex with Act1 and CCT. 
Two truncations, PLP2 1-244 and PLP2 60–286, were expressed for use in 
Act1 folding assays.  
 
Crosslinking experiments between CCT, Act1 and PLP2 have shown 
interactions between CCT1 and the C-terminal extension of PLP2, CCT4 
and the region between 60 and 89 of PLP2, and CCT8 and the TRX 
domain [40]. 
  
The His-tagged proteins were purified by nickel based immobilised metal 
affinity chromatography using small disposable spin columns for rapid 
purification. Only low volumes of PLP2 could be purified in this way, but as 
a high concentration was expressed in E. coli, sufficient protein was 
obtained for use in folding assays. After cell lysis with detergents, PLP2 
was bound to the resin and washed. If fluorescent labelling was required, 
the thiol-reactive derivative of the dye was added to a final concentration of 
50 µM while the protein was still resin-bound. After incubation overnight, 
the resin was washed and PLP2 was eluted with 250 mM imidazole.  In 
order to remove the high levels of imidazole and NaCl in the elution buffer 
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used, PLP2 and the two truncations were dialysed against 20 mM HEPES 
and 75 mM KCl.  
 
The protein obtained in this very quick purification, taking under an hour for 
unlabelled PLP2, was typically between 0.3 and 1 mg/ml after dialysis. A 
high level of purity was obtained, with only a slight doublet observed for 
PLP2, and a faint band at around 45 kDa, otherwise visible by Coomassie 
staining (Figure 41). 
 
 
Figure 41: His-tagged PLP2, PLP2 60-286 and PLP2 1-244 after nickel affinity 
purification. 
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4.6 Conclusion 
The proteins used to investigate folding of Act1 and the Cdh1 fragment 
342-469 can either be bacterially expressed in the case of PLP2, CaM and 
Cdh1 342-469, or purified from yeast lysate in the case of CCT and Act1. 
High levels of purity can be achieved through the introduction of affinity 
tags into the protein constructs which allow rapid, selective purification of 
the protein of interest. Affinity tags can also be used to isolate full length 
protein from any which has been subject to proteolytic cleavage during the 
purification process. In some cases low levels of impurities were still 
present, which are particularly visible upon labelling with thiol reactive dyes. 
However, isolation of CCT complexes by sucrose gradient can be used to 
remove these at a later stage. 
 
95 
 
5 Folding of the WD40 Repeat Containing Protein 
Cdh1 
5.1 Aims 
While the WD40 repeat containing proteins Cdc20 and Cdh1 are known to 
require CCT for folding [65], little is known about the way in which the 
binding and folding processes occur. The interaction between these 
proteins seems to be transient, although probably of high affinity, making it 
challenging to investigate the binding site of the substrate within the 
chaperonin. Regions of the WD40 propeller of Cdc20 have been identified 
which can bind to CCT (Figure 42) [65], and due to the high level of 
sequence homology between Cdc20 and Cdh1, it is likely that similar 
regions are involved in binding to the chaperonin. 
 
 
Figure 42: Representation of the WD40 repeat domain of Cdh1. Cdh1 
fragments containing blades 3 to 5 and blades 3 to 6 are known to bind to 
CCT [65]. 
 
Stable complexes can be formed between fragments of the WD40 propeller 
and CCT, although at low concentrations which are not suitable for many 
techniques for structure determination. It was hoped that by fluorescent 
labelling of a fragment of Cdh1 capable of binding to CCT, and introduction 
of a second fluorophore using fluorescently labelled CaM which can bind to 
the affinity tag in either CCT3 or CCT6, it would be possible to use FRET to 
measure distances within the complex. The aim was to locate the subunit to 
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which the Cdh1 propeller binds by calculating the relative distances 
between the fluorophores within either the CCT3 or the CCT6 complex. 
 
  
97 
 
5.2 A FRET Control: Fluorescently Labelled 
Oligonucleotides 
Complimentary oligonucleotides labelled with either AF488 or AF555 were 
used to confirm that FRET occurs between these fluorophores with the 
technical setup and conditions to be used in these experiments. The 
oligonucleotides (see Figure 43) were incubated together and also with 
unlabelled complimentary oligonucleotides, and the fluorescence emission 
was observed. Since these fluorophores should be in very close proximity 
to one another, it would be expected that highly efficient energy transfer 
would be observed. Gel electrophoresis was used to purify the double-
stranded DNA from any remaining single-stranded oligonucleotides, 
although the bands were close together so there was some contamination 
of the double stranded DNA with single stranded DNA after electroelution 
from the gel which prevented the calculation of distance between the 
probes. Scanning fluorescence emission when exciting at 488 nm showed 
a strong FRET signal for both pairs of oligonucleotides (Figure 44), with 
oligonucleotides 1 and 2, which are of the same length, exhibiting a 
stronger FRET signal than oligonucleotides 1 and 3, in which the 
fluorophores are further apart. 
 
 
 
Figure 43: Sequences of the complimentary, fluorescently labelled 
oligonucleotides; (1) is labelled at the 5’ end with AF488 whilst (2) is labelled 
at the 3’ end with AF555. (3) is a slightly shorter sequence labelled with the 
acceptor fluorophore. 
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Figure 44: FRET occurs between complimentary oligonucleotides labelled 
with AF488 and AF555. Using two different lengths of oligonucleotide with 
the acceptor fluorophore (oligonucleotide 2, purple, and oligonucleotide 3, 
blue), a strong FRET signal could be observed. The fluorescence emission 
spectrum of the donor-only labelled fluorophore is shown in green. 
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5.3 Purification of CCT-Cdh1 342-469 Complexes 
As discussed in section 1.2.3.2, there is a significant amount of CCT 
binding information found in blades 3 to 5 of the WD40 propeller of Cdc20 
which is very similar to that of Cdh1 (Figure 42) [65]. Fragments of Cdh1 
were purified and labelled (see section 4.3), and these were used to form a 
stable complex with CCT in order to investigate the folding reaction. A large 
excess of the Cdh1 fragment had to be added relative to CCT, so the 
complex then had to be purified in order to remove any unbound 
fluorescently labelled protein which would mask the fluorescence of the 
CCT-Cdh1 342-469 complex. 
 
In order to bind the Cdh1 fragment, and where applicable CaM, to either 
CCT3 or CCT6, the mixture was incubated at room temperature prior to 
loading onto a sucrose gradient (section 5.3). After ultracentrifugation 
overnight, fractions were collected and analysed by SDS-PAGE. In Figure 
45, it can be seen that 488Cdh1 342-469 C349A runs at the top of the 
gradient (fractions 7 to 9) in the absence of CCT. However, in the presence 
of CCT, 488Cdh1 342-469 C349A is found in fraction 4 alongside CCT, 
indicating that a complex is formed between these proteins. Fluorescein-
labelled Cdh1 342-469 bound to CCT can also be isolated in this way. A 
large excess of the Cdh1 fragment must be added to increase the level of 
binding to CCT, as the interaction is of relatively low affinity (see section 
3.7).  
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Figure 45: Purification of complexes of CCT and 
488
Cdh1 342-469 C349A. The 
Coomassie stained SDS gel is shown on the left and fluorescence is imaged 
on the right. (a) CCT and 
488
Cdh1 342-469 C349A; (b) 
488
Cdh1 342-469 C349A 
in the absence of CCT. 
 
While sucrose gradients can be used to isolate the CCT-Cdh1 342-469 
complex, it is not an ideal purification method because despite loading 
equivalent amounts of the sample containing the donor fluorophore, 
acceptor fluorophore or both, the variability between the gradients means 
that the protein concentration is unlikely to be exactly the same in the 
fractions being compared. Since there is no online method to monitor the 
protein concentration, and the sample is very dilute, accurate determination 
of the concentration is difficult. Gel filtration is another method that can be 
used to purify protein complexes based on their size; whilst this has been 
used to isolate the CCT-fluorescein-Cdh1 342-469 complex [123], a large 
amount of protein is required to observe a sufficient signal based on 
absorbance. This makes it impractical as various different complexes must 
be made to be compared, and too much CCT would be required. Whilst 
purification of the CCT-Cdh1 342-469 complex by sucrose gradient has 
been used to prepare samples for FRET measurements within this report, 
other methods of purification are needed to avoid the variability issues 
described above. 
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5.4 FRET Measurements within the CCT-Cdh1 342-469 
Complex 
To make accurate fluorescence measurements, samples with very low 
absorption are required to minimize any inner filter effects. This is a 
problem even at very low concentrations, as for a sample with an 
absorbance of 0.06 in a 1 cm pathlength cuvette the error caused by inner 
filter effects can be as high as 8 % [128]. As a result, fluorescence emission 
intensity is not proportional to the concentration of the fluorophore in 
solution. 
 
In order to minimise the amount of sample required, a 2 mm pathlength 
cuvette was used. Fractions from sucrose gradients were loaded directly 
into the cuvette, and emission scans were obtained exciting at 450 nm in 
order to reduce direct excitation of the acceptor fluorophore. Based on the 
area under the entire spectrum, the concentrations of the samples were 
adjusted using a buffer containing 30 % w/v sucrose to obtain 
approximately comparable samples. This is an inaccurate method of 
comparison of samples, but since the protein concentration of the gradient 
fraction was too low to be determined accurately by any method other than 
fluorescence, absolute quantification of the protein was not possible. 
Approximate concentrations were obtained by measuring the fluorescence 
intensity of bands on an SDS gel, but since the donor-labelled Cdh1 
fragment is very similar in size to the acceptor-labelled CaM, this approach 
was only used for an estimation of the relative concentrations. 
 
Both the NCL product fluorescein-Cdh1 342-469 and 488Cdh1 342-469 
C349A bound to CCT, so 488Cdh1 342-469 C349A was used for the FRET 
studies. Sample preparation and labelling of this fragment were much 
easier and there appeared to be a greater proportion of the full-length 
protein fragment relative to the breakdown product during refolding than 
was observed for the fragment with the wild-type sequence labelled by 
NCL. Alexa Fluor 555 (AF555) was used as the acceptor fluorophore. It 
was chosen as the Förster distance (R0) for the AF488-AF555 FRET pair is 
slightly longer than that of the AF488-AF568 pair (70 Å in comparison to 62 
Å) [129]. The emission scans obtained while exciting at 540 nm were used 
to approximate the concentration of the CaM, so that corrections for direct 
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excitation of the acceptor fluorophore at the donor excitation wavelength 
could be made. 
 
In this series of experiments, a slight FRET signal was observed between 
488Cdh1 342-469 C349A and 555CaM bound to CCT6, whereas for the 
CCT3 complex no FRET signal was observed. An example of this 
behaviour is shown in Figure 46. However, upon repetition of the 
experiment there are variations in the amplitude of the signal observed 
meaning that distance could not be accurately calculated from this data. 
Errors based on correcting for direct acceptor excitation by the incident light 
beam are probably caused by issues in the sample preparation since the 
concentration of samples cannot be measured accurately and fluorescence 
intensity does not necessarily correlate with the concentration of the 
fluorophore in solution. There should be close to 100 % occupancy of the 
CaM binding sites as the interaction between CaM and the CBP is very 
high. As such it can be assumed that there is an acceptor fluorophore 
present for every donor. However, the occupancy of CCT complexes with 
the Cdh1 fragment is unknown and may well be as low as 10 to 20 %. With 
such low levels of the donor fluorophore present in the complex, slight 
variations in the occupancy between samples could have a significant 
effect on the ability to compare the different complexes. This may account 
for some of the differences in the signal observed at the acceptor emission 
wavelength. 
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Figure 46: Emission scans of CCT, 
488
Cdh1 342-469 C349A and 
555
CaM 
complexes purified by sucrose gradient, exciting at 488 nm. (a) Complex 
formed using CCT3, (b) complexes containing CCT6. 
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5.5 Discussion 
5.5.1 Purification of Cdh1 342-469-CCT-CaM Complexes 
Although the interaction between Cdh1 and CCT is too weak to be picked 
up by many assays to identify CCT binding partners, the complex formed 
between partial fragments of the Cdh1 WD40 propeller, which cannot be 
folded and released, and the chaperonin are much more stable. The 
binding affinity of 488Cdh1 342-469 for CCT must still be relatively low since 
a large excess of substrate must be added to ensure a sufficient 
fluorescent signal. As a result, purification of the complex from free 488Cdh1 
342-469 was essential to maximise any possible FRET signal within the 
488Cdh1 342-469-CCT-555CaM complex. Fortunately, since CCT cannot 
release the Cdh1 fragment, the complex could be readily purified by 
sucrose gradient. This allowed addition of an excess of both 488Cdh1 342-
469, as well as 555CaM, which binds to CCT much more readily and should 
essentially saturate all possible binding sites. 
 
Purification of the 488Cdh1 342-469-CCT-555CaM complex can be achieved 
by sucrose gradient. The advantage of this method is that a relatively small 
amount of sample can be loaded, and multiple sucrose gradients can be 
run simultaneously. Intact protein complexes can be purified away from any 
dissociated monomers. However, since there is no automated sample 
collection or online monitoring of the content of the fractions collected, this 
is a lengthy process for protein purification. Since the fractions are 
manually collected, there is always going to be some variation in the 
composition of the samples since the volume collected is not exact and this 
will lead to slight variations in the percentage of sucrose present in 
samples. Furthermore, since the gradients are prepared manually there will 
inevitably be some disparity between gradients, and as such while the 
distribution of fractions containing the desired proteins is the same, the 
location within the gradient may differ slightly. 
 
Fractions containing the Cdh1 342-469-CCT-CaM complex were identified 
by SDS-PAGE, and the concentration of these fractions was estimated. 
Similar concentrations were generally obtained, although this depended on 
whether the protein eluted predominantly in one fraction or across multiple 
fractions. 
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Purification of Cdh1 fragments bound to CCT can be carried out by gel 
filtration [123]. Although this does provide online monitoring of the elution of 
proteins and the opportunity to quantify proteins based on absorbance, only 
one sample can be run at a time. Since for any one set of conditions at 
least three samples are required (donor-only, acceptor-only and dual-
labelled complexes) and ideally to compare different conditions samples 
should be produced at the same time, this is a significant limit to the use of 
FPLC to purify the Cdh1 342-469-CCT-CaM complexes. Samples are also 
diluted substantially in the process. 
 
5.5.2 Measuring FRET within the 488Cdh1 342-469-CCT-555CaM 
Complex 
It can be seen from the control using complementary oligonucleotides 
labelled with AF488 and AF555 can be used as a FRET pair. Quantitative 
measurements of distance cannot be made since during purification since 
there was some contamination of the dual-labelled, double stranded DNA 
which affects the ratio of peak heights. The exact distance is not known 
between the probes, which are attached via linkers and presumably able to 
freely rotate. Nonetheless, FRET is clearly occurring, and since the 
literature value for the Förster distance of these two fluorophores is 
relatively long at 70 Å [114], this seems like an appropriate pair for 
investigating the Cdh1 342-469-CCT-CaM complex. 
 
Fluorescence emission spectra exciting at 488 nm were obtained for 
purified complexes of 488Cdh1 342-469-CCT-555CaM and their singly-
labelled counterparts. Ideally, samples should contain the minimum amount 
of sucrose possible since this makes samples very difficult to load into the 
cuvette. A 2 mm pathlength cuvette was used to minimise the sample 
volume required; however, pipette tips could not reach to the bottom of the 
cuvette so care had to be taken to ensure that there were no bubbles which 
might interfere with the gathering of data. The greater the percentage of 
sucrose, the more challenging it was to clean the cuvette thoroughly in 
between samples. A further issue arising due to the presence of high 
percentages of sucrose and to a lesser extent glycerol was the effect on the 
refractive index, which is greater in the presence of these more dense 
substances. Small changes in the refractive index can have a significant 
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effect on the Förster distance and reduce the range over which energy 
transfer can occur.  
 
Since the Cdh1 fragment had a relatively low affinity for CCT, the samples 
obtained following purification by sucrose gradient were relatively dilute. 
This meant that further dilution to reduce the amount of sucrose present 
was not possible as samples were then too dilute to measure fluorescence 
emission. 
 
Although it appears that FRET occurred between the AF488-labelled Cdh1 
fragment and the AF555-labelled CaM, only a very small signal could be 
observed when using CCT6. No FRET was observed using CCT3. 
Furthermore, the signal was not reproducible, and as a result no 
measurement of the distance between the two fluorophores could be made. 
For identifying the location of the Cdh1 fragment on CCT, a FRET signal 
within both the complexes would be necessary. A weak signal within the 
CCT6 complex may suggest that the probe on the Cdh1 fragment is closer 
to subunit CCT6 than to subunit CCT3. However, since there were 
difficulties in generating comparable samples with the double- and single-
labelled complexes, it could be that the signal observed is due to errors in 
correction for direct excitation of the acceptor fluorophore. Therefore no 
reliable FRET measurements can be made using this system. There are 
several reasons why this could be the case. Using the AF488-AF555 FRET 
pair, distances of around 100 Å can be measured. It is not unlikely that the 
fluorophores are too far away from each other due to the size of the CCT 
complex. Extra distance is added into the complex by the linker which joins 
the CBP tag to CCT. The fluorophores themselves contain linkers between 
the reactive group and the fluorescent moiety. 
 
In addition, while under optimal conditions the Förster distance for the 
AF488-AF555 FRET pair is 70 Å, in practise this may well not be the case. 
There are many factors which affect the range over which FRET can occur. 
As mentioned above, the refractive index of the sample can have an effect. 
A more common and significant factor is the orientation factor κ2, which is 
awkward to calculate. This can take any value from 0 and 4 depending on 
the relative orientation of the two fluorophores; however, it is generally 
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assumed to be 2/3 since this is the value for two freely rotating fluorophores 
[107]. In reality, this may not be the case as motion of one or both of the 
fluorophores may be restricted. Furthermore, the environment of the probe 
may have an effect on the quantum yield. If the quantum yield of the donor 
is reduced, this will reduce the distance over which FRET may be 
observed. 
 
The various factors which could prevent FRET from occurring mean that 
while an absence of energy transfer could be due to the distance between 
the fluorophores, there are also other reasons that could be responsible. As 
such, while a positive FRET result can be used to confirm that two probes 
are in close proximity to one another, a negative result cannot conclusively 
give any indication of the relative locations of the two fluorophores. This is a 
major disadvantage to the technique. 
 
Based on this, nothing can be conclusively determined regarding the 
binding site of Cdh1 on CCT. Although there may be slight evidence to 
suggest that it the Cdh1 fragment is located closer to CCT6 than CCT3, this 
is inconclusive. This method of studying the Cdh1-CCT complex is 
therefore not appropriate. 
 
It may be that through the introduction of affinity tags into other subunits of 
CCT, a fluorophore could be introduced into the complex in a different 
location which would yield a more promising result. However, the size of 
the complex, plus the bulky method of introducing the acceptor fluorophore 
through a third protein, makes it likely that this would not be successful. 
Moreover, since an additional component is introduced into the system it 
makes it more likely that not all complexes will contain the acceptor 
fluorophore. Although both the labelling of CaM and the binding of the 
protein to CCT are very efficient, it is likely that a small proportion of 
labelling and binding sites will remain unoccupied. Saturation of complexes 
with the donor fluorophore, while helpful in that a larger signal will be 
generated, is not essential, since complexes which do not contain the 
donor will clearly not be able to contribute to FRET. It is much more 
important that all complexes contain the acceptor fluorophore, as 
complexes only labelled with the donor will affect the apparent FRET 
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efficiency. Ideally, it would be possible to introduce a fluorophore directly 
into the CCT complex. However, there are too many potential labelling sites 
within the complex to make this a sensible course of action.  
 
The use of different fluorophores affects the likelihood of observing FRET 
with a system. The pair of Alexa Fluor dyes were chosen for their high 
photostability, relatively small size, the particularly high quantum yield of 
AF488, and the relatively long Förster distance. Whilst other FRET pairs 
may affect the outcome, it seems unlikely that this would be the case. 
 
The low binding affinity of Cdh1 for CCT mean that the complexes 
generated are not very concentrated. There may well be a cofactor that 
assists in the loading of Cdh1 onto the chaperonin; if such a protein were to 
be discovered, it might assist in the generation of more highly fluorescent 
samples. With the current concentrations, only a small fluorescent signal is 
observed meaning that no further dilution of the sucrose in the sample was 
possible. Quantification of samples purified by sucrose gradient is also 
challenging. At the moment, substantial errors originating from sample 
preparation mean that any FRET signal observed in this complex cannot be 
accurately quantified. Ideally, it should be possible to keep a constant 
amount of both the donor and the acceptor throughout all samples. This 
would enable a direct comparison of the ratio of the two peaks, so 
variations in concentration should be less significant. However, the sucrose 
gradient purification is not consistent enough to produce directly 
comparable samples. 
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5.6 Conclusions 
FRET does not appear to be an appropriate tool to study the binding of 
Cdh1 to CCT at this point in time. There are many contributing factors; the 
difficulties which arise in the selective labelling of such a complex protein 
as CCT is a particularly large obstacle, and at this time has only been 
achieved through introduction of a fluorescently labelled protein which can 
bind selectively to CCT. Cdh1, whilst confirmed as a substrate for CCT, 
seems to bind relatively weakly to the chaperonin. The size of the complex 
means that unless the acceptor fluorophore is located on a subunit very 
close to the binding site of the substrate, FRET would not be possible due 
to the distance between the fluorophores. Errors in sample production due 
to the low concentration of fluorescent protein make it difficult to compare 
samples, and as such make the accurate detection of small signals 
impossible. Although the results obtained may indicate that the fragment 
Cdh1 342-469 is closer to subunit CCT6 than CCT3, this cannot be 
confirmed in the absence of any signal when the fluorescently labelled 
Cdh1 fragment is bound to CCT3. 
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6 A Spectroscopic Actin Folding Assay 
6.1 Aims 
Actin is an essential cytoskeletal protein in eukaryotes and requires the 
molecular chaperonin CCT to fold to its native state. As well as CCT and 
actin, the thioredoxin-like protein PLP2 is involved in the folding process in 
yeast. A ternary complex of these three proteins is formed, and can be pre-
assembled by chemical unfolding of Act1 in the presence of CCT and 
PLP2. Here, the aim was to develop a spectroscopic folding assay suitable 
for studying the release of actin from the pre-assembled Act1-CCT-PLP2 
complex. The conditions for folding of 488Act1 in the in vitro folding assay 
have already been optimised for gel-based analysis [76]. By labelling Act1 
with a suitable probe, it should be possible to transfer this assay to a 
cuvette-based spectroscopic assay in which actin folding by CCT can be 
followed in real time. This would allow more rapid investigation of the 
reaction and as such would facilitate the study of a wider range of 
conditions. Furthermore, continuous monitoring of the folding reaction 
would be possible resulting in the determination of more accurate rate 
constants and allowing smaller differences between different folding 
conditions which would not be identified by the gel-based assay to be 
distinguished. As discussed in section 1.5.3, a range of environmentally 
sensitive fluorophores exist in which fluorescence varies depending upon 
the polarity of the surroundings.  
 
Two conditions must be met regarding the choice of fluorescent tag: 
1) A significant change in the fluorescence emission spectra must occur 
upon unfolding of the native actin monomer to the intermediate I3, and 
2) Modification of Act1 with the dye must be compatible with the 
unfolding/folding cycle. 
 
By selective labelling of the C-terminus of actin with one of these probes, 
the kinetics of actin folding by CCT could be studied. First, a suitable probe 
had to be identified and its use as part of a functional actin folding assay 
established. Much of this work and that described in subsequent chapters 
is discussed in Stuart et al (2011) [130], a copy of which can be found in 
Appendix 2. 
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6.2 Gel-based Actin Folding Assay: Release of 488Act1 
from CCT 
The established in vitro folding assay [76] was used to confirm the release 
of 488Act1 from CCT preparations and to use as a comparison for folding 
assays using other fluorescent tags. 488Act1 was loaded onto CCT by 
unfolding with 1.5 mM EDTA in the presence of the chaperonin for 3 hours 
at room temperature. This was done in 10 % v/v glycerol to prevent 
breakdown of the CCT complex. After loading onto CCT, 488Act1 was 
released from CCT by the addition of 2 mM ATP and 10 mM MgCl2. The 
reaction mixture was incubated at 30°C and aliquots were taken at five 
minute intervals. These samples were diluted in 20 mM HEPES, 10 % v/v 
glycerol, 1 mM CaCl2 and kept on ice to prevent further folding. Release of 
actin can clearly be seen by native PAGE, and the shift in the band upon 
binding to DNase I confirms that the protein is correctly folded to its native 
state [76] (Figure 47). 
 
 
Figure 47: Time course of release of 
488
Act1 from CCT monitored by native 
PAGE. Coomassie staining (left panel) and in-gel fluorescence exciting at 488 
nm (right panel) are shown for the same 6 % native gel containing 1 mM ATP. 
The time in minutes after addition of ATP and MgCl2 is shown, and in the final 
lane DNase I has been added which binds G-actin. 
 
Release of 488Act1 was also carried out at 20°C to confirm the temperature 
dependence of the rate of release in vitro. By quantification of the 
fluorescence on the CCT, band which corresponds to CCT-bound 488Act1, it 
can be seen that actin is released at a slower rate from CCT (Figure 48). 
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Figure 48: An example of 
488
Act1 fluorescence on the CCT band following 
release with 2 mM ATP, 10 mM MgCl2 at 20°C (purple) or 30°C (blue). 
 
A difference in the rate of release can be observed, however without 
collecting many more time-points accurate determination of the rate of 
release is very difficult and error-prone due to human errors when collecting 
samples and accuracy of the quantification of bands in the gel. While the 
same band across a time course can be compared directly, counts on 
different bands within the same lane cannot since the quantification of 
fluorescence emission is not absolute. For example, the number of 
fluorescence counts lost from the 488Act1-CCT band upon release of 488Act1 
is not the same as the number of counts on the actin band. This could be 
because the 488Act1-CCT band is more compact and there is some self-
quenching of the dye. 
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6.3 Labelling of Act1 
6.3.1 AEDANSAct1 
AEDANS-labelled actin has been used to characterise a range of different 
processes, such as exchange of Ca2+ for Mg2+ at the high affinity cation 
binding site within the actin cleft [131] and the interaction between actin 
filaments and myosin [132] due to the resulting changes in fluorescence 
emission of the dye. As such, it seemed a reasonable starting point for the 
development of a spectroscopic actin folding assay. IAEDANS is a widely 
used solvatochromic fluorophore which reacts selectively with thiols at 
physiological pH, and is cheap and readily available. Attack of the thiol of a 
cysteine leads to labelling with the AEDANS moiety by an SN2 nucleophilic 
substitution mechanism [133] (Figure 49). 
 
 
Figure 49: Act1 can be labelled with AEDANS by nucleophilic substitution at 
the iodoacetyl group of the fluorescent dye. 
 
A labelling efficiency of approximately 80 % was achieved (see section 
4.4.3). Since the rate of unfolding of unlabelled Act1 is very slow [103], and 
any unlabelled actin is invisible with respect to the in vitro folding assay, no 
further purification was performed and this AEDANSAct1 was used to test 
whether AEDANS was an appropriate dye for this assay. 
 
To confirm that the fluorescence emission of AEDANSAct1 differed between 
the native and unfolded states, AEDANSAct1 was unfolded at room 
temperature by addition of 1.5 mM EDTA. EDTA chelates the Ca2+ cation 
essential to the stability of G-actin, which leads to loss of the nucleotide 
from the actin monomer and unfolding to the I3 state [100]. Fluorescence 
emission spectra were collected for native and chemically unfolded 
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AEDANSAct1 exciting at 335 nm and scanning emission from 400 to 550 nm. 
As actin was unfolded, the wavelength of maximum AEDANS emission was 
blue shifted from 485 nm to 475 nm, and an increase of approximately 15 
% in the intensity of emission was observed (Figure 50).  
 
 
Figure 50: Fluorescence emission spectra for native 
AEDANS
Act1 (purple) and 
EDTA-unfolded 
AEDANS
Act1 (blue) exciting at 335 nm. 
 
Since a clear difference could be observed between the fluorescence 
emission spectra of native and unfolded AEDANSAct1, the next step was to 
test the compatibility with the in vitro folding assay. 488Act1 was replaced 
with AEDANSAct1, and after EDTA unfolding of actin and loading onto CCT, 2 
mM ATP and 10 mM MgCl2 were added and the reaction mixture was 
incubated at 30°C. Aliquots were taken over time and diluted in a buffer 
containing calcium to stabilise the released actin. The in-gel fluorescence of 
AEDANSAct1 can be detected by illumination with a UV lamp; however, the 
excitation wavelength of 365 nm is not ideal, and the signal was not strong 
enough for accurate quantification of the fluorescent bands. It was not 
possible to detect any release of native AEDANSAct1 from CCT over the 20 
minute timescale sufficient for maximum release of 488Act1 by in-gel 
fluorescence, and by western blot only a small amount of native actin is 
seen to be released (Figure 51). 
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Figure 51: Western blot for actin; release of 
AEDANS
Act1 from CCT following 
addition of 2 mM ATP and 10 mM MgCl2. The time is shown in minutes 
following addition of nucleotide. 
 
This meant that AEDANSAct1 was unsuitable for use in the spectroscopic 
folding assay, since in order to make accurate measurements of the rate of 
actin folding a significant change in the emission throughout the folding 
process was required. Furthermore, a major advantage of a spectroscopic 
assay would be the ability to make repeat measurements of the same 
sample throughout the process, thereby eliminating errors in pipetting when 
collecting aliquots for a gel based assay. For this, folding needs to take 
place over a timescale during which photobleaching does not interfere with 
any environment induced change in the emission of the fluorophore. 
Release of AEDANSAct1 from CCT did not occur within a reasonable 
timescale or with an adequate level of efficiency to allow monitoring of the 
reaction spectroscopically. 
 
6.3.2  AcrylAct1 
AEDANSAct1 could not be incorporated into the pure in vitro folding assay. 
However, the fact that 488Act1 can be released efficiently within this system 
indicates that the nature of the fluorescent probe can affect the ability of 
CCT to fold labelled actin correctly. Therefore, labelling of Act1 with a 
different environmentally sensitive probe, acrylodan, was attempted. 
Acrylodan [117] is a thiol reactive derivative of the fluorophore 6-propionyl-
2-(dimethylamino)-napthalene (prodan), another naphthalene-based dye 
which is substituted in the 2 and 6 positions, maximising the distance 
between the alkylamino electron donor group and carbonyl electron 
acceptor group [134]. Acrylodan can react with cysteine residues through 
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Michael addition of the thiol at the acryloyl group to form a stable thioether 
bond (Figure 52) [135]. A similar labelling efficiency of 60 to 80 % was 
achieved for AcrylAct1 compared to the 80 % labelling with AEDANSAct1.  
 
 
Figure 52: Act1 can be labelled with acrylodan at Cys 374 through Michael 
addition to form a thioether bond [135]. 
 
Unfolding of AcrylAct1 was performed as before by addition of 1.5 mM EDTA 
to the actin solution. The fluorescence emission of AcrylAct1 was scanned 
from 425 to 525 nm, exciting at 380 nm. The change in fluorescence 
emission as the acrylodan-labelled actin is unfolding is substantial, with a 
decrease in the maximum emission wavelength from 489 nm to 463 nm, 
which is accompanied by a 35 % increase in the intensity of emission 
(Figure 53) [130]. The fluorescence emission of the CCT-bound AcrylAct1 is 
the same as that of unfolded AcrylAct1I3. 
 
 
Figure 53: Normalised fluorescence emission spectra of 
Acryl
Act1 (purple), 
Acryl
Act1I3 (blue) and 
Acryl
Act1-CCT (green) [130], exciting at 380 nm. 
 
By fitting of a single exponential to the increase in fluorescence emission as 
determined by the integrated area under the curve, the rate constant for 
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unfolding of AcrylAct1 at 24°C was found to be 7.85 x 10-3 ± 0.61 x 10-3 s-1. In 
the presence of 10 % v/v glycerol, which is required for the stability of the 
CCT complex, the rate constant was 1.48 x 10-3 ± 0.10 x 10-3 s-1 (Figure 
54). The three hour unfolding step used in the gel-based folding assay was 
retained in sample preparation for the spectroscopic assay to ensure 
maximum unfolding and loading onto CCT. 
 
 
Figure 54: The fluorescence emission of 
Acryl
Act1 increases as it is 
chemically unfolded with EDTA in the presence (blue) or absence (purple) of 
10 % v/v glycerol. 
 
Since there was a clear change in the fluorescence emission of AcrylAct1 as 
unfolding occurred, the next step was to confirm that modification with 
acrylodan did not prevent release from CCT as was the case for AEDANSAct1. 
After unfolding of AcrylAct1 with EDTA for 3 hours in the presence of CCT, 2 
mM ATP and 10 mM MgCl2 were added and the folding reaction was 
followed by native PAGE (Figure 55). It can be seen that unlike AEDANSAct1, 
AcrylAct1 is released from CCT, indicating that modification of the C-terminus 
of actin with acrylodan does not affect the folding and release from CCT. 
The gel was imaged on a UV lamp which excites at a lower wavelength 
than the optimal excitation wavelength of acrylodan and is of lower power 
than the laser used for in-gel fluorescence scans of 488Act1 release. 
Furthermore, the quantum yield of acrylodan is much lower than that of 
dyes such as Alexa Fluor 488, so a very concentrated sample had to be 
loaded on to the gel in order to visualise bands, and the bands were too 
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faint to quantify. Residual unlabelled actin is therefore visible by Coomassie 
staining. 
 
 
 
Figure 55: Time course of release of 
Acryl
Act1 followed by native PAGE. The 
time in minutes after addition of 2 mM ATP and 10 mM MgCl2 is shown, and 
in the final lane DNase I has been added to bind G-actin. Coomassie blue 
staining (left) and in-gel fluorescence (right) of the same native gel are 
shown. 
 
6.3.3 Confirmation of the Formation of Native Actin within the in vitro 
Folding Assay 
DNase I is frequently used to demonstrate that native actin has been 
formed, however the binding site is relatively remote from the modification 
site. To further confirm that the CCT-refolded actin is native in structure, 
binding of another actin binding protein, vitamin D binding protein (VDBP) 
was added following the refolding of both 488Act1 and AcrylAct1. The Act1-
DNase I complex runs higher on a native gel than the uncomplexed Act1, 
with the Act1-VDBP complex running higher still (Figure 56) [130]. 
  0      5    10    15    20    D      0     5    10    15    20    D
AcrylAct1-CCT
AcrylAct1NAT
AcrylAct1-DNase I
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Figure 56: Release of native Act1 from CCT can be confirmed by binding to 
both DNase I (D) or VDBP (V) [130]. Coomassie blue stained gels (left-hand 
side) and in-gel fluorescence (right-hand side) are shown for release of (A) 
488
Act1, and (B) 
Acryl
Act1 from CCT. The time in minutes after addition of ATP 
is shown. Unlabelled PLP2 is also visible on these gels, as shown by . 
 
To confirm further that native Act1 was formed in the release assay, co-
polymerisation of CCT-refolded 488Act1 and AcrylAct1 with unlabelled Act1 
was performed. Following centrifugation, the pellets were analysed by SDS 
PAGE (Figure 57) [130]. In order to ensure maximum polymerization of the 
labelled actin, the reaction was carried out overnight on ice with a final 
concentration of less than 4 % v/v glycerol. Under these conditions, CCT is 
prone to aggregation and as such can also be observed in the pellet. Due 
to the low concentrations required for the folding assay to prevent 
aggregation of unfolded actin and CCT, the refolded actin cannot be 
directly polymerized and the only way to assess this capability is through 
co-polymerisation with native G-actin. This does not allow for the extent of 
polymerization to be determined, and it is likely that not all the labelled actin 
is incorporated into the filament. Nonetheless, it is clear from the SDS gels 
120 
 
that fluorescent actin is present in the pellet, demonstrating that CCT-
refolded Act1 labelled at Cys374 is capable of forming filaments. This 
provides further evidence that native G-actin is formed in the in vitro folding 
assay. 
 
 
Figure 57: CCT-refolded 
488
Act1 and 
Acryl
Act1 were co-polymerised with 
unlabelled Act1 [130]. The spun-down pellets of F-actin filaments were 
analysed by SDS PAGE. The Coomassie blue stained gel is shown on the left 
hand side, followed by in-gel fluorescence. Residual CCT aggregates under 
the polymerization conditions and is also observed in the pellet. 
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6.4 Use of AcrylAct1 in a Spectroscopic Folding Assay 
Since the fluorescence emission spectra of unfolded and native AcrylAct1 
were significantly different, and the acrylodan moiety did not inhibit folding 
by CCT, release was next carried out in a cuvette, with the fluorescence 
emission monitored over time. One of the major advantages of this 
technique is that the reaction could be monitored in real time and in situ, 
without the requirement to remove aliquots in order to observe the system. 
This not only reduces the major source of human error, but also makes 
data collection much faster, thereby allowing wider range of conditions to 
be investigated.  Furthermore, there is the potential to monitor the change 
in fluorescence continuously, which means that the rate of unfolding can be 
determined more accurately than is possible using the gel based assay. 
 
Acrylodan is very photostable, and can be exposed to light continuously for 
at least 15 minutes without any significant change in the emission of the 
AcrylAct1-CCT complex (Figure 58). 
 
 
Figure 58: Fluorescence emission for 
Acryl
Act1-CCT is not affected by 
photobleaching within the 15 minute time frame in which folding occurs. 
 
AcrylAct1 was loaded onto CCT as for the gel based assay, and then aliquots 
were frozen and thawed on ice as required for the release reaction. This 
was to ensure that the start point of the reaction was consistent as 
conditions such as ATP concentration and temperature of the release 
reaction were varied. There was also an additional advantage in that the 
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three hour unfolding reaction, which was the most time-consuming step of 
the process, could be performed in bulk. 
 
Initially, fluorescence spectra were collected, exciting at 380 nm and 
repeatedly measuring the fluorescence emission from 425 to 525 nm with 
an integration time of 0.5 s, throughout the release assay. The shortened 
scan and the reduced integration time reflected the requirement to collect 
as many time points as possible within the timescale of the folding process; 
using these settings the scans were approximately one minute apart.  The 
first and last spectra from a set of scans of the fluorescence emission 
following addition of 2 mM ATP and 10 mM MgCl2 to 
AcrylAct1-CCT are 
shown in Figure 59. A decrease in the fluorescence emission, typically of 
approximately 20 %, was observed upon release of AcrylAct1, as well as a 
shift in the emission wavelength to around 480 nm. As can be seen from 
native PAGE analysis, some actin is not released from CCT, and as such 
the emission spectrum following release does not return fully to that of 
native actin alone.  
 
 
Figure 59: Fluorescence emission spectra of 
Acryl
Act1NAT following release 
from CCT (blue) and 
Acryl
Act1-CCT (purple) exciting at 380 nm. 
 
Collecting of emission spectra throughout the folding process was time 
consuming, and only a select few time points could be collected. This was 
because using the equipment available, fluorescence emission could only 
be measured at one wavelength at any point in time. Relatively low 
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concentrations of the labelled complex were used to prevent aggregation, 
so high integration times were required to obtain clear spectra. The limiting 
factor in the number of data points that could be collected was the length of 
time it took for each scan. It was found that monitoring the fluorescence 
emission at 470 nm could be used to determine the rate of release since 
the decrease was the same as for the decrease in the area underneath the 
fluorescence emission spectrum as actin was released (Figure 60). 
 
Figure 60: Release of 
Acryl
Act1 monitored by fluorescence spectroscopy, 
either by integrating the area under fluorescence emission spectra (purple) 
or by using the fluorescence emission at 470 nm from the spectra obtained 
(blue) as the folding reaction progresses. 
 
It was therefore decided to measure fluorescence at 470 nm continuously 
so that the sensitivity of the assay could be improved. When measuring the 
fluorescence emission in this way, it could be seen that an initial mixing and 
equilibration phase occurred even in the absence of ATP, indicating that 
the slight change in fluorescence emission during the first minute did not 
reflect a folding event by CCT (Figure 61). For this reason, when fitting data 
to obtain release rates the first 50 seconds of the scan were disregarded. 
 
0 5 10 15
70
80
90
100
Area
470 nm
Time (min)
F
lu
o
r
e
sc
e
n
c
e
F
lu
o
re
sc
en
ce
 i
n
te
n
si
ty
 
124 
 
 
Figure 61: Fluorescence emission of 
Acryl
Act1-CCT at 470 nm following 
addition of 10 mM MgCl2 (purple) or 2 mM ATP, 10 mM MgCl2 (blue).  
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6.5 Kinetics of AcrylAct1 Folding by CCT 
A single exponential was fitted to the curves obtained for fluorescence 
emission allowing the rate constants for the release of AcrylAct1 to be 
determined. The rate of release of AcrylAct1 from CCT was initially 
determined using PLP2 which had not been buffer exchanged from the 
elution buffer used for affinity purification, meaning that the folding reaction 
was carried out in the presence of approximately 4 mM imidazole and 4 
mM NaCl as well as the other buffer components of the folding assay. The 
rate of release with 2 mM ATP and 10 mM MgCl2 was determined over a 
range of temperatures from 17.5°C to 37°C, and the rate constants 
determined were used in the Arrhenius equation.  
 
The Arrhenius equation (equation 4) describes the relationship between the 
rate constant k and the temperature of a reaction: 
    (4) 
where A is a pre-exponential factor, Ea is the activation energy of a 
reaction, R is the gas constant, and T is the temperature. This can be 
rearranged to give equation 5: 
   (5) 
which can be used to determine the activation energy of a reaction by 
plotting ln k against 1/T. Changes to the mechanism of a reaction at 
different temperatures can be identified by deviations from a linear 
Arrhenius plot. 
 
From the Arrhenius plot for release of AcrylAct1 from CCT in the presence of 
non-buffer exchanged PLP2, it can be seen that the response of the rate of 
actin folding by CCT to changes in temperature is linear over this range 
(Figure 62). However, it was also found that by buffer-exchanging of PLP2 
into 20 mM HEPES pH8, 75 mM KCl, the overall temperature dependence 
of the reaction was lowered (see Figure 63), indicating that something in 
the buffer, most likely the imidazole, interferes with the folding reaction and 
in fact enhances the rate of release at higher temperatures. 
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Figure 62: Arrhenius plot of release of 
Acryl
Act1 from CCT with 2 mM ATP 
using PLP2 in Zymo Elution Buffer (50 mM sodium phosphate pH 7.8, 300 mM 
NaCl, 250 mM imidazole). This shows a linear dependence on temperature 
between 22.5°C and 37°C, with a gradient of -8369 ± 466 which corresponds 
to an Ea of 69.6 ± 4 kJ mol
-1
. 
 
In S. cerevisiae, the intracellular ATP concentration ranges between 1.1 
mM and 4.6 mM [136], so for simplicity the rate of release of AcrylAct1 from 
CCT was measured in the presence of 1 mM, 2 mM and 4 mM ATP. A five-
fold excess of MgCl2 was added at the same time as the ATP based on 
work by McCormack et al [76] which showed that this was sufficient Mg2+ 
for chaperonin function over and above that chelated by ATP. The release 
rate was determined for these ATP concentrations at 25°C, 30°C and 35°C. 
The rate constants obtained are shown in Table 2. 
 
 CCT 
1 mM ATP 2 mM ATP 4 mM ATP 
25°C 1.3 x 10
-3
  
± 0.2 x 10
-3
 
2.8 x 10
-3
  
± 0.5 x 10
-3 
4.1 x 10
-3
  
± 0.2 x 10
-3 
30°C 2.8 x 10
-3 
± 0.2 x 10
-3 
3.8 x 10
-3
  
± 0.3 x 10
-3 
5.7 x 10
-3
  
± 0.5 x 10
-3
  
35°C 4.1 x 10
-3
  
± 0.3 x 10
-3
  
4.3 x 10
-3  
± 0.4 x 10
-3 
6.4 x 10
-3
  
± 0.6 x 10
-3 
 
Table 2: Observed rate constants k (s
-1
) for release of 
Acryl
Act1 from CCT at 
different temperatures and concentrations of ATP. 
 
0.00320 0.00325 0.00330 0.00335 0.00340
-7.0
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-5.0
-4.5
T (K)
ln
(k
)
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The rate of release of AcrylAct1 determined in this assay appears to be 
slightly slower than reported for the release of 488Act1 with 1 mM ATP at 
30°C as measured by the gel-based assay [76], from which a rate constant 
of approximately 4 x 10-3 s-1 was obtained, although with 4 mM ATP the 
rate of release was the same. This could be due to differences between 
488Act1 and AcrylAct1; as can be seen by the inhibitory effect of the AEDANS 
moiety on actin folding, the nature of the fluorescent probe can influence 
folding of the protein by CCT. It could also reflect the degree of resolution 
that can be achieved through these two assays. The spectroscopic assay 
can be used to measure the rate of folding continuously and in situ, 
whereas in the gel-based assay snap-shots of the reaction at different time 
points are observed. Since the folding reaction occurs within a matter of 
minutes, the resolution is limited by the time taken to collect samples. 
Furthermore, while dilution of the folding reaction mixture and incubation on 
ice should largely prevent any further folding activity, some small amount of 
actin could be released following sample collection.  
 
The Arrhenius plots for release of AcrylAct1 at different concentrations of 
ATP are shown in Figure 63. The activation energy for release of AcrylAct1 
from CCT can be found to be 29 ± 19 kJ mol-1, 32 ± 8 kJ mol-1 and 34 ± 8 
kJ mol-1 for release with 1 mM, 2 mM and 4 mM ATP respectively [130], 
demonstrating the same temperature dependence across the different ATP 
concentrations and indicating that the reaction proceeds by the same 
mechanism in all three cases.  
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Figure 63: Arrhenius plot of the release of 
Acryl
Act1 from CCT with 1 mM 
(purple), 2 mM (blue) or 4 mM (green) ATP, using PLP2 dialysed into 20 mM 
HEPES pH8, 75 mM KCl [130].  
 
As demonstrated for 488Act1 [76] it can be seen that there is an increase in 
the rate of release of AcrylAct1 from CCT in the presence of higher ATP 
concentrations, although this increase is more marked between 1 mM and 
2 mM ATP than between 2 mM and 4 mM ATP. The maximal rate for 
488Act1 release at 30°C was found to occur at 5 mM ATP with slower 
release at higher concentrations [76], so the general trend is consistent with 
existing data.  
 
The temperature dependence has not previously been assessed so 
comprehensively using the pure in vitro gel based folding assay, but the 
increase in the rate of release as the temperature is increased is in 
agreement with in vitro transcription/translation assays using human CCT 
[47]. 
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(A) Fluorescence emission of
AC
ACT1 at 470 nm following release from CCT with 2
mM ATP, 10 mM MgCl 2; (B) Arrhenius plot based on rate constants for release of
AC
Act1 from CCT with 1 mM ATP, 5 mM MgCl 2 (), 2 mM ATP, 10 mM MgCl 2 (),
or 4 mM ATP, 20 mM MgCl 2 ()  based on fitting of a single exponential to
fluorescence emission at 470 nm.
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6.6 Discussion 
6.6.1 Importance of the C-terminus of Actin for Folding by CCT 
Labelling of Act1 at Cys374 helps destabilise the actin monomer sufficiently 
to allow chemical unfolding within approximately 10 minutes in the absence 
of glycerol, whereas unmodified Act1 needs to be left overnight to unfold. 
The different dyes used had the same general effect of enhancing the rate 
of actin unfolding. Therefore, it was surprising that although Act1 could be 
labelled with the AEDANS moiety and unfolded in the same way as 488Act1, 
it could not be released from CCT. Since AEDANS is small relative to Alexa 
Fluor 488 and of a similar size to acrylodan, it is unlikely to be a steric effect 
that causes this inhibition. Perhaps there is some interaction between the 
polar groups or the aromatic system of AEDANS, either within the unfolded 
actin molecule or with CCT, which prevents folding and release of actin. 
This could be by interference with interactions essential for the folding 
process, or it could lead to tethering of the actin monomer to the 
chaperonin. 
 
The rate constants measured relate to conformational changes at the C-
terminus of actin. Actin folding occurs concomitantly with release from CCT, 
as can be seen by comparing the results of the folding assays analysed 
spectroscopically and by native PAGE. The implications of the rate of 
conformational changes at the C-terminus with respect to the mechanism of 
actin folding will be discussed in section 8.6. 
 
6.6.2 Advantages and Limitations of the Spectroscopic Folding 
Assay 
While there are many advantages to the spectroscopic folding assay, it 
should be noted that it cannot be used completely independently of the gel-
based assay and under some circumstances it is not suitable for 
measurement of the rate of release of actin from CCT. The conversion of 
AcrylAct1 from the CCT-bound, I3-like actin to native actin is followed in these 
assays. Any actin aggregates formed during the unfolding reaction remain 
constant throughout the folding assay and as such do not contribute to 
changes in fluorescence emission. It can be seen by native PAGE that little 
or no further aggregation occurs within the timescale of the folding reaction 
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using CCT and PLP2. If gel-based time courses of release indicate that 
actin is released in a non-native form as a result of ATP binding and 
hydrolysis by CCT, the spectroscopic assay is not applicable since the 
effect on the fluorescence of aggregates cannot be distinguished from that 
of folding of native actin. The gel-based assay also confirms that the CCT 
complex remains intact throughout the process. However, the suitability of 
the spectroscopic assay for studying a set of conditions for actin folding, be 
they buffer conditions or the effect of mutations within the constituent 
proteins of the folding apparatus, can readily be assessed by native PAGE 
prior to measuring acrylodan fluorescence throughout the reaction. 
 
There are significant advantages of the spectroscopic folding assay over 
the gel-based assay. Firstly, it is less time consuming. Following the three 
hour unfolding reaction, only a further 15 minutes is required for each 
release time course using the spectroscopic folding assay. For the gel-
based assay, samples must then be loaded onto a gel, which can be 
particularly time-consuming if many time courses are carried out in tandem. 
After the running of the gel, the gel must then be scanned for in-gel 
fluorescence and stained. Several times as many samples can be analysed 
by the spectroscopic assay in this time, allowing comparison of many more 
conditions. Secondly, since the reaction can be monitored continuously, 
smaller variations in the rate of reaction can be observed with greater 
accuracy, thereby allowing analysis of more subtle variations in conditions. 
Thirdly, there is less room for human error, since after making up the 
reaction mixture and loading it into a cuvette, the same sample is monitored 
throughout. Since very small volumes are used in the gel-based folding 
assay, accurate pipetting is difficult and may lead to some slight errors. 
Since the folding reaction takes only a few minutes, many samples must be 
taken in a short time period meaning that there is potential for errors in the 
time at which the sample is collected. This is avoided using the cuvette-
based spectroscopic assay. 
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6.7 Conclusion 
Here I have shown that through introduction of the environmentally 
sensitive fluorophore acrylodan at the C-terminus of actin, the kinetics of 
actin folding can be investigated spectroscopically. The use of the 
spectroscopic actin folding assay in conjunction with the gel-based assay to 
confirm folding of native actin makes analysis of the folding much more 
rapid and allows more detailed analysis of the conditions which affect the 
folding process. The spectroscopic assay has been validated by 
comparison with the pure in vitro gel-based actin folding assay, and it has 
been shown that native actin capable of binding DNase I and VDBP and 
able to form F-actin filaments is produced. Furthermore, the effect of 
varying the ATP concentration used for release of actin from CCT across 
the intracellular range of concentrations correlates well with the effect of 
ATP concentration on the rate of ATP hydrolysis by CCT. 
 
It can be seen that the rate of actin folding by CCT responds linearly to 
changes in temperatures over a physiological range at the same rate 
across intracellular ATP concentrations. This indicates that the same 
mechanism of actin folding predominates across these conditions. 
However, it can also be seen that some small molecule buffer components 
may affect the rate at which CCT is able to fold actin, so care must be 
taken to ensure consistency of the buffer conditions. 
 
The importance of the C-terminus of actin with respect to folding and 
stability of the actin monomer is clear from the effect of the dye on the 
unfolding rate. Rearrangement of the C-terminus of actin is also key to the 
folding process, and occurs alongside release of actin from CCT. 
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7 Investigating the Effect of CCT Mutations on 
Actin Folding 
7.1 Aims 
The pure in vitro folding system has been used for wild type CCT. However, 
actin folding within the pure system has not previously been investigated for 
CCT mutants. CCTanc2 is found in the temperature-sensitive yeast strain 
ANC2, and contains a mutation in the apical domain of CCT4. Allostery is 
impaired in CCTanc2, leading to a two-fold reduction in the yield of native 
actin as observed in vivo [47]. CCT-TCP1-1.2 is derived from another heat-
sensitive yeast strain, TCP1-2, and contains a mutation in CCT1 [137]. 
Actin folding by these mutants was studied through a combination of the 
native PAGE and the spectroscopic folding assay, with a view to observing 
the effect of temperature on actin folding within these systems. In vivo, 
ANC2 contains defective actin structures, whereas TCP1-2 is associated 
with tubulin and microtubule defects. 
 
A higher proportion of PLP2 appears to associate with CCTanc2 than with 
wild type CCT [49]. The role of PLP2 in actin folding by CCTanc2 was 
investigated to further understand the role of this cofactor in actin folding by 
the mutant. This was done by observation of the effect of N- and C- 
terminal truncations of PLP2. 
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7.2 CCTanc2: The G345D Mutation in CCT4 
7.2.1 Gel-based Folding Assay 
Release of both AcrylAct1 and 488Act1 from CCTanc2 was first investigated to 
ensure that the spectroscopic assay was suitable for study of this system. 
Act1 was unfolded with EDTA in the presence of CCTanc2 as for wild type 
CCT. Following loading onto CCTanc2, actin was released by incubation at 
30°C in the presence of 2 mM ATP and 10 mM MgCl2. The reaction was 
followed by native PAGE, and binding to DNase I was used to confirm that 
the actin released from CCT was native (Figure 64). Native actin is 
released from CCTanc2 with no further aggregation after addition of ATP, 
indicating that the spectroscopic folding assay can be used. 
 
 
Figure 64: Release of 
Acryl
Act1 from CCTanc2, showing native 
Acryl
Act1 before 
unfolding (N), after unfolding and loading onto CCTanc2 (0) and the time in 
minutes following addition of 2 mM ATP and 10 mM MgCl2. The final lane 
shows binding of the released actin to DNase I (D). 
 
7.2.2 Spectroscopic Folding Assay 
AcrylAct1 was loaded onto CCTanc2 as for CCT. Release from CCT was 
measured from 25°C to 37°C. The permissive temperature for growth of the 
ANC2 yeast strain is 30°C [47], so it would be expected that above this 
temperature the rate of actin folding would be reduced. Since actin folding 
by CCTanc2 is less efficient than for wild type CCT, release was only 
studied for 2 mM and 4 mM ATP. The rate constants for release from 
CCTanc2 under these conditions are shown in Table 3. 
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 CCTanc2 
2 mM ATP 4 mM ATP 
25 °C 2.6 x 10
-3
  
± 0.1 x 10
-3 
3.7 x 10
-3
  
± 0.2 x 10
-3 
30 °C 3.3 x 10
-3
  
± 0.4 x 10
-3 
4.7 x 10
-3
  
± 0.5 x 10
-3 
35 °C 4.5 x 10
-3
 
± 0.1 x 10
-3 
5.3 x 10
-3
  
± 0.8 x 10
-3 
 
Table 3: Observed rate constants k (s
-1
) for release of 
Acryl
Act1 from CCTanc2 
at different temperatures and ATP concentrations. 
 
The rate of release of AcrylAct1 from CCTanc2 is lower than from CCT, as 
would be expected for a mutant defective in actin folding. In the same way 
as for the rate constants for release from wild type CCT, an Arrhenius plot 
of ln(k) against 1/T was used to show the effect of temperature on the rate 
of release of AcrylAct1 from CCTanc2 (Figure 65). 
 
 
Figure 65: Arrhenius plot of the rate of release of 
Acryl
Act1 from CCTanc2 with 
either 2mM ATP (pink) or 4 mM ATP (blue) [130]. 
 
It can be seen that overall, the rate of release from CCTanc2 is faster at the 
higher ATP concentration. The temperature dependence of the rate of 
release from the mutant is different at the different temperatures, with a 
drop in the rate observed for release of AcrylAct1 from CCTanc2 at 
temperatures above 32.5°C. At 37°C, the rate of release is very similar for 
both ATP concentrations. 
 
0.00320 0.00325 0.00330 0.00335 0.00340
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-5.0
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(k
)
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7.2.3 Release of 488Act1 from CCT and CCTanc2 in the absence of 
PLP2 
PLP2 is essential for yeast actin folding in vivo and stabilises the complex 
formed between CCT and Act1 [76]. In the absence of PLP2, wild type CCT 
still binds and releases Act1. However, the folding and release process is 
much less efficient as a significant amount of the actin released is non-
native. This can be seen by native gel (Figure 66), where non-native 488Act1 
released from CCT forms aggregates which remain in the stack of the gel. 
In contrast, in the absence of PLP2 virtually no actin is released from 
CCTanc2 (Figure 66).  
 
 
 
 
Figure 66: In-gel fluorescence of a native gel showing release of 
488
Act1 from 
CCT and CCTanc2 in the absence of PLP2. Native actin (N), then the number 
of minutes after addition of ATP, and finally binding to DNase I (D) are 
shown. 
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7.2.4 Release of 488Act1 from CCT and CCTanc2 using truncations of 
PLP2 
Truncations of PLP2 which retain the intact thioredoxin fold at the centre of 
PLP2 have been shown to affect binding and release of Act1 to CCT [76]. 
Since in the absence of PLP2 there is such a marked difference in the 
release of 488Act1 from CCT and CCTanc2, the effect of an N-terminal 
truncation, PLP2 60-286, and a C-terminal truncation, PLP2 1-244 on 
release of 488Act1 from CCTanc2 relative to CCT was studied. Replacing 
PLP2 in the folding reaction with PLP 1-244, a similar amount of native 
488Act1 was released to that using full length PLP2 for both wild type and 
the mutant CCT (Figure 67), although the rate of release was slower 
(Figure 68). In contrast, using PLP2 60-286, only slightly more 488Act1 was 
released than in the absence of PLP2, although this was not accompanied 
by as much aggregation of the released 488Act1 using CCT (Figure 67 and 
Figure 68). 
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Figure 67: In-gel fluorescence of native PAGE analysis of release of 
488
Act1 
from CCT or CCTanc2 with PLP2, PLP2 1-244, PLP2 60-286 and in the 
absence of PLP2. 
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Figure 68: An example of native 
488
Act1 counts following release from (A) 
CCT and (B) CCTanc2 with no PLP2 (green), PLP2 60-266 (dark blue), PLP2 1-
244 (light blue) and full length PLP2 (pink). Please note the vertical scales are 
different for the two graphs. 
 
7.2.5 Levels of PLP2 in Non-nucleotide Washed CCT and CCTanc2 
The amount of PLP2 which can be eluted from CCT during the purification 
process was analysed by western blot for CCTε and PLP2. The ratio of 
PLP2 to CCT for nucleotide washed and non-nucleotide washed CCT and 
CCTanc2 is shown in Figure 69. There is more PLP2 relative to CCT for the 
mutant with or without the nucleotide wash step, although in both cases the 
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majority of PLP2 is removed from the complex following incubation with 
ATP. 
 
Figure 69: Relative ratios of PLP2 to CCTε for nucleotide washed (n) and non-
nucleotide washed CCT and CCTanc2 as measured by Western blot using 
monoclonal antibodies and detection by fluorescence. 
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7.3 Release of 488Act1 from CCT-TCP1.1-2 
CCT-TCP1-1.2 contains the mutation G423D in subunit 1 and leads to 
defective development of microtubules [137]. The mutant was used in the in 
vitro actin folding assay using 488Act1 and release of actin was observed by 
native PAGE (Figure 70). The amount of actin released is much less than 
from wild-type CCT (Figure 71), and is released in a non-native form which 
can be seen in the stack of the native gel (Figure 70 and Figure 72). 
 
 
Figure 70: In-gel fluorescence of the native gel analysis of release of 
488
Act1 
from CCT-TCP1-1.2 and to wild-type CCT. 
 
 
Figure 71: 
488
Act1 counts on CCT following addition of ATP using wild type 
CCT (blue) or CCT-TCP1-1.2 (pink). 
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Figure 72: Native 
488
Act1 counts following ATP induced release from wild-
type CCT (blue) or CCT-TCP1-1.2 (pink). 
 
Clearly this CCT mutant is incapable of folding actin within the pure folding 
assay. Since the majority of 488Act1 is released in a non-native state, the 
spectroscopic folding assay cannot be used to monitor this reaction as the 
labelled actin would be present in too many different states to be able to 
distinguish. This demonstrates the use of the gel-based folding assay to 
assess the applicability of the spectroscopic assay to a given set of 
conditions.  
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7.4 Discussion 
7.4.1 Release of Actin from CCT in the in vitro Folding Assay 
Release of actin from CCT occurs at a faster rate than from the mutant 
CCTanc2, which is unsurprising since the mutant is associated with 
defective actin folding. A decrease in the yield of native actin from 
CCTanc2 has previously been reported within in vitro 
transcription/translation systems [47]. This observation is supported by this 
work although it is not known whether this simply reflects the level of 
release from the mutant chaperonin or if the efficiency of loading actin onto 
CCTanc2 is less than that of wild-type CCT. 
 
Due to the slower rate of actin release relative to CCT, only 2 mM and 4 
mM ATP were used since if the release rate was too slow, the reaction 
would be far from completion by the end of the 15 minute time period 
monitored. This would make data much more challenging to fit and some 
variables would have to be constrained in order to give a reasonable rate 
which would reduce the accuracy of these measurements. Since release 
from CCT with 1 mM ATP was significantly slower than at higher ATP 
concentrations, it was decided to measure only the two higher 
concentrations for the mutant. 
 
The difference in the effect of changing the temperature at different ATP 
concentrations is surprising; above temperatures of 32.5°C a decrease in 
the rate of release of actin from CCTanc2 was observed at 4 mM ATP, 
although for 2 mM ATP this effect was not observed. This is also very 
different to the trend seen for wild-type CCT, with the rate of release 
increasing with temperature. The mutant is known to behave very 
differently to CCT with respect to ATP hydrolysis, with a significant 
reduction in the allostery of the chaperonin [47]. Interestingly, in the same 
study no significant change in the rate of actin folding by CCTanc2 was 
observed upon increasing the temperature from 30°C to 37°C [47], 
although this was within a coupled in vitro transcription/translation system 
and so may have contained other cofactors which may have affected the 
rate of actin folding by the mutant. It appears that actin folding by CCTanc2 
has a greater dependence on PLP2 than the wild type chaperone (see 
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section 7.4.2), so it is not unreasonable to think that there may be other 
factors that have a similar effect. 
 
The effect of higher temperatures on the rate of folding by CCTanc2 is 
much more pronounced at the higher ATP concentration of 4 mM than for 2 
mM ATP (Figure 65). At 35°C there is significant deviation from the trend 
observed in the presence of 4 mM ATP, whereas at 2 mM ATP no effect is 
observed at this temperature, and there is only a slight difference at 37°C. 
At 37°C the rate of release is the same at both ATP concentrations. At both 
ATP concentrations there is sufficient nucleotide present to fully saturate all 
the binding sites within the chaperonin. Clearly for wild type CCT, and for 
CCTanc2 below the permissive temperature, the maximum rate is not 
reached at the lower ATP concentrations used, despite the apparent 
excess of nucleotide present. This could reflect the sequential nature of 
ATP hydrolysis within CCT, and the fact that the maximum rate at higher 
temperatures in the allosterically impaired mutant appears to be slower 
than below the permissive temperature is indicative that ATP-induced 
allostery within the complex is the cause of the relatively large 
concentrations of ATP relative to the chaperonin required. 
 
7.4.2 The Effect of PLP2 on Actin Folding by CCT and CCTanc2 
PLP2 is known to be essential in yeast [74, 76] and greatly enhances the 
yield of native actin in the pure in vitro  folding assay [76]. Truncations of 
PLP2 affect not only the rate of actin folding but also the yield of native 
actin, with the N-terminal truncation causing a particularly large reduction in 
the yield of native actin. This effect is seen to an even greater effect in the 
mutant CCTanc2. The N-terminal region of PLP2 is associated with binding 
to CCT whereas the C-terminal region is known to be involved in actin 
binding. This could relate to the way in which PLP2 assists in the folding of 
actin by CCT, as it may well assist in correct loading of the substrate onto 
the chaperonin. This may be particularly important in the case of CCTanc2, 
which shows a much greater dependence on PLP2 for folding and release 
of actin. A larger amount of PLP2 associates with CCTanc2 than with the 
wild type CCT, which is agreement with analysis of CCT interacting 
proteins by Dekker et al [49]. It could be that actin has a greater tendency 
to bind to the mutant in a non-functional manner which can be overcome 
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with the assistance of the cofactor PLP2. Alternatively, PLP2 could aid CCT 
to assume the correct conformation for actin binding. Impairment of the 
CCT-binding function of PLP2 affects the yield most significantly, while 
removal of the C-terminus only seems to affect the rate of folding of actin, 
with little impact on the yield of native protein formed.  
 
There is a substantial amount of release of actin from wild type CCT even 
in the absence of PLP2. However, much of this is non-native and can be 
seen in the stack of a native gel. In contrast, actin is not released from 
CCTanc2 in the absence of PLP2. Once again this indicates a greater 
reliance on the cofactor for actin folding by CCTanc2, and could suggest 
that loading of actin in the correct conformation is an important role of 
PLP2. This is further evidence to suggest a role for PLP2 in the loading of 
actin onto CCT, meaning that in the absence of the cofactor only a 
relatively small fraction of actin binds in the correct conformation to yield 
native actin. This would then imply that virtually no actin binds correctly to 
CCTanc2 in the absence of PLP2, and the substrate remains bound even 
in the presence of ATP.  
 
7.4.3 Actin Folding by CCT-TCP1-1.2 
The folding of actin by the mutant CCT-TCP1-1.2 was surprisingly impaired 
very significantly within the pure in vitro folding cycle. Although some effect 
on the rate or yield might be expected to be observed, folding of actin within 
this strain is not known to be defective [137]. Although actin is released 
from this mutant, it is primarily non-native actin and analysis of the reaction 
by native PAGE reveals a pattern similar to that of actin folding by wild-type 
CCT in the absence of PLP2. PLP2 may be unable to aid actin folding by 
CCT-TCP1-1.2 as efficiently directly as a result of the mutation, or because 
of a conformational change in the chaperonin. It is possible that another 
cofactor is required for actin folding by this mutant, with PLP2 unable to 
perform this function alone in this strain. Clearly actin can be folded by this 
mutant in vivo so perhaps a different component is able to compensate for 
the inability to correctly fold actin within the pure in vitro folding system, 
either in conjunction with PLP2 or independently.  
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The spectroscopic folding assay is not suitable for studying the kinetics of 
actin folding by CCT-TCP1-1.2. Since only a small amount of native actin is 
released, it would be difficult to monitor the reaction with any accuracy, and 
owing to the large amount released as non-native aggregates, any change 
in the fluorescence emission would not be quantifiable. This is a good 
example of the use of the gel-based assay to determine the applicability of 
the spectroscopic folding assay for studying actin folding by CCT. 
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7.5 Conclusion 
Actin folding in the pure in vitro folding assay is affected in both CCTanc2 
and CCT-TCP1-1.2. This was expected for CCTanc2, which is known to 
cause defects in actin structures within the cell and has impaired allostery 
within the chaperone relative to the wild-type CCT.  
 
For the mutant CCTanc2, actin folding appears to be most significantly 
affected at higher ATP concentrations and at temperatures above the 
permissive temperature. At 2 mM ATP the trend as the temperature was 
increased was the same as for wild-type CCT, although the overall rate was 
slower. 
 
PLP2 appears to be even more important for folding by CCTanc2 than for 
CCT, with more of the cofactor bound to the mutant chaperonin in yeast. In 
the absence of PLP2, no actin is released from CCTanc2, in comparison to 
release from CCT where actin is released but largely in a non-native form. 
Truncated forms of PLP2 are able to restore folding activity to both mutant 
and wild-type CCT, although not to the same level and efficiency as in the 
presence of full-length PLP2. 
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8 Investigating the Mechanism of Actin Folding by 
CCT 
8.1 Aims 
Analysis of the kinetics of actin folding by CCT using the spectroscopic 
folding assay has so far only revealed one step in the process relating to 
the C-terminus of actin. However, the folding of any protein is unlikely to 
occur by such a simple mechanism. Non-hydrolysable analogues of ATP 
such as adenosine 5′-[γ-thio]triphosphate (ATPγS) and adenylyl-
imidodiphosphate (AMP-PNP) can bind to CCT and close the cavity but 
cannot undergo the hydrolysis step essential to complete the folding cycle. 
 
Structural studies of ATPγS- and AMP-PNP-bound actin-CCT complexes 
have suggested conformational rearrangements occur to the bound 
substrate upon nucleotide binding. However, these analyses have not been 
carried out on the ternary actin-CCT-PLP2 complex and as such no 
intermediates have been determined within a functional folding cycle. 
 
Through incubation of the ternary complex with these non-hydrolysable 
ATP analogues, it should be possible to follow the C-terminus of actin and 
any changes it undergoes during the nucleotide binding step. This would 
allow further insight into the mechanism of actin folding within the pure in 
vitro folding assay. 
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8.2 The Non-hydrolysable ATP Analogues ATPγS and 
AMP-PNP 
Two commonly used analogues of ATP are ATPγS and AMP-PNP. In these 
compounds, the oxygen atom which bridges between the β- and γ-
phosphate groups of ATP is replaced by either a sulphur (ATPγS) or 
nitrogen (AMP-PNP), as shown in Figure 73. 
 
Figure 73: The structure of ATP and the non-hydrolysable analogues ATPγS 
and AMP-PNP. 
 
This is where hydrolysis of ATP normally occurs, and these substitutions 
result in analogues with a much slower rate of hydrolysis making them very 
useful as mimics in the ATP binding step of a reaction. EM studies of CCT 
suggest that these analogues are capable of closing the lid of the 
chaperonin [44], although work on the thermosome suggests that lid 
closure occurs following ATP hydrolysis, not binding [36]. It was hoped that 
by incubating CCT with these ATP analogues, it would be possible to 
investigate the mechanism of actin folding by trapping a folding 
intermediate and observing the fluorescence emission of this complex. 
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8.3 Binding of ATPγS to the Ternary Act1-CCT-PLP2 
Complex 
The ternary AcrylAct1-CCT-PLP2 complex was formed as previously 
described by chemically unfolding AcrylAct1 in the presence of CCT and 
PLP2. In order to maximise occupancy of the ATP binding sites, ATPγS 
was added to a final concentration of 10 mM, and a five-fold excess of 
MgCl2 over nucleotide was also added. The complex was incubated for 10 
minutes at 30°C. ATP was added to a final concentration of 2 mM, and care 
was taken to ensure concentrations of glycerol and KCl were kept the same 
across all folding assays.  
 
The fluorescence emission of the ATPγS-bound AcrylAct1-CCT-PLP2 
complex was measured, and following addition of ATP to the pre-formed 
complex the fluorescence emission of the sample was scanned repeatedly 
to see if release of actin was occurring. Figure 74 shows two of these 
scans, in which no change in the fluorescence emission is observed, 
indicating that binding of ATPγS to the ternary complex has no effect on the 
C-terminus of actin, and that ATP cannot displace the ATPγS to allow 
release of the native substrate protein. 
 
 
Figure 74: Fluorescence emission scans of 
Acryl
Act1-CCT-PLP2 pre-incubated 
with ATPγS immediately after addition of ATP (purple) and 3.5 minutes after 
addition of ATP (blue). No change is observed in the fluorescence emission 
following addition of ATP. 
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8.4 Binding of AMP-PNP to the Ternary Act1-CCT-PLP2 
Complex 
The ternary AcrylAct1-CCT-PLP2 complex was pre-incubated with 10 mM 
AMP-PNP and 50 mM MgCl2 in the same way as for ATPγS. Again, binding 
of AMP-PNP and closure of the lid had no effect on the fluorescence 
emission of AcrylAct1. However, upon addition of 2 mM ATP, a change in the 
emission spectrum corresponding to release of native actin could be 
observed (Figure 75). 
 
 
Figure 75: Fluorescence emission spectra of 
Acryl
Act1-CCT-PLP2 pre-
incubated with AMP-PNP immediately after addition of ATP (purple) and 3.5 
minutes after addition of ATP (blue). 
 
To confirm that this change was ATP dependent, ADP was added to the 
AMP-PNP-bound complex. This did not induce any change in the 
fluorescence emission indicating that folding and release did not occur 
(Figure 76). 
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Figure 76: Fluorescence emission spectra of 
Acryl
Act1-CCT-PLP2 pre-
incubated with AMP-PNP immediately after addition of ADP (purple) and 3.5 
minutes after addition of ADP (blue). 
 
By monitoring the decrease in fluorescence emission at 470 nm following 
addition of ATP to the complex pre-incubated with AMP-PNP, the rate 
constant for release could be obtained (Figure 77). At 30°C in the presence 
of 2 mM ATP, k = 11.8 x 10-3 ± 0.7 x 10-3 s-1, which is a three-fold increase 
in rate relative to release under these conditions without pre-incubation with 
AMP-PNP, for which k = 3.8 x 10-3 ± 0.3 x 10-3 s-1 [130]. 
 
 
Figure 77: Fluorescence emission of 
Acryl
Act1 at 470 nm following release 
from CCT with (purple) or without (blue) pre-incubation with AMP-PNP [130]. 
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8.5 Native PAGE of Actin Release Following Incubation 
with AMP-PNP 
In order to confirm that the change in fluorescence corresponded to release 
of actin and not just further folding of the substrate, the same experiment 
was carried out using 488Act1. Samples for native PAGE were taken before 
and after incubation of the ternary 488Act1-CCT-PLP2 complex with AMP-
PNP, demonstrating that release is not induced by binding of the non-
hydrolysable analogue (Figure 78). Following addition of 2 mM ATP, 488Act1 
release from the complex is completed in 5 minutes (Figure 79), in 
agreement with the results of the spectroscopic folding assay [130]. 
 
 
Figure 78: In-gel fluorescence of native PAGE analysis of ATP-dependent 
release of 
488
Act1 from CCT following pre-incubation with AMP-PNP showing 
488
Act1 unfolded onto CCT in the presence of PLP2 (U), and then the time in 
minutes after addition of ATP following 10 minutes pre-incubation with AMP-
PNP [130]. 
 
Figure 79: Fluorescence intensity of the actin band of a native gel following 
addition of ATP to the 
488
Act1-CCT-PLP2 complex with (blue) or without 
(purple) pre-incubation with AMP-PNP [130]. 
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8.6 The Mechanism of Actin Folding by CCT 
Previous structural studies on the actin-CCT complex have identified 
structural rearrangements of both the chaperonin and the substrate upon 
binding of AMP-PNP and closure of the cavity. Using cryo-EM, actin is 
observed to form a more compact structure upon lid closure, with the large 
domain remaining bound to the apical domain of a CCT subunit [44]. A 
more detailed view of conformational changes within the actin monomer 
upon binding to CCT has been obtained using homo-FRET [55]. In this 
work, site-directed mutagenesis was used to remove cysteine residues and 
labelling sites were introduced at various positions throughout the four 
subdomains of actin. Following labelling with fluorescein, distances within 
the protein were calculated after denaturation with Gu-HCl, binding to CCT 
and closure of the lid of the chaperone. This showed stretching of actin as it 
bound to CCT followed by formation of a more compact state upon binding 
of AMP-PNP, with distances between the probes different to those of native 
actin. However, whilst this could represent a folding intermediate, it could 
also be due to the size and orientation of the dye molecules within the 
CCT-bound actin monomer [55]. 
 
These studies all indicate at least partial folding of actin upon closure of the 
lid of CCT. However, they cannot conclusively discriminate between the 
presence of a folding intermediate and native actin which remains bound to 
CCT. Furthermore, mammalian CCT and actin were used, for which the 
necessary components for a pure functional folding assay have not as yet 
been identified. As such, while these conformational rearrangements most 
likely represent real transitions occurring with the CCT-actin folding cycle, 
this cannot be confirmed as native actin cannot be released within these 
systems. The use of the pure in vitro folding assay using yeast CCT, actin 
and PLP2 allows the mechanism of actin folding to be investigated in situ. 
The mammalian system is undoubtedly more complex; nonetheless, the 
level of homology across species means that the general mechanism of 
actin folding in yeast is highly relevant to actin folding in higher organisms. 
This can be seen by the single amino acid mutation required to allow 
folding of rabbit skeletal muscle actin by yeast CCT [138]. 
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Through observation of the dynamics of binding and release of various 
alanine mutants of actin from CCT in coupled in vitro 
transcription/translation reactions, a mechanism for actin folding was 
suggested by Neirynck et al [66]. They propose that binding of the actin 
molecule across the cavity of CCT is followed by rearrangements of the 
actin monomer brought about by the sequential binding of ATP to the 
chaperonin.  This starts with release of the small domain of actin and 
rotation at the hinge region to close the molecule. Next they suggest that 
actin is released into the cavity and rebinds, and finally the interaction 
between the C-terminus and subdomain 1 is established [66]. This detailed 
mechanism is in good agreement with structural studies on the folding 
process, but none of these stages are isolated, and the question regarding 
the role of ATP binding versus ATP hydrolysis is not addressed. 
 
Based on the kinetics of actin release from the spectroscopic in vitro actin 
folding assay, it can clearly be seen that there is an increase in the rate of 
release of Act1 from CCT when the complex has been pre-incubated with 
AMP-PNP, which mimics the effect of ATP binding by inducing closure of 
the lid of the chaperonin. Folding of actin is not complete at this stage, as 
can be seen from the fluorescence emission spectrum of the AMP-PNP 
bound complex which is the same as AcrylAct1-CCT-PLP2 in the absence of 
nucleotide as opposed to that of native actin. It is possible that the 
substrate protein is released into the cavity of CCT upon lid closure, as is 
the case for GroEL [33]. However, EM structures of the CCT-actin complex 
suggest that actin remains bound in the closed structure [44], and recent 
simulations of actin folding also provide evidence that the C-terminus is 
likely to remain fixed throughout the reaction [139]. A second distinct step in 
the folding pathway of actin occurs upon ATP hydrolysis which involves 
packing of the C-terminus, lid opening and release of the native monomer 
(Figure 80) [130].  
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Figure 80: Two-step mechanism for actin folding and release from CCT [130]. 
(A) Actin binds in a 1,4-conformation across the cavity of CCT. In step 1, 
binding of nucleotide closes the lid of the chaperonin leading to the 
formation of (B), the closed complex in which actin is partially folded. The 
second step of actin folding is brought about by nucleotide hydrolysis and 
involves the correct folding of the C-terminus of actin and release of the 
native monomer. 
 
Since only the C-terminus of actin is monitored in this assay, little can be 
concluded about the structure of the intermediate. It seems likely that the 
unfolded actin which is stretched across the CCT complex in the open form 
is allowed to rotate upon release of one domain as ATP binds to the 
chaperonin, as suggested Neirynck et al [66]. In this way, the main 
structure of the actin monomer is allowed to take shape without 
interference or steric hindrance at the C-terminus.  
 
There is an approximately three-fold increase in the rate of the folding 
reaction following addition of ATP to the AMP-PNP-bound ternary complex 
relative to that without the pre-incubation step. This is significant with 
respect to the kinetics of the two different stages, since clearly following lid 
closure, the final folding step is allowed to proceed much more rapidly. The 
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rate determining step for the folding of actin under these conditions must 
occur during the first step. This could correspond to nucleotide binding, 
although this seems unlikely since AMP-PNP can be displaced by ATP 
rapidly so it seems reasonable to assume that binding to the nucleotide-
free complex occurs at a similar rate. The rate of actin folding therefore 
seems more likely to depend upon one of the conformational 
rearrangements which occur within the complex. While there are most likely 
a large number of individual rearrangements which must take place, these 
can be broadly defined as those involving the chaperonin, and those 
involving the actin monomer. The lid of CCT must close which involves 
significant movements of the apical domains of the subunits. This could 
occur sequentially or simultaneously. The actin monomer must form its 
more compact state, which could occur concomitantly with the closure of 
the cavity, or may occur as a consequence.  
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8.7 The Importance of the Actin C-terminus for Folding 
and Stability 
The C-terminus of actin has been found to be important in the stability of 
the monomer [140]. Unfolding of unlabelled Act1 is a very slow process 
relative to unfolding of Act1 labelled with dyes such as AF488, acrylodan 
and AEDANS. This indicates that disruption at the C-terminus of actin 
through introduction of a fluorophore acts a mutation in actin and affects the 
stability of the monomer. It therefore is not surprising that the C-terminus 
appears to be important to the folding of actin, as demonstrated by the 
change in acrylodan fluorescence which accompanies only the second step 
of actin folding by CCT. 
 
The results obtained from the use of AMP-PNP demonstrate that there is 
no observable effect on the C-terminus of actin following lid closure. This 
rearrangement only occurs upon nucleotide hydrolysis as demonstrated by 
the change in fluorescence emission upon addition of ATP. Addition of ATP 
to CCT bound to AEDANSAct1 does not result in any change to the 
fluorescence emission of the complex, and no release of native AEDANSAct1 
is observed. It is not known whether the initial rearrangement occurs upon 
addition of nucleotide, however it seems likely that this folding step is 
completed since it does not involve the modified region of actin. It may well 
be that CCT is incapable of performing the final folding step which allows 
the formation of native AEDANSAct1 and the subsequent release. 
 
The results seem to indicate that while the basic structure of native actin 
can be formed by closure of the two domains at the hinge region, a stable 
monomer cannot be released from CCT without the protein being locked in 
this conformation. For this the C-terminus must be in the correct orientation 
within the actin structure. This may occur simply as a result of release of 
the C-terminus from the chaperonin as ATP is hydrolysed, or CCT could 
play a more active role in this step. 
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8.8 The Effect of CCT Mutants on Actin Folding 
Allostery plays an important role in the ATP-induced folding of actin by 
CCT, as is clearly demonstrated by the significant effect on the reaction 
using the temperature sensitive mutant CCTanc2. This is indicated by the 
substantial change in folding behaviour above the permissive temperature 
for the mutant, and may well be the reason for the dependence of the rate 
of actin folding on the ATP concentration. The order in which ATP binds 
and is hydrolysed by the subunits is as yet unknown. The crystal structure 
of CCT has been determined using CCTanc2 due to the reduced ATP 
hydrolysis in the mutant [40]. In this structure, not all the nucleotide binding 
sites are occupied by the ADP-BeF found in the crystals. The chaperonin is 
closed and bound to actin, indicating that not all sites are occupied at this 
stage of the folding cycle.  
 
The rearrangement of the actin C-terminus appears to be dependent on 
ATP hydrolysis, and is likely to be stimulated by the reaction at one or more 
of the subunits. In order to investigate this further it would be interesting to 
look at the actin folding reaction in vitro using the recently developed set of 
yeast strains containing equivalent mutations in the ATP hydrolysis site of 
CCT across all eight subunits [141]. These strains all display different 
phenotypes, and affect different pathways in which CCT is involved. All the 
mutants incorporate the CBP tag which can be used to readily purify CCT 
for use in vitro [141]. Through the use of the gel-based and spectroscopic 
folding assays, it may be possible to learn more about the roles of the 
different subunits in actin folding. Considering the results obtained using 
CCT-TCP1-1.2 (see section 7.3), it is likely that even those mutations not 
generally associated with defects in actin folding in vivo may still have a 
significant effect on the rate and efficiency of actin folding.  
 
There are various aspects of the folding reaction that could be studied 
using these mutants in vitro. It would be interesting to compare their 
behaviour in the pure in vitro gel-based folding assay to that of the coupled 
in vitro transcription-translation system, which would help to reveal the role 
of PLP2 in actin folding by the different mutants. If no significant effect on 
actin folding by the mutant in rabbit reticulocyte lysate but PLP2 was unable 
to enhance the reaction in the purified system, it would indicate that another 
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cofactor was required to overcome the mutation as appears to be the case 
for CCT-TCP1-1.2. General observations of the folding reaction as 
monitored by native PAGE could be very interesting, and would allow the 
efficiency of binding and folding of actin by the chaperonin to be studied. It 
could be that a mutation in a certain subunit inhibits or substantially 
reduces the amount of actin released, which might imply an important role 
for ATP binding or hydrolysis at that site. Measuring the rate of release of 
actin where appropriate using the spectroscopic assay, as well as the effect 
of the non-hydrolysable ATP analogues on release, could also be 
informative. 
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8.9 Relative Affinity of the Non-hydrolysable ATP 
Analogues AMP-PNP and ATPγS for CCT 
It is interesting and perhaps surprising to observe that while AMP-PNP can 
be displaced from CCT by ATP, ATPγS cannot. As such, the folding of 
actin can proceed following incubation of the ternary AcrylAct1-CCT-PLP2 
complex with AMP-PNP by the addition of ATP which has allowed the 
elucidation of the two separate stages of the actin folding mechanism. It 
appears that ATPγS has a higher affinity for CCT than AMP-PNP, and as a 
result nucleotide exchange with ATP cannot occur, thereby preventing 
release of any folded actin.  
 
FRET studies of actin bound to CCT as well as EM structures of the 
complex have indicated that AMP-PNP is capable of closing the chaperonin 
cavity [55, 142]. Therefore, particularly in light of the effect of pre-incubation 
of the CCT complex with AMP-PNP on the rate of release following addition 
of ATP, it seems clear that AMP-PNP is binding sufficiently to induce lid 
closure. A high concentration of AMP-PNP (10 mM final concentration) was 
used to maximise binding. The thermosome can also be closed using AMP-
PNP [143], indicating that this is a universal feature of the Group II 
chaperonins. Interestingly, folding of some substrates by GroEL can be 
achieved with AMP-PNP [144], demonstrating that ATP hydrolysis is not 
always required for chaperonin-assisted protein folding.  
 
The crystal structure of the tubulin-bound CCT complex in the presence of 
ATPγS at 5.5 Å reveals a more open structure to the complex [145]. There 
is no data available to directly compare the structures of the tubulin-bound 
complex in the presence of ATPγS and AMP-PNP, but the cryo-EM 
structure in the presence of AMP-PNP reveals a closed, symmetrical 
structure [44]. The chaperonin may take on a slightly different conformation 
in the presence of ATPγS in which ATP is less able to access the binding 
site to displace it. However, directly comparable structures of the actin-CCT 
complex in the presence of ATPγS and AMP-PNP would be necessary to 
investigate this further. 
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8.10 Conclusions 
Actin folding by CCT proceeds by a mechanism that is comprised of two 
main stages, the first of which is dependent on nucleotide binding and the 
second nucleotide hydrolysis. This has been demonstrated within the 
functional pure in vitro folding cycle through the use of AMP-PNP, which 
allows a partially folded intermediate formed following nucleotide binding to 
be isolated. In this intermediate, actin folds to a more compact state within 
the closed chaperone complex as observed by EM [44, 142] and FRET 
[55], but the environment of the C-terminus is unaffected at this stage. In 
the second stage of the folding process, ATP hydrolysis occurs and a 
rearrangement at the C-terminus of actin which locks the protein into the 
correct conformation. The lid of the chaperonin opens and the substrate is 
released. These final events cannot be distinguished with either the gel-
based or the spectroscopic folding assay, and may well occur 
concomitantly. 
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9 Conclusions and Future Directions 
9.1 FRET as a Technique to Observe Folding of Cdh1 by 
CCT 
While FRET can be a very powerful technique for measuring distances and 
observing conformational changes within a protein complex, it is not always 
appropriate.  As well as the limits to the distance over which energy transfer 
can be observed, other factors such as the orientation of the fluorophores 
can have a significant effect on the likelihood of a FRET being observed. 
As such, while no definitive FRET was observed between the fluorophores 
attached to CaM and the Cdh1 fragment within the CCT complex, it does 
not signify that these fluorophores are definitely outside of a certain 
distance of one another. However, owing to the extra distance introduced 
into the system by the use of fluorescently labelled CaM it seems likely that 
the labels were too far apart to be able to measure the distance in this way. 
It has recently been found that the distances within the open, nucleotide-
free CCT complex are much larger than those within in the closed complex 
[145] which further suggests that labelling the complex in this way is not 
suitable for studies by FRET. It might be possible to use FRET to determine 
the CCT subunits that Cdh1 binds to if the proteins were labelled at 
different sites, and perhaps by direct labelling of CCT. However, the 
complexity of the protein makes it very hard to specifically introduce labels 
into the system. As such, FRET is not well suited to the study of folding of 
Cdh1 by the chaperonin. 
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9.2 Development of a Spectroscopic Actin Folding Assay 
Although the gel-based pure in vitro actin folding assay is very useful for 
observing the release of native actin from CCT and can also be used to 
identify the release of non-native actin, it is hard to accurately measure the 
rate of release. An assay using acrylodan-labelled yeast actin has been 
developed which can be folded by CCT within the previously established in 
vitro system. The fluorescence emission of the acrylodan moiety is highly 
dependent on the environment in which it is found and as such changes in 
the emission wavelength and intensity are observed as the labelled actin is 
folded and unfolded. By monitoring the change in fluorescence emission 
throughout the CCT-mediated actin folding reaction, the rate of release can 
be measured with greater accuracy than is possible with the gel-based 
assay. This has been used to measure the rate of release of actin from 
CCT under a range of different conditions, where it is hard to differentiate 
between these conditions with any confidence using the gel-based assay.  
 
The major disadvantage of the spectroscopic assay is that the formation of 
non-native aggregates of actin cannot be detected. However, by using the 
technique in conjunction with analysis by native PAGE, conditions that are 
compatible with the spectroscopic assay can readily be determined. Using 
these two methods of analysing the folding reaction, various features can 
be studied including the efficiency of the folding reaction, whether the actin 
released is native or non-native, and the rate of reaction. As a result of the 
spectroscopic assay, the comparison of actin folding by CCT under 
different conditions can be performed much more rapidly, with a high level 
of reproducibility and with much greater sensitivity than was previously 
possible. 
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9.3 The Effect of Mutations in CCT on Actin Folding 
Actin folding by two CCT mutants, CCTanc2, which contains a mutation in 
subunit CCT4, and CCT-TCP1-1.2, which contains a mutation in subunit 
CCT1, has been investigated using the native gel-based pure in vitro 
folding assay. CCT-TCP1-1.2 was unable to fold actin within this 
environment, despite the fact that actin folding within the yeast strain from 
which it is derived does not appear to be impaired. Since native actin is not 
released, the spectroscopic folding assay could not be used for CCT-TCP1-
1.2. 
 
Using the gel-based folding assay for CCTanc2, it can be seen that actin is 
released from this mutant, and as such the spectroscopic folding assay was 
used to investigate the kinetics of the folding reaction. The effect of 
temperature on the rate of actin folding is markedly different above the 
permissive temperature for the yeast strain, indicating a possible change in 
mechanism.  
 
The effect of PLP2 on actin folding by CCTanc2 was also observed using 
native PAGE through monitoring the reaction in the presence of N- and C-
terminal truncations of PLP2, and in the absence of PLP2. In the absence 
of PLP2, actin cannot be released from CCTanc2, demonstrating that within 
the in vitro system PLP2 is required to overcome the mutation in the 
chaperonin. It may be that in vivo there are other proteins that can perform 
this role, as appears to be the case for CCT-TCP1-1.2. 
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9.4 Investigating the Mechanism of Actin Folding using 
Non-hydrolysable Analogues of ATP 
The non-hydrolysable ATP analogues ATPγS and AMP-PNP were used to 
investigate the mechanism of actin folding. This was done by incubating the 
pre-assembled AcrylAct1-CCT-PLP2 complex with the non-hydrolysable 
analogues and then adding ATP. No change in the environment of the C-
terminus was observed upon incubation of the ternary complex with ATPγS 
or AMP-PNP, indicating that although actin may take on a more compact 
conformation under these conditions, it is not fully folded to its native state. 
Following pre-incubation of the complex with AMP-PNP, addition of ATP 
led to release of actin with a three-fold increase in the rate of release. 
 
It can be concluded that there are two major stages to the actin folding 
process. Upon nucleotide binding, the cavity of CCT is closed and actin is 
partially folded to a more compact state. This most likely involves the 
rearrangement of the large and small domain into their correct conformation 
from the stretched form found in the nucleotide-free complex. This step is 
slow compared to the second stage, which occurs upon nucleotide 
hydrolysis. The C-terminus of actin moves into place in this stage, locking 
the monomer in its native conformation. Native actin is not recognised by 
CCT and as such is rapidly released from the chaperonin.  
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9.5 Future Directions 
The development of a spectroscopic actin folding assay allows a range of 
different conditions to be studied and compared. It would be interesting to 
develop it further so as to be used in stopped flow measurements which 
would allow a much more detailed analysis of the early stages of the 
reaction. This may enable the ATP binding and hydrolysis phases to be 
visualised without the need to trap the folding intermediate using AMP-
PNP. In this case, it would be possible to look in greater detail at the 
relative rates of the two steps under the conditions of the folding assay, as 
there would be no added complications arising from the need to displace 
AMP-PNP with ATP for the reaction to proceed. It is also possible that 
transitions involved at the C-terminus of actin which occur too rapidly to 
investigate using the current method may be visible. In order to perform this 
sort of analysis, apparatus which allows a very small sample volume and a 
sensitive detector is necessary so as to minimise the amount and the 
concentration of the ternary complex required. High concentrations of actin 
cannot be used, since it can aggregate when being unfolded, and the high 
cost of CCT prohibits use of large quantities of the chaperonin. Since for 
stopped flow several times the volume of the sample chamber are required 
for mixing, the size of the chamber would need to be as small as possible 
whilst maintaining a sufficient pathlength for fluorescence emission to be 
observed. 
 
It would also be of interest to determine if a similar assay could be 
developed to study other CCT substrates as the cofactors involved in the 
folding process are identified. 
 
9.5.1 PLP2 
While PLP2 has been shown to be important for actin folding, the role it 
plays is unknown. It may well be involved in loading actin onto the 
chaperonin in the correct conformation for a productive folding cycle, but it 
could also play a part in the later stages of the folding cycle. It would be 
interesting to know at what stage PLP2 leaves the complex, and if it is still 
present in the nucleotide bound intermediate. Since PLP2 interacts with 
CCT even in the absence of actin, this could be difficult to quantify 
accurately, and is difficult to follow by gel electrophoresis. It may be 
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possible to label PLP2 with an environmentally sensitive fluorophore and 
monitor changes in the protein as the folding reaction progresses. PLP2 
contains two cysteine residues, both of which are found in the thioredoxin 
fold domain of the protein. Mutation of either cysteine seems to have an 
adverse effect on expression of the protein in E. coli making selective 
labelling of the protein more complex, although potentially labelling at 
multiple sites is not a problem as long as a change can be observed as the 
reaction progresses. 
 
It can be seen that truncations of PLP2 have a significant effect on the 
efficiency of actin folding, and it would be interesting to investigate this 
further, perhaps with the spectroscopic folding assay, as well as with other 
mutants of CCT. 
 
9.5.2 CCT mutations 
The different subunits of CCT clearly play an important role in the folding of 
proteins by the chaperonin. Mutations have been made in the ATP binding 
site of all the subunits of CCT [141], which could be used within the pure in 
vitro folding assay to investigate actin folding by these mutants. This could 
be used to provide information on the order of ATP binding and hydrolysis 
as well as those subunits most actively involved in actin folding, thereby 
allowing a more detailed analysis of the process. 
 
The spectroscopic in vitro actin folding assay has been used to investigate 
the kinetics of actin folding by the chaperonin but there are many more 
ways in which it could be used. Fluorescence spectroscopy is a very useful 
tool for the study of protein folding and the labelling of the actin C-terminus 
with acrylodan means that conformational changes at this important area of 
the actin monomer can be readily investigated.  
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Appendix 1 - Protein sequences 
His-Cdh1 342-469 
HHHHHHAPAKQCGHIDRVACLSWNNHVLTSGSRDHRILHRDVRMPDPFF
ETIESHTQEVCGLKWNVADNKLASGGNDNVVHVYEGTSKSPILTFDEHKA
AVKAMAWSPHKRGVLATGGGTADRRLKIWNVNTSIKMSDID 
 
His-Cdh1 342-512 
HHHHHHAPAKQCGHIDRVACLSWNNHVLTSGSRDHRILHRDVRMPDPFF
ETIESHTQEVCGLKWNVADNKLASGGNDNVVHVYEGTSKSPILTFDEHKA
AVKAMAWSPHKRGVLATGGGTADRRLKIWNVNTSIKMSDIDSGSQICNM
VWSKNTNELVTSHGYSKYNLTLWDCNSMDPIAI LK 
 
CBP-Cdh1 342-512 
KRRWKKNFIAVSAANRFKKISSSGALAPAKQCGHIDRVACLSWNNHVLTS
GSRDHRILHRDVRMPDPFFETIESHTQEVCGLKWNVADNKLASGGNDNV
VHVYEGTSKSPILTFDEHKAAVKAMAWSPHKRGVLATGGGTADRRLKIW
NVNTSIKMSDIDSGSQICNMVWSKNTNELVTSHGYSKYNLTLWDCNSMD
PIAI LK 
 
His-Cdh1 342-469-strep 
HHHHHHAPAKQCGHIDRVACLSWNNHVLTSGSRDHRILHRDVRMPDPFF
ETIESHTQEVCGLKWNVADNKLASGGNDNVVHVYEGTSKSPILTFDEHKA
AVKAMAWSPHKRGVLATGGGTADRRLKIWNVNTSIKMSDIDSGWSHPQF
EK 
 
FMDV 3Cpro  
HHHHHHESGAPPTDLQKMVMGNTKPVELILDGKTVAICCATGVFGTAYLV
PRHLFAEQYDKIMLDGRAMTDSDYRVFEFEIKVKGQDMLSDAALMVLHR
GNKVRDITKHFRDTARMKKGTPVVGVVNNADVGRLIFSGEALTYKDIVVS
MDGDTMPGLFAYKAATRAGYAGGAVLAKDGADTFIVGTHSAGGNGVGY
CSCVSRSMLQKMKAHVEH 
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CaM-Cys4 
HHHHHHADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPT
EAELQDMINEVDADGNGTIDFPEFLTMMARKMKCTDSEEEIREAFRVFDK
DGNGFISAAELRHVMTNLGEKLTDEEVDEMIREADIDGDGQVNYEEFVTM
MTSK 
 
6H-Cdh1 342-469-strep 
HHHHHHGHIDRVACLSWNNHVLTSGSRDHRILHRDVRMPDPFFETIESH
TQEVCGLKWNVADNKLASGGNDNVVHVYEGTSKSPILTFDEHKAAVKAM
AWSPHKRGVLATGGGTADRRLKIWNVNTSIKMSDIDSGWSHPQFEK 
 
6H-Cdh1 342-469-strep C349A 
HHHHHHGHIDRVAALSWNNHVLTSGSRDHRILHRDVRMPDPFFETIESHT
QEVCGLKWNVADNKLASGGNDNVVHVYEGTSKSPILTFDEHKAAVKAMA
WSPHKRGVLATGGGTADRRLKIWNVNTSIKMSDIDSGWSHPQFEK 
 
6H-Cdh1 342-469-strep C379A 
HHHHHHGHIDRVACLSWNNHVLTSGSRDHRILHRDVRMPDPFFETIESH
TQEVAGLKWNVADNKLASGGNDNVVHVYEGTSKSPILTFDEHKAAVKAM
AWSPHKRGVLATGGGTADRRLKIWNVNTSIKMSDIDSGWSHPQFEK 
 
His-PLP2 
MHHHHHHQNEPMFQVQVDESEDSEWNDILRAKGVIPERAPSPTAKLEEA
LEEAIAKQHENRLEDKDLSDLEELEDDEDEDFLEAYKIKRLNEIRKLQERS
KFGEVFHINKPEYNKEVTLASQGKKYEGAQTNDNGEEDDGGVYVFVHLS
LQSKLQSRILSHLFQSAACKFREIKFVEIPANRAIENYPESNCPTLIVYYRG
EVIKNMITLLELGGNNSKMEDFEDFMVKVGAVAEGDNRLIMNRDDEESRE
ERKLHYGEKKSIRSGIRGKFNVGIGGNDDGNINDDDDGFFD 
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Appendix 2 – A Two-step Mechanism for the Folding of 
Actin by the Yeast Cytosolic Chaperonin, Stuart et al 
(2011) 
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